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ABSTRACT 
 
 Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections cause a wide range of 
liver diseases including hepatocellular carcinoma (HCC) worldwide. Because these two viruses 
have the same modes of transmission, HBV HCV co-infections are found in approximately 7 to 
20 million people globally. HBV HCV co-infections are associated with more severe liver 
diseases and higher risk of HCC. Previous studies have established that HBV and HCV mono-
infection can cause hepatic steatosis, and steatosis is a confirmed risk factor for HCC. However, 
whether and how HBV HCV co-infections synergistically increase the risk of HCC development 
through modulating lipid metabolism is not well understood. 
PTEN is a phosphatase which contains both lipid and protein phosphatase activities. 
PTEN acts as a tumor suppressor by down-regulating the phosphoinositide-3-kinase (PI3K)/Akt/ 
sterol regulatory element-binding protein (SREBP) signaling pathway. It has been reported that 
PTEN is frequently mutated or deleted in tumors including HCC. PTEN-Long, a longer isoform 
of PTEN, which is able to be exported into the extracellular compartments, enter neighboring 
cells, and induce signaling events in recipient cells. Both HBV and HCV infections can inhibit 
PTEN and activate SREBP. However, how regulation of PTEN/SREBP pathway affects HBV 
and HCV infections is not fully understood. Therefore, the effect of the PTEN/SREBP pathway 
on HBV and/or HCV infections is worthy to study. 
In this study, we showed that both HBV X protein (HBx) and HCV core protein regulate 
PTEN/SREBP pathway. We established that HBx activates SREBP-1a and SREBP-1c through 
different mechanisms. This process is involved in up-regulating of HBV enhancer I or HBV 
enhancer II. We demonstrated multiple mechanisms of how HBx regulates HBV replication. We 
also showed that HCV core interacts with PTEN and PTEN-Long which is involved in regulating 
of HCV life cycle. In an HBV HCV co-infection cellular model, HBx and HCV core have similar 
regulatory effects on the PTEN/SREBP pathway as in mono-infections. However, PTEN and 
SREBP differentially regulate HBV and HCV replication in HBV HCV co-infection.  
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1.0 LITERATURE REVIEW  
 
1.1 Hepatitis B Virus 
 
1.1.1 Identification and molecular characteristics 
  
 In 1967, the hepatitis B virus (HBV) surface antigen (HBsAg) was first identified by 
Blumberg et al. [1,2]. The HBV particle was first observed by Dan et al. in 1970 [3]. These 
findings of HBV contribute to the development of effective surveillance tools, vaccines and HBV 
therapies [4]. The HBV vaccine is available which induces protective antibody response in 90% 
to 99% vaccinees [5]. However, the protective antibody response is not permanent, and therefore 
vaccination renewal is required [6].  
 The human HBV is an enveloped incomplete double-strand DNA virus which belongs to 
the family Hepadnaviridae [4]. The genome of HBV is unusual because the DNA is not fully 
double-stranded. One end of the full length strand is linked to the viral DNA polymerase. The 5'-
end of the two strands of DNA contain two direct repeats (DRs) which are DR1 and DR2. DR1 
and DR2 play important roles in maintaining the circular configuration and HBV viral replication 
[7]. The HBV DNA genome is 3.2 kb in size and contains a 3020 - 3320 nucleotides long 
negative strand DNA (for the full-length strand) and an 1700 - 2800 nucleotides long positive 
stand DNA (for the short length-strand) [8]. HBV genome encodes four highly overlapping open 
reading frames (ORF) which are called C, P, S and X, respectively [9]. The HBV core protein, 
known as HBV core antigen (HBcAg), is encoded by the C gene and produced by proteolytic 
processing of the precore protein. After cleavage of the N-terminal signal peptide and C-terminal 
arginine-rich sequence, the precore/core protein is converted to HBV e antigen (HBeAg). HBeAg 
can secrete into the serum which is not necessary for HBV replication but essential for chronic 
infection [10]. HBV P proteins are encoded by gene P. HBV P proteins are important for 
reconstitution of HBV DNA synthesis. Gene S has the gene that codes for the surface antigen 
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(HBsAg). The gene S has one long open reading frame but contains three in-frame "start" (ATG) 
codons that divide the gene into three sections, pre-S1, pre-S2, and S. Because of the multiple 
start codons, polypeptides of three different sizes called large, middle, and small (L, M and S) are 
produced. A nonstructural protein, HBV X protein (HBx), is encoded by gene X which functions 
as a transcriptional transactivator of host genes [7] (Fig. 1.1). HBV gene transcription is regulated 
by two HBV enhancers: HBV enhancer I/X promoter, HBV enhancer II/core. HBx activates 
HBV enhancers and thus increases HBV replication [11,12].  
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Fig. 1.1. Organization of hepatitis B virus (HBV) genome. The HBV DNA genome contains a 
long negative strand DNA and a short positive stand DNA. HBV proteins are encoded by four 
open reading frames (ORFs) which are called C, P, S and X.  
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1.1.2 Epidemiology 
  
 The World Health Organization (WHO) has established that there are more than 257 
million chronic hepatitis B (CHB) patients [13]. HBV causes around 600,000 deaths per year and 
it is ranking the 15
th
 of the causes of death [14]. HBV has been divided into 10 genotypes (A-J) 
(genome diversity > 8% at the nucleotide level) and further divided into more than 40 sub-
genotypes (genome diversity > 4% at the nucleotide level) [15]. The prevalence of HBV varies 
significantly in different regions of the world. Up to 70-90% of the population are positive for 
serological markers in Southeast Asia, China, the Korean peninsula, sub-Saharan Africa and 
many Caribbean Islands. In North America and Europe, less than 2% of the population are HBV 
positive [16-18]. The common routes of HBV transmission include perinatal, early inapparent 
childhood infection, tribal tattooing and scarification, sexual contact, blood transfusions, unsafe 
injection practices, injecting drug use and occupational exposure of health care workers [4]. 
 
1.1.3 HBV life cycle 
 
HBV particle entry requires host receptors hepatocyte-associated heparin sulphate 
proteoglycans (HSPGs) and sodium taurocholate co-transporting polypeptide (NTCP). After 
HBV particle uncoating, HBV releases relaxed circular DNA (rcDNA) in endosomes, rcDNA 
then associates with nuclear pore complex (NPC) to import into the nucleus. After the 
translocation, rcDNA is converted to covalently closed circular DNA (cccDNA). Then cccDNA 
is transcribed to pregenomic RNAs (pgRNAs) and subgenomic RNA which act as both the 
templates for reverse transcription to generate viral DNA and message RNAs (mRNAs) for viral 
protein translation after export into the cytoplasm by associating with a cellular Tip-associated 
protein/nuclear export factor-1 (TAP/NFX1) and HBcAg. The pgRNAs are selectively packaged 
inside core particles, and then followed by P protein-mediated negative strand DNA synthesis. 
After the degradation of pgRNAs, the positive strand DNA is synthesized to generate rcDNA. At 
last, HBV virions are assembled in the endoplasmic reticulum (ER)-Golgi compartment and then 
released from the cell. HBV rcDNA may also return to the nucleus to repeat the replication 
process producing more cccDNA [19,20] (Fig. 1.2). 
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Fig. 1.2. HBV life cycle. HBV life cycle starts with HBV entry which is assocated with the host 
factors: hepatocyte-associated heparin sulphate proteoglycans (HSPGs) and sodium taurocholate 
co-transporting polypeptide (NTCP) and then followed by uncoating, and nuclear transport of the 
relaxed circular DNA (rcDNA). The rcDNA is converted to covalently closed circular DNA 
(cccDNA), which acts as the template for transcription of four RNAs. The size of the RNAs are 
3.5, 2.4, 2.1 and 0.7 kb. These RNAs are exported to cytoplasm for protein translation and 
rcDNA generation. Then rcDNA is either enveloped in the endoplasmic reticulum (ER)-Golgi 
compartment and then released from the cell or transported to the nucleus to generate more 
cccDNA.  
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1.2 Hepatitis C Virus 
 
1.2.1 Identification and molecular characteristics 
 
The hepatitis C virus (HCV) was first identified in 1989 [21]. However, after more than 
25 years of research, a vaccine to prevent HCV infection is still unavailable [22]. 
HCV is a small (55-65 nm in size) RNA virus of the family Flaviviridae. HCV is an 
enveloped virus with a single positive-strand RNA genome of about 9.6 kb. At the 5' and 3' ends 
of the genome are untranslated regions (UTRs), which are important for HCV translation and 
replication. Structural proteins include: core, which forms viral nucleocapsid; E1 and E2, which 
are envelope proteins. P7, a viroporin, is an ion channel and regulates membrane permeability 
and secretion. Other nonstructural proteins include NS2, NS3, NS4A, NS4B, NS5A, and NS5B. 
NS2, NS3 and NS4A are involved in proteolytic processing of the viral polyprotein. Two 
different proteinases are required for the proteolytic processing: the NS2-NS3 zinc-dependent 
metalloproteinase and the NS3 serine proteinase located in the N-terminal region of NS3. The C-
terminal region of NS3 has RNA helicase and NTPase activities. NS4A is a cofactor of NS3 
proteinase. NS4B is required for the formation of an intracellular membrane structure, the 
membranous web, which is essential for viral replication. NS5A is a phosphorylated protein with 
two phosphorylated forms: p56 and p58. One of the main functions of NS5A is RNA binding 
which is important for viral replication and assembly. NS5A interacts with cellular proteins and 
thus modulates cellular pathways associated with the immune system, cellular signaling, cell 
adhesion, cellular growth and death. These processes contribute to HCV pathogenesis. NS5B is 
the RNA-dependent RNA polymerase (RdRp) [23,24]. In 2001, a bioinformatics- and protein- 
based study has demonstrated that a new HCV ORF exists in the -2/+1 alternative reading frame 
(ARF) [25]. In the same year, another study has reported that the HCV core protein-coding 
sequence also expresses a 17 kDa protein, which is synthesized by ribosomal frame shift [26]. In 
the following studies, it has been reported that in different HCV genotypes, various lengths of 
proteins were synthesized from the ARF [27-32]. These proteins were named ARFP [33]. The 
function of ARFP in HCV life cycle is still not clear. However, they may involve in regulation of 
immune response of host cells, such as inhibition of interferon-α secretion [34,35] (Fig. 1.3). 
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1.2.2 Epidemiology 
 
The WHO has established that approxmately 71 million patients are chronicly infected by 
HCV [36]. HCV is a blood borne virus. The common routes of HCV transmission include: 
injecting drug use through the sharing of injection equipment, the reuse or inadequate 
sterilization of medical equipment, and the transfusion of unscreened blood and blood products, 
sexual contact,  being born to a mother who has HCV [14]. After HCV infection, about 15%-20% 
of patients will spontaneously clear the acute infections. Otherwise, patients will develop chronic 
HCV infections [37]. The prevalence rate of hepatocellular carcinoma (HCC) in HCV patients 
varies in different geographic regions. More than 70% of the HCC patients in Japan and Egypt 
have chronic hepatitis C (CHC), whereas the rate is much lower in Italy and Spain (40-50%), the 
USA (20%) and China (10%) [38,39]. HCV can be divided into seven genotypes with more than 
30% nucleotide variation, and each genotype can be divided into several subgenotypes [40]. HCV 
genotype 1 is the most prevalent genotype globally. HCV genotype 3 causes more serious liver 
diseases than other genotypes [41]. 
 
1.2.3 HCV life cycle 
 
 HCV entry involves a complex series of interactions with host factors, such as cluster of 
differentiation 81 (CD81), scavenger receptor class B type I (SRB1), claudin 1, occludin, 
glycosaminoglycans (GAGs) and low density lipoprotein receptors (LDL-R). After entry to the 
target cell, HCV induces pH-dependent membrane fusion to release HCV RNA genome into the 
cytoplasm. Then the HCV genomic RNA acts as mRNA to be translated into a single large 
polyprotein which is further processed by host and viral proteases to generate ten viral proteins 
(core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). The HCV core protein-coding 
sequence also expresses a 17 kDa protein, which is synthesized by ribosomal frame shift [26]. 
The ER is modified by viral and cellular factors to generate a membranous web which contains 
double-membrane vesicles containing HCV NS proteins, HCV RNA, ER membranes and lipid 
droplets. Membranous web is the major site of viral RNA amplification where HCV NS5B 
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protein, drives a positive-negative-positive strand RNA replicating cycle to complete HCV RNA 
replication. The newly synthesized RNAs are packaged into nucleocapsids and associated with 
the HCV glycoproteins to achieve viral maturation. The mature virions are associated with lipid 
droplets to release from the host cell [42,43] (Fig. 1.4).  
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Fig. 1.3. Organization of hepatitis C virus (HCV) genome. The single positive-strand RNA 
HCV genome is about 9.6 kb in length. At the 5' and 3' ends of RNA exist untranslated regions 
(UTRs). Structural proteins include core, E1 and E2. The HCV core protein-coding sequence also 
expresses alternative reading frame proteins (ARFP). P7 is a viroporin. Nonstructural proteins 
include NS2, NS3, NS4A, NS4B, NS5A and NS5B. 
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Fig. 1.4. Hepatitis C virus (HCV) life cycle. The HCV life cycle starts with HCV virions 
interacting with several host receptors. Then HCV glycoproteins, E1 and E2, induce pH-
dependent membrane fusion and resulting in the release of nucleocapsid into the cytoplasm. The 
positive-strand RNA is translated to generate a single large polyprotein which is processed by 
host and viral proteases to generate ten mature HCV proteins. The endoplasmic reticulum (ER) is 
modified by viral and cellular factors to form a membranous web, where NS5B drives a positive-
negative-positive strand RNA replicating cycle. Newly synthesized RNA, nucleocapsid and 
glycoproteins are assembled to generate new virions. Then the virions bud from the ER and 
achieve maturation. Mature HCV virions are associated with lipid droplets released from the cell 
to complete the life cycle. 
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1.3 PTEN Suppresses PI3K/Akt/SREBP Pathway  
 
1.3.1 PI3K/Akt pathway 
 
Phosphoinositide-3-kinases (PI3Ks) are members of a lipid kinase family. PI3Ks can be 
divided into three classes. All three classes of PI3Ks contain a C2 domain, a helical domain and a 
catalytic domain [44]. Class IA PI3Ks are heterodimers which contain a p110 catalytic subunit 
and a p85 regulatory subunit. There are three isoforms of p110, p110α, p110β and p110δ; and 
there are five regulatory isoforms: p85α, the splicing variants of p85α (p55α and p50α), p85β and 
p55γ. Class IA PI3Ks are stimulated by tyrosine kinase receptors (RTKs) or Ras and catalyze the 
generation of phosphatidylinositol-3,4,5 trisphosphate (PIP3) from phosphatidylinositol-4,5 
bisphosphate (PIP2). The Class IA PI3Ks are most related to PI3K/Akt pathway [45]. Class IB 
PI3Ks are heterodimers which contain a p110γ catalytic subunit and regulatory isoforms p101 or 
p87. Class IB PI3Ks are stimulated by heterotrimeric G proteins or Ras and are essential for 
generation of PIP3 in neutrophils [46]. Class II PI3Ks contain three isoforms, PI3K-C2α, PI3K-
C2β and PI3K-C2γ. Class II PI3Ks are stimulated by insulin receptors, growth factor receptors 
and integrins. Class II PI3Ks catalyze the generation of phosphatidylinositol 4-phosphate and 
phosphatidylinositol 3,4-bisphosphate from phosphatidylinositol and phosphatidylinositol 4-
phosphate [47]. Class III PI3Ks contain a catalytic subunit VPS34 and an adaptor subunit VPS15. 
Class III PI3Ks are constitutively active and catalyze the generation of phosphatidylinositol 3-
phosphate from phosphatidylinositol. Class III PI3Ks regulate autophagy and endosomal protein 
sorting [45,48]. 
Akt is a serine/threonine kinase and has three isoforms (Akt1, Akt2 and Akt3). All three 
isoforms share approximately 80% amino acid sequence identity. Akt has an N-terminal 
pleckstrin homology (PH) domain, a central catalytic domain and a C-terminal regulatory domain 
[45]. The PH domain of Akt directly binds to both PIP2 and PIP3 at the cell membrane [48]. Class 
IA PI3Ks stimulates PIP3 accumulation, and PIP3 recruits the PH domain, including Akt and 3-
phosphoinositide-dependent kinase 1 (PDK1). PDK1 phosphorylates Akt1 on threonine 308 
(Thr308), Akt2 on Thr309 or Akt3 on Thr305, and this phosphorylation of Akt results in Akt 
activation. The complete activation of Akt also requires phosphorylation of Akt1 on serine 473 
(Ser473), Akt2 on Ser474 or Akt3 on Ser 472. These processes are regulated by PDK1, integrin-
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linked kinase (ILK), an ILK-associated kinase, DNA-dependent protein kinase (DNA-PK), 
mammalian Target of Rapamycin complex 2 (mTORC2) and Akt itself [45,48]. 
 
1.3.2 PTEN 
 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a phosphatase 
which acts on both polypeptide and phosphoinositide substrates [45]. PTEN consists of 403 
amino acids and contains a short N-terminal PtdIns (4,5)P2-binding domain (PBD), a phosphatase 
domain, a C-2 domain, a C-terminal tail and PDZ motif binding domain [45,49]. Two naturally 
occurring mutations in the phosphatase domain disrupt the phosphatase activities of PTEN: 
C124S mutation abrogates both lipid and protein phosphatase activities; and G129E mutation 
abrogates lipid phosphatase activity only [49]. The Y138L mutation, identified in 2010, abrogates 
protein phosphatase activity only [50] (Fig. 1.5). PTEN localizes both to the cytoplasm and 
nucleus. Different subcellular localizations of PTEN display various biological functions [51]. In 
the cytoplasm, PTEN displays both lipid and protein phosphatase activities. PTEN is considered 
as an essential tumor suppressor since PTEN phosphatase activity dephosphorylates PIP3 to 
generate PIP2 and thus suppresses one of the most critical cancer-promoting pathways, the 
PI3K/Akt pathway [45] (Fig. 1.6). Therefore, PTEN regulates various downstream functions 
controlled by the PI3K/Akt pathway, such as cell cycle progression, cell death, stimulation of 
angiogenesis and stem cell self-renewal. PTEN is frequently mutated or deleted in tumors 
including HCC. 
Moreover, PTEN protein phosphatase activity displays several Akt-independent functions. 
PTEN stimulates cell migration through dephosphorylation of focal adhesion kinase (FAK) and 
activation of p130
cas
 [52,53]. PTEN also dephosphorylates SHC by association with SHC and 
induces cell migration [53]. SHC is an SH2-phosphoty-rosine-binding adapter protein and 
recruits the Grb2-SOS complex which regulates mitogen-activated protein kinase (MAPK) [51]. 
In the nucleus, PTEN regulates centrosome stability through association with centromere specific 
binding protein C (CENP-C) [54]. Nuclear PTEN also contributes to the repair of DNA double-
strand breaks through enhancement of the transcription of RAD51 [54]. In addition, cytoplasmic 
PTEN inhibits the activity of Akt to restore the activation of checkpoint kinase 1 which 
modulates the G2-M cell cycle checkpoint and thus contributes to the repair of the DNA double-
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strand breaks [55]. In the nucleus, PTEN also contributes to maintaining a condensed chromatin 
structure through association with histone H1, C-terminus of PTEN is required for this process 
[56]. Nuclear PTEN down-regulates MAPK and leads to reduced cyclin D1 level and G0–G1 cell 
cycle arrest [57]. Moreover, nuclear PTEN modulates cellular senescence through inducing the 
formation of anaphase promoting complex (APC)-cadherin-1 complex [58]. Loss of nuclear 
PTEN is associated with more aggressive cancers [45]. A PTEN variant, PTEN-Long was 
identified in recent studies [59]. The start codon of PTEN-Long is located at the upstream of the 
coding region of PTEN. In comparison to classical PTEN, PTEN-Long contains a 173-amino 
acid domain at the N-terminus of the classical 403 amino acids of PTEN. PTEN-Long allows 
secretion in exosomes and function outside of the cell, such as regulation of Akt [59,60].  It has 
been reported that PTEN-Long enhances cytochrome c oxidase activity and ATP production in 
mitochondria [61]. 
Previous studies have reported that the PTEN gene is mutated in 5 % of human HCC 
tumors [62], and both the PTEN mRNA level and protein expression are significantly inhibited in 
HCC tissues in comparison to non-tumor liver tissues [63,64].  Moreover, the inhibition of PTEN 
expression is more frequent in higher stage HCC tumors in comparison to stage 1 HCC tumors 
[65,66]. These studies indicate that inhibition of PTEN expression plays a critical role in the 
pathogenesis of HCC development. 
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Fig. 1.5. The domain structure of phosphatase and tensin homolog deleted on chromosome 
10 (PTEN). PTEN protein is composed of five functional domains: a PIP2-binding domain 
(PBD), a phosphatase domain, a C2 domain, a C-terminal tail and a PDZ-binding domain. Three 
mutations in the phosphatase domain disrupt the phosphatase activities of PTEN: C124S, G129E 
and Y138L.   
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Fig. 1.6. The PTEN/PI3K/Akt pathway. Activation of phosphoinositide 3-kinase (PI3K) results 
in phosphatidylinositol 3,4,5-trisphosphate (PIP3) accumulation. This process recruits the 
pleckstrin homology (PH) domain, including Akt and 3-phosphoinositide-dependent kinase 1 
(PDK1). Once localized at the plasma membrane, Akt is activated by PDK1-mediated 
phosphorylation at Thr308 and phosphorylation at Ser473 by mTOR complex 2 (mTORC2). 
PTEN negatively regulates PI3K function, leading to inactivation of Akt.   
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1.3.3 SREBP 
 
Sterol regulatory element-binding proteins (SREBPs) are transcription factors which 
belong to the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) family [67]. Three isoforms of 
SREBPs, namely SREBP-1a, SREBP-1c and SREBP-2, are encoded by the mammalian genome 
[67,68]. SREBP-1a functions as a potent activator of all SREBP-responsive genes involving fatty 
acid synthesis (FASN) and cholesterol synthesis, while SREBP-1c only activates FASN but not 
cholesterol synthesis [69,70]. SREBP-2 is also a potent activator which is mainly involving 
cholesterol synthesis [71]. FASN is an essential enzyme which catalyzes de novo lipid synthesis. 
The abnormal activation of FASN is associated with the development of cancer [72]. SREBP-1a 
and -1c are encoded from the same gene. However, the promoters are different. The SREBP-2 
isoform is encoded from a different gene [73]. The precursor SREBPs are synthesized as 
endoplasmic reticulum (ER) membrane proteins. Then precursor SREBPs form a complex with 
the SREBP-cleavage activating protein (SCAP) [74]. When the cholesterol concentration is low, 
the hexapeptide MELADL of SCAP is exposed into the cytoplasm and interacts with a COPII 
vesicle protein, Sec24. This process leads to the movement of the SREBP-SCAP complex from 
ER to Golgi apparatus [75]. In the Golgi apparatus, SREBPs are cut by two membrane-bound 
serine proteases, site-1 protease (S1P) and site-2 protease (S2P) [76,77]. Then, the mature 
SREBPs migrate to the nucleus, where SREBPs bind to sterol regulatory element (SRE) on the 
promoters of lipogenic genes and thus modulate lipid synthesis [78]. When the cholesterol 
concentration is high, a conformational change in SCAP occurs and results in the binding of the 
SREBP-SCAP complex to Insulin induced gene (Insig). This process inhibits SREBP activation 
through inhibition of SREBP-SCAP transport from ER to Golgi [79].  
The activation of Akt inhibits proline-rich Akt substrate 40 kDa (PRAS40) and tuberous 
sclerosis 1/2 (TSC1/2) and thus induces the activation of mammalian target of rapamycin 
complex 1 (mTORC1) [78]. The Akt/mTORC1 pathway activates SREBP-1 through regulation 
of SREBP-1 expression, cleavage and nuclear localization [80]. A substrate of mTROC1, p70 
ribosomal S6 kinase (S6K), plays a role in regulation of SREBP-1 expression [81]. S6K 
phosphorylates liver X-receptor (LXR) and stimulates the expression of SREBP-1 [82]. 
Activation of mTORC1 can induce ER stress and unfolded protein response (UPR) which results 
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in stimulation of SREBP-1 cleavage [83-85]. Moreover, activation of mTROC1 induces SREBP-
1 nuclear accumulation by regulation of Linpin-1 localization [86]. 
 
1.4 HBV HCV Co-infection  
 
1.4.1 Permission to use  
 
This section contains an amended version of our previously published article: Wu, Q., and 
Q. Liu. 2012. Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular 
carcinoma occurrence through synergistically modulating lipogenic gene expression? Hepatology 
Research: the official journal of the Japan Society of Hepatology 42:733-740. As per Hepatology 
Research policy, no formal permission is required for reuse or modification by the author. Details 
are available at http://onlinelibrary.wiley.com/journal/10.1111/%28ISSN%291478-
3231/homepage/Permissions.html  
 
1.4.2 HBV HCV co-infection and HCC 
  
 HCC is the fifth most common cancer and the third leading cause of cancer death 
worldwide [87]. Infection by HBV or HCV is responsible for up to 80% of HCC cases [88]. The 
occurrence of HBV HCV co-infection is relatively common, particularly in areas with high 
prevalence of HBV or HCV infection. Generally, approximately 2–10% of anti-HCV-positive 
patients are HBsAg positive; on the other hand, approximately 5–20% of CHB patients are found 
to be anti-HCV positive. High prevalence of HBV HCV co-infection is found in some high-risk 
populations, such as injection drug users (IDU), patients on hemodialysis, patients undergoing 
organ transplantation, HIV positive individuals and beta-thalassemia patients [89-94].  
One typical characteristic of cancer cells is their uncontrolled growth and proliferation in 
comparison to normal cells. This will definitely require more energy consumption by cancer cells 
and therefore it has long been recognized that abnormal lipid metabolism, especially de novo 
fatty acid synthesis, is a significant cause for carcinogenesis [95]. Not surprisingly, the activity of 
FASN, a major enzyme for fatty acid synthesis, has been found to be increased in a number of 
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cancers including HCC and FASN inhibitors are pursued as novel therapeutics for cancers [95-
97]. 
 
1.4.3 Both HBV and HCV infections are confirmed risk factors for HCC 
  
 Transmission of HBV occurs mainly through parental, sexual and vertical (perinatal 
transmission) routes [16,17]. Intravenous drug use is another important route for transmitting 
HBV [98]. Infection of HBV causes acute and chronic liver disease, such as liver cell 
proliferation, steatosis, liver failure, fibrosis and cirrhosis. Moreover, HBV infection has been 
shown to enhance the risk for HCC 100-fold in chronic carriers. Consequently, approximately 
54.4% of HCC cases are caused by HBV infection globally and as high as 89% of the HCC cases 
can be attributed to HBV infection in developing countries [99-102]. 
 Hepatitis C virus is a blood-borne pathogen. Transfusion of HCV contaminated blood is 
the major route of transmitting HCV before implementation of HCV screening tests [103]. 
Therapeutic injections using contaminated needles and syringes are one important route of 
transmitting HCV, especially in developing countries [103]. In addition, intravenous drug use has 
been recognized as a major risk factor for transmitting HCV in both developing and developed 
countries [98,103]. HCV infection is also associated with HCC. HCV is an indirect cause of HCC 
due primarily to chronic tissue damage resulting from chronic inflammation, cell proliferation, 
steatosis and cirrhosis. It has been established that HCV infection increases the risk for HCC 
approximately 17-fold with approximately 31.1% of HCC cases being caused by HCV infection 
[100,101,104,105]. 
 
1.4.4 Steatosis associated with HBV or HCV infection is a risk factor for HCC 
  
 The term steatosis refers to the excessive accumulation of fat in the liver [106]. Clinical 
studies have been performed to determine a link between hepatic steatosis and CHB and CHC. A 
wide range of steatosis prevalence (4.5–71%) has been documented in CHB patients [107]. A 
mega-analysis does not suggest a direct link between CHB infection and steatosis [108]. 
However, clinical studies have yet to be performed to demonstrate whether HBV can cause HCC 
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through steatosis. Recent experimental data have shown that the X-protein of HBV can increase 
lipid accumulation in cell culture and cause steatosis and HCC in transgenic mouse models [109-
111]. 
 Both clinical and experimental data have demonstrated that steatosis is a risk factor for 
HCC in HCV-infected individuals. A clinical study of 1279 patients with CHC who received 
interferon therapy from 1994–2005 at a single regional hospital in Japan has shown that 68 
patients (5.32%) developed HCC. It was concluded that steatosis is a significant factor for 
developing HCC in CHC patients, independent of other risk factors such as age, sex, obesity, 
fibrosis stage, and response to interferon therapy [112]. Another long-term research has also 
shown that hepatic steatosis is a risk factor for HCC in CHC patients [113]. This study involved 
161 patients with CHC who were diagnosed at Nagasaki University Hospital, Japan, between 
January 1980 and December 1999. Overall, the cumulative incidence rates of HCC were 24% at 5 
years, 51% at 10 years and 63% at 15 years. Steatosis developed in 90 patients (56%), and the 
relative risk of steatosis for HCC was 2.81, which was statistically different from the relative risk 
of age, cirrhosis, and interferon treatment. To understand the pathogenic effects of HCV proteins, 
a number of transgenic mouse lines have been generated to express either the structural proteins 
or the entire polyprotein [114,115]. It can be concluded that the HCV core protein itself is both 
steatogenic and oncogenic when expressed at high levels in mouse livers. Interestingly, when 
protein expression is at a very low level, only the transgenic mice expressing HCV polyprotein 
develop steatosis and HCC, suggesting a possible role of non-structural proteins [116]. However, 
the exact effects of HCV non-structural proteins on carcinogenesis are not well defined with 
various results being documented [117,118]. 
 
 
1.4.5 HBV HCV co-infection can enhance the risk of HCC 
 
 HBV HCV co-infection has been shown in numerous studies to correlate with an 
increased risk of HCC [93,94]. A case-control study conducted in Qidong County, an area of 
higher incidence of HCC in China, showed that the odds ratio (OR) values for HCC were similar 
in patients with the HBV (3.90) and HCV (3.89) infection, and highest in HBV HCV co-infection 
(6.48) [119]. Benvegnù et al. conducted a prospective study of 290 cirrhotic patients in Italy and 
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found that HBV HCV co-infection was an independent predictor for the development of HCC by 
both univariate and multivariate analyses. During a follow-up study of 8-96 months, HCC was 
observed in 12.2% of anti-HCV positive patients, in 19.6% of HBsAg positive patients, and in 
40.0% of patients with dual positivity for HBsAg and anti-HCV [120]. A meta-analysis, 
conducted by Donato et al. has enrolled 32 case-control studies to investigate the impact of HBV 
HCV co-infection on the development of HCC [121]. This study has shown that the relative risk 
of HCC in co-infected patients (OR = 165) was significantly higher than HBV (OR = 22.5) and 
HCV (OR = 17.3) mono-infections [121]. 
 
1.4.6 Molecular mechanisms of how HBV can cause steatosis and HCC 
 
The HBV nonstructrual protein, HBx, is considered as a transcriptional transactivator of 
the host genes [100]. Previous studies have determined that HBx stimulates genes that promote 
cell growth and inactivates growth-regulating molecules [122]. HBx contains 154 amino acids 
with a molecular weight of 17 kDa and it is localized in the nucleus and cytoplasm [123-125]. 
Different subcellular localizations of HBx display different transactivational activities. In 
comparison to wild-type HBx, nuclear-localized HBx significantly activates the HBV enhancer 
I/X but not the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) or 
activator protein 1 (AP-1); on the other hand, cytoplasmic-localized HBx is crucial for the 
activation of Ras/Raf/mitogen-activated protein (MAP) kinase cascade, NF-κB and AP-1 
[126,127]. A follow-up study demonstrated that amino acids 58-119 of HBx is required for 
activating the MAP kinase pathway [128]. Nuclear-localized HBx but not cytoplasmic-localized 
HBx is required for HBV replication in cell culture [129]. Previous studies have established that 
truncated forms of HBx are more commonly found in HBV-associated HCC tissues than non-
tumor tissues [130-132]. Compared to the full-length HBx, truncated forms of HBx play different 
roles in HBx stability and functions. Several studies have demonstrated that the C-terminal region 
of HBx is essential for HBx stability [132-134]. The C-terminal region of HBx also plays 
important roles in stimulating HBV replication by HBx in cell culture [12,133,135]. Deletion of 
23 amino acids at the C-terminal end of HBx abrogates its ability to activate NF-κB [133]. 
Na et al. has used transgenic mice and cell lines to show that HBx can enhance the 
expression of LXR and its lipogenic target genes, such as SREBP-1c, FASN and the peroxisome 
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proliferator-activated receptor (PPAR)-γ, which are accompanied by the lipid droplet 
accumulation and eventually HCC [110]. Several studies have also reported that HBx activates 
SREBP-1a, SREBP-1c and FASN [136,137], and this activation leads to lipid accumulation and 
cell proliferation in human liver cells [110,138]. Another study has shown in vivo and in vitro 
that HBx can enhance the transcriptional activation of SREBP-1 and the peroxisome proliferator-
activated receptor-γ (PPAR-γ), and leads to hepatic steatosis [139]. Furthermore, this study has 
shown that HBx induces the activation of SREBP-1 through the PTEN/PI3K/Akt pathway and 
that HBx-induced CCAAT enhancer-binding protein C/element binding protein (EBP)-α can up-
regulate PPAR-γ expression. Hye-Lin Ha and Dae-Yeul Yu have established that HBx can induce 
reactive oxygen species (ROS) production which can inactivate tumor suppressor PTEN and lead 
to live cell proliferation through Akt activation in vivo and in vitro [111]. Activation of Akt can 
enhance cyclin D1 expression and leads to the development of HCC [111]. 
 
1.4.7 Molecular mechanisms of how HCV can cause steatosis and HCC 
 
The mechanisms underlying chronic HCV infection and HCC development are not well 
understood. It has been postulated that HCV may induce HCC by modulating lipid metabolism in 
hepatocytes, suggesting a link between steatosis and HCC [112,140,141]. This notion is 
supported by a recent demonstration of the coordinated activation of lipogenic genes in clinical 
HCC samples [96]. However, mechanistic studies are lacking due largely to the unavailability of 
an immune competent small-animal model permissive for HCV replication which can 
recapitulate pathology associated with both viral replication and protein expression. As such, data 
collected so far are from transgenic mouse and in vitro studies in cell culture. 
The Hepatitis C virus infection of human hepatocytes transplanted into severe combined 
immunodeficiency (SCID), SCID/Alb-uPA mice induces lipid metabolism [142]. In addition, 
hepatocyte damage and apoptosis are observed, which may lead to fibrosis and cirrhosis [142]. 
Transgenic mouse lines expressing the HCV core protein develop hepatic steatosis followed by 
the appearance of HCC [115,143]. This provides direct evidence that the core protein encoded by 
HCV is a prominent viral factor for steatogenesis and carcinogenesis. No tissue damage is 
observed in transgenic mice expressing HCV envelope proteins E1 and E2, suggesting that they 
do not play a role [144]. Transgenic mice expressing both structural and non-structural proteins 
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develop abnormal lipid metabolism [116,145] and tumors [116], suggesting that HCV non-
structural proteins may also play a role in steatogenesis and carcinogenesis. However, it is not 
clear which non-structural protein(s) are involved at this moment. Apparently, NS4B is not 
steatogenic and carcinogenic because NS4B transgenic mice did not show any abnormality [146]. 
The role of NS5A is not certain because one transgenic mouse line generated from the BCF1 
strain with genotype 1b NS5A develops steatosis and liver tumors [118], whereas a genotype 1a 
NS5A transgenic mouse line based on the FVB strain does not show pathology [117]. Additional 
studies are needed to answer this question. 
In vitro studies in cell culture demonstrated that HCV infection and protein expression 
result in abnormal lipid metabolism. Previous studies have demonstrated that both HCV core and 
NS5A proteins are involved in the regulation of PTEN [147-149]. A previous study has 
demonstrated that although the HCV 3a core does not affect the PTEN mRNA level, it inhibits 
PTEN expression through a 3'-UTR-dependent inhibition of PTEN translation [147]. In addition, 
PTEN expression is transcriptionally inhibited by the activation of NF-κB [150]. NF-κB is a 
group of closely related transcription factors including NF-κB1 (p50 and its precursor p105), NF-
κB2 (p52 and its precursor p100), RelA (p65), c-Rel and RelB. NF-κB proteins can form homo- 
or heterodimers and display diverse transcriptional activities. While, unlike p65, c-Rel and RelB, 
p50 and p52 subunits of NF-κB show a lack of transactivation domain. NF-κB plays important 
roles in the regulation of cell apoptosis, proliferation and invasiveness, and coordination of innate 
and adaptive immune response [151,152]. NF-κB p65:p50 heterodimers are most common in 
most cell types [123]. Both p65 and p50 contain nuclear localization signals (NLS). The 
activation of NF-κB requires the translocation to the nucleus and binding to the target genes. 
However, inhibitor of NF-κB (IκB) can interact with NF-κB and retain it in the cytoplasm 
through either masking the NLS or exporting to the cytoplasm through strong nuclear export 
signals (NES) [151]. IκB can be phosphorylated on two serines sites by IκB kinase (IKK). IKK 
contains two catalytic subunits (IKKα and IKKβ) and the regulatory subunit (IKKγ). After 
phosphorylation of IκB, IκB undergoes polyubiquitination and fast degradation by proteasome 
which leads to translocate NF-κB into nucleus [153,154].  The HCV core can repress inhibitor 
NF-κB (IκB) expression and thus enhances the protein level of nuclear NF-κB. This process leads 
to inhibiting the protein level of PTEN and enhancing the protein level of the phosphorylated Akt 
[149]. Interestingly, the activation of IKK is regulated by Akt phosphorylation [155]. Therefore, 
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the HCV core may drive a positive feedback loop of NF-κB/PTEN/Akt and contribute to the 
development of HCC [150]. A previous study has reported HCV NS5A can inhibit the activity of 
the PTEN promoter and down-regulate the PTEN mRNA transcription and PTEN protein level. 
Two mechanisms are involved in this process: NS5A induces ROS-mediated NF-κB activation 
and NS5A enhances the activity of PI3K [156]. ROS modulates the activation of  NF-κB through 
the inhibition of its DNA binding activity, regulation of IKK and alternative phosphorylation of 
IκB on Tyrosine 42 [154]. In addition, a previous study has reported that ROS can regulate the 
lipid phosphatase activity of PTEN through formation of a disulphide bond between Cyc71 and 
Cys124 [157]. These studies suggest that NS5A may also drive the positive feedback loop of NF-
κB/PTEN/AKT [154-157]. Moreover, a previous study has reported a decline of nuclear PTEN 
protein in HCV-infected human hepatocytes [158]. PTEN does not contain a classical nuclear 
localization sequence but PTEN can interact with major vault protein (MVP) and translocate into 
the nucleus [159]. HCV infection inhibits Transportin-2 and blocks PTEN translocation into the 
nucleus [158]. Since the loss of nuclear PTEN is associated with more aggressive cancers [45], 
this study may implicate a mechanism whereby HCV infection induces HCC development. 
HCV infection of hepatocytes can induce SREBP-1, SREBP-2, and their target lipogenic 
genes such as FASN [160,161]. Waris et al. have shown that HCV infection induces oxidative 
stress, inactivates PTEN by phosphorylation (HBx inactivates PTEN by oxidization) and 
enhances the trans-activation of SREBP through the PI3K/Akt pathway [160]. 
Studies from our laboratory and others have established that HCV core protein induces 
lipid accumulation in hepatocytes through FASN activation which can lead to the higher 
prevalence and severity of steatosis [162,163]. In addition, because SREBP-1 is the major 
transcriptional factor for modulating FASN transcription, they have also proved that the HCV 
core protein up-regulates the FASN promoter in an SREBP-1-dependent manner [163]. After that, 
they have determined that HCV core protein enhances SREBP-1 activity through the PI3K/Akt 
pathway [164]. Unlike HBx, HCV core protein has no effect on PPAR-γ gene expression; 
however, it can enhance the transcriptional activation of PPAR-γ [139]. Although PPAR-α seems 
not to be regulated by HBx, PPAR-α contributes to HCV core protein-induced steatosis and HCC 
[165]. 
Hepatitis C virus non-structural proteins also play a role in modulating lipid metabolism. 
The HCV NS2 can activate SREBP-1c and FASN transcription [166]. Moreover, the sterol 
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regulatory element and liver X-receptor element (LXRE) are involved in SREBP-1c activation by 
HCV NS2 [166]. HCV NS4B protein can activate SREBP-1 and SREBP-2 through the Akt 
pathway [161]. HCV NS5A protein can also activate SREBP. An in vitro study has shown that 
HCV NS5A protein can up-regulate SREBP-1c transcription through the transcription factor 
specificity protein 1 (Sp1), and therefore increase the level of mature SREBP-1c protein [167]. 
HCV NS5A has also been reported to activate the transcriptional level of PPAR-γ and induce the 
hepatic lipid accumulation [168]. 
Taken together, it can be concluded that HCV has developed multiple mechanisms for 
activating the host lipogenic pathway. 
 
1.4.8 Possible mechanisms of how HBV HCV co-infections enhance the risk of HCC 
through steatosis 
 
Although many studies have examined the mechanisms of how HBV or HCV mono-
infections cause HCC, very few studies are directed towards the understanding of the molecular 
mechanisms of how HBV HCV co-infection enhances the risk of HCC. Here, we will review the 
available published work and provide our thoughts on future directions. 
A seminal study by Dr. Slagle demonstrated that co-expressing HBx and HCV 
polyprotein in double transgenic mice results in more severe steatosis and an increased incidence 
of HCC, suggesting a synergy between HBV and HCV in pathogenesis [169]. Consistent with 
this finding, it has been shown that HBx and HCV core proteins can enhance cell transformation 
and proliferation and result in higher tumorigenicity in mice [170,171]. Additional study has 
shown that HBx and HCV core protein can synergistically inhibit the cyclin-dependent kinase 
inhibitor p21 gene and lead to cell proliferation [172]. 
What are the possible mechanisms for the observed synergy between HBV and HCV for 
steatogenesis and carcinogenesis (Fig. 1.7)? In general, activation of SREBP and abnormal 
activation of PPAR are two of the common reasons for abnormal lipid metabolism, and they are 
both are related to carcinogenesis [173-175]. 
Sterol regulatory element binding protein can be activated by the PI3K/Akt pathway [176]. 
The activation of SREBP induces the expression of FASN, and thus results in membrane lipid 
biosynthesis [177]. It has been demonstrated that loss or inactivation of the tumor suppressor 
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gene PTEN leads to the activation of the PI3K/Akt pathway. The PTEN/PI3K/Akt pathway plays 
a critical role in carcinogenesis [178-181]. We previously reviewed the fact that HBV and HCV 
protein expression as well as HBV or HCV infections have been shown to activate the PI3K/Akt 
pathway. Therefore, it is worth studying whether HBV and HCV co-infection may further 
increase the degree of activation of the PTEN/PI3K/Akt pathway, leading to more enhanced 
SREBP activity, more severe steatosis and eventually a higher incidence of HCC. 
The UPR is another important mechanism involved in modulating SREBP activity [182]. 
UPR is an adaptive intracellular stress response to the accumulation of unfolded or mis-folded 
proteins in the ER. Activation of the UPR contributes to several kinds of liver disease, including 
hepatic steatosis and HCC [183-186]. ER stress can enhance the activation of SREBP [187,188]. 
Both HBV and HCV infection can activate UPR and lead to ER stress [185]. As such, enhanced 
UPR may be another mechanism responsible for the HBV and HCV synergy in causing steatosis 
and HCC. 
Peroxisome proliferator-activated receptors are a group of nuclear receptor proteins with 
three members: PPAR-α, PPAR-β/δ and PPAR-γ [175]. In the liver, PPAR-α plays an important 
role in regulating fatty acid oxidation, lipoprotein synthesis, inflammatory responses and cancer 
development [175]. PPAR-β/δ acts as a plasma-free fatty acid sensor [189]. Moreover, it protects 
the liver by down-regulating inflammatory genes [190,191]. There are two isoforms of PPAR-γ: 
PPAR-γ1 and PPAR-γ2. A high level of PPAR-γ1 in mouse liver can lead to the development of 
hepatic steatosis [192]. As discussed previously, PPAR-α and PPAR-γ are involved in lipid 
accumulation and tumor formation induced by HBV and HCV. It appears that synergistic 
activation of PPAR activities may play an important role in increased steatogenesis and 
carcinogenesis in HBV and HCV co-infections.  
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Fig. 1.7. Potential mechanisms of how HBV and HCV co-infections synergistically activate 
steatogenesis and carcinogenesis. ER, endoplasmic reticulum; HBV, hepatitis B virus; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; PI3K, phosphatidylinositol 3-kinase; PPAR, 
peroxisome proliferator activatedreceptors; PTEN, phosphatase and tensin homologdeleted on 
chromosome 10; SREBP, sterol regulatory element binding proteins; UPR, unfolded protein 
response. 
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2.0 HYPOTHESES AND OBJECTIVES 
 
2.1 Rationale 
 
The term “steatosis” is used to refer to the deposition of fat in the interstitial spaces of an 
organ. Specifically, steatosis is commonly used to refer to depositions of fat in the liver. Steatosis 
is an independent and significant risk factor for HCC in chronic HBV and/or HCV infected 
patients. Previous studies have already established that HBV HCV co-infection enhances the risk 
for development of HCC. However the mechanisms are still not fully understood. Abnormal 
regulation of the PTEN/PI3K/Akt/SREBP pathway relates to HCC in vitro. Both HBV and HCV 
infections inhibit PTEN and thus activate the PI3K/Akt/SREBP pathway. However, the effect of 
PTEN and SREBP on HBV and HCV infection is not fully understood. Our research will study 
the potential mechanisms of how HBV or HCV mono-infection and HBV HCV co-infection 
enhance the activation of the lipogenic genes and leads to the higher risk for HCC. Moreover, we 
will also study if activation of the lipogenic genes affects HBV or HCV infection in HBV or 
HCV mono-infection and HBV HCV co-infection. 
 
2.2 Hypothesis 
 
(i) HBx may stimulate SREBP-1 activation and this process may be involved in HBx-
mediated HBV replication. 
 (ii) HCV may inhibit PTEN which is benefit to HCV infection. 
(iii) Compared to HBV or HCV mono-infection, HBV HCV co-infection may enhance 
hepatic steatosis and the occurrence of HCC by synergistically up-regulating lipogenic 
gene expression through the PTEN/SREBP pathway.  
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2.3 Objectives 
 
(i) To determine how HBx regulates the activities of SREBP, FASN and HBV enhancers and 
how HBx affects lipid accumulation and cell proliferation. 
(ii) To determine the effects of PTEN and SREBP-1a on HBV/HCV replication and to 
determine the effects of the PTEN/SREBP pathway on HBV/HCV induced steatosis and cell 
proliferation.  
(iii) To determine how HBV HCV co-replication regulates the PTEN/SREBP pathway and 
determine the effect of the PTEN/SREBP pathway on HBV and HCV replications in HBV 
and HCV co-replicating cells. 
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3.3 Abstract 
 
Hepatitis B virus (HBV) X protein (HBx) plays an important role in HBV pathogenesis 
by regulating gene expression. Sterol regulatory element binding protein-1a (SREBP-1a) is a key 
transcriptional factor for modulating fatty acid and cholesterol synthesis. Here we demonstrated 
that HBx increased mature SREBP-1a protein level in the nucleus and its activity as a 
transcription factor. We further showed that the up-regulation of SREBP-1a by HBx occurred at 
the transcriptional level after ectopic expression and in the context of HBV replication. 
Deletional analysis using SREBP-1a promoter revealed that the sequence from -436 to -398 in 
the promoter was required for its activation by HBx. This promoter region possesses the binding 
sequences for two basic leucine zipper (b-ZIP) transcription factors, namely C/EBP and E4BP4. 
Mutagenesis of the binding sequences on the SREBP-1a promoter and ectopic expression 
experiments demonstrated that C/EBPα enhanced SREBP-1a activation by HBx, while E4BP4 
had an inhibitory effect. C/EBPα was able to significantly reverse the inhibitory activity of 
E4BP4 on SREBP-1a promoter. These results demonstrated that HBx activates SREBP-1a 
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activity at the transcription level through a complex mechanism involving two bZIP transcription 
factors C/EBP and E4BP4 with C/EBP being the dominant positive factor. Finally, we showed 
that knocking down SREBP-1 abolishes HBV enhancer II/core promoter activation by HBx.  
 
3.4 Introduction 
 
Sterol regulatory element-binding proteins (SREBPs) belong to the family of basic-helix–
loop–helix-leucine zipper (bHLH-ZIP) transcription factors [67]. SREBPs directly activate the 
expression of numerous genes linked to the synthesis and uptake of cholesterol, fatty acids, 
triglycerides, and phospholipids. The mammalian genome encodes three SREBPs, designated 
SREBP-1a, SREBP-1c, and SREBP-2 [68]. In comparison to SREBP-1c, SREBP-1a has a longer 
transcription activation domain at its N-terminus which is capable of recruiting co-activators for 
transcription [68]. As such, SREBP-1a is a more potent activator of all SREBP-responsive genes 
for fatty acid and cholesterol synthesis, whereas SREBP-1c can only activate fatty acid synthesis 
[69,70]. SREBPs are synthesized as in active precursors and the N-terminal portion, released 
from the SREBP precursor by proteolysis, enters the nucleus and becomes active transcriptional 
factors [193]. Nuclear SREBPs activate transcription by binding to SRE sequence in the promoter 
regions of target genes [67]. 
Hepatitis B virus (HBV) infection is a global health problem with 350-400 million people 
being chronic carriers [194]. HBV has a partially double-stranded circular DNA genome coding 
for core, surface, polymerase, and the X (HBx) proteins [123]. Two viral enhancers promote 
HBV transcription [195]. Enhancer II/core promoter sequence regulates the transcription of 3.5-
kb pregenomic RNA, a key step in HBV replication cycle. HBx increases HBV replication and 
activates HBV enhancer II/core promoter [11,196,197]. HBx also modulates host cellular 
functions including lipid metabolism [198,199]. In this study, we investigated activation of 
SREBP-1a by HBx and its involvement in regulating HBV enhancer II/core promoter by HBx. 
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3.5 Materials and Methods 
 
3.5.1 Plasmids and antibodies 
 
The coding sequence of HBx was amplified by PCR from plasmids pRBK HBx or 
pawy1.2 [200,201] and cloned in-frame with the myc tag into the pEF/cyto/myc vector 
(Invitrogen). HBV enhancer II/core promoter sequence [202] was cloned into pGL4.14 vector 
(Promega), generating pGL4-HBV EN2/CP where the expression of luciferase gene was 
controlled by HBV enhancer II/core promoter. Flag-tagged SREBP-1a (aa. 1-517) was amplified 
from an SREBP-1a plasmid [203] and inserted into the pCMV2 Flag vector (Sigma-Aldrich) 
[164]. Plasmid pSRE-Luc containing three copies of SRE sequences was provided by Shimano 
[204]. Human SREBP-1a promoter- luciferase reporters containing different lengths of the 
SREBP-1a promoter were described previously [205]. Mutant SREBP-1a promoters with 
mutations for the binding sequences for C/EBP (CCAAT/enhancer binding protein) and E4BP4 
(Adenovirus E4 promoter binding protein 4) were generated by site-directed mutagenesis and 
confirmed by DNA sequencing (Fig. 3.3). Plasmids expressing C/EBPα [206] and E4BP4 (Open 
Biosystems) were used.SREBP-1-targeting microRNA (miRNA) with target sequence of 5' 
CCTGGTCTACCATAAGCTGCA 3' was constructed in pcDNA6.2-GW/EmGFP miR vector 
(Invitrogen). 
SREBP-1, Flag (M2), fibrillarin, β-actin and Myc epitope antibodies were from Santa 
Cruz Biotechnology, Sigma-Aldrich, and Cell Signaling Technology, respectively. Anti-HBx 
antibody was provided by Richardson [201]. 
 
3.5.2 Cell culture, transfection and nuclear fractionation 
 
Huh-7 cells [207] were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
with 10% (v/v) fetal bovine serum (FBS). Huh-7 cells were transfected using the calcium 
phosphate precipitation method as previously described [163]. Nuclear fractions were isolated as 
described [167]. 
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3.5.3 Immunoblotting analysis 
 
Huh-7 cells were collected with a Cell Lysis Buffer (Cell Signaling Technology) 
containing 1 mM phenylmethylsulphonyl fluoride (PMSF). Immunoblotting was performed as 
described [164,167]. For SREBP experiments, cells were treated with a protease inhibitor ALLN 
(25 µg/ml, Calbiochem) for 1 h prior to lysis. 
 
3.5.4 Reverse transcription and real-time PCR 
 
RNA was isolated from Huh-7 cells with Trizol (Invitrogen) followed by DNase I 
(Invitrogen) digestion. Reverse transcription was carried out by Superscript II (Invitrogen) and 
random priming. Real-time PCR was performed with primers SREBP-1a-FD (5' 
CGCTGCTGACCGACAT 3') and SREBP-1a-rev (5' CAAGAGAGGAGCTCAATG 3') using 
SYBR Green based detection system. Housekeeping gene GUSB was amplified in parallel by 
primers GUSB-FD (5' GGTGCTGAGGATTGGCAGTG 3') and GUSB-rev (5' 
CGCACTTCCAACTTGAACAGG 3'). Data was analyzed by Bio-RadiQ5 program. 
 
3.5.5 Luciferase assay 
 
Huh-7 cells were lysed in a Passive Lysis Buffer (Promega) and luciferase activity was 
determined using luciferase assay reagents (Promega) in a TD 20/20 Luminometer (Turner 
Designs). Results were analyzed for statistical differences using Student's t test. A p value of ≤ 
0.05 was considered statistically significant. 
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3.6 Results 
 
3.6.1 HBx increases the level of SREBP-1a in the nucleus 
 
HBx coding sequence was cloned into the pEF-cyto-myc vector in-frame with the myc 
tag. The resulting plasmid was transfected into Huh-7 cells and the cell lysates were analyzed in 
immunoblotting. As shown in Fig. 3.1A, a specific protein band was recognized by an HBx-
specific antibody and a myc-tag antibody (not shown) in cells transfected with HBx-expressing 
plasmid, but not in vector transfected cells. The level of β-actin was used as loading control. 
These results demonstrated the expression of HBx protein after transfection. 
Given the importance of SREBP-1a in modulating lipid metabolism, we explored the role 
of HBx in SREBP-1a activation. Huh-7 cells were transfected with HBx-expressing plasmid and 
vector control. The level of SREBP-1 was analyzed by immunoblotting using an anti-SREBP-1 
antibody. As shown in the upper panel of Fig. 3.1A, expression of HBx was associated with 
increased level of SREBP-1 compared to control. Because we were interested in SREBP-1a 
levels especially in the nucleus as the active form, however the SREBP-1 antibody cannot 
distinguish SREBP-1a from another isoform SREBP-1c. Therefore we used a plasmid expressing 
Flag-tagged SREBP-1a and an anti-Flag antibody to examine nuclear SREBP-1a levels (lower 
panel of Fig. 3.1A). The results showed that the nuclear SREBP-1a protein level was increased in 
HBx transfected cells than in vector transfected cells. To determine whether the increased 
SREBP-1a correlates with its enhanced activity as a transcription factor, we used an SRE-
luciferase reporter where the luciferase expression is directly controlled by three copies of SRE 
sequences (ATCACCCCAC, pSRE-Luc) [204]. This is because SREBP-1a activates transcription 
of its target genes by binding to the SRE sequence. As shown in Fig. 3.1B, HBx expression 
significantly increased SRE-driven luciferase activity by SREBP-1a compared to control. These 
results indicate that expression of HBx increases SREBP-1a level in the nucleus and its 
transcription factor activity.  
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Fig. 3.1. Expression of HBx increases the level of nuclear SREBP-1a and its transactivation 
activity.  (A) In the top panel, the levels of HBx, SREBP-1, and β-actin in Huh-7 cells after 
transfection with an HBx-expressing plasmid or the vector were analyzed by immunoblotting. In 
the bottom panel, levels of SREBP-1a in the nuclear fraction were analyzed by immunoblotting 
after co-transfection with plasmids expressing Flag-SREBP-1a and HBx or vector. The blots 
were probed with antibodies against Flag-tag or fibrillarin. This experiment was performed three 
times. (B) A luciferase reporter driven by SRE sequences was co-transfected with a plasmid 
encoding Flag-SREBP-1a together with HBx-expressing plasmid or vector control into Huh-7 
cells. Luciferase assay was performed using the cell lysates. Luciferase activity was expressed as 
fold change relative to vector control. The statistical difference between samples was 
demonstrated as ** if p ≤ 0.01. This experiment was performed three times. 
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3.6.2 HBx activates SREBP-1a transcription 
 
SREBPs are often regulated at the transcription level. To determine whether HBx 
regulates SREBP-1a transcription, we measured the level of SREBP-1a transcript by real-time 
PCR after HBx expression in Huh-7 cells. As shown in Fig. 3.2A, HBx expression resulted in 
more than 2-fold increase in SREBP-1a transcript level in comparison to control. A greater than 
one genome length HBV plasmid is a widely used model for HBV. As such, we transfected HBV 
wild-type genome (pawy1.2) and HBV without HBx (pawy1.2*7) [200] into Huh-7 cells and 
determined SREBP-1a transcript levels. As shown in Fig. 3.2B, SREBP-1a transcript level in 
HBV-transfected cells was significantly higher than those in vector- or HBV ∆HBx-transfected 
cells. The expression of HBx was confirmed after HBV plasmid transfection, whereas no HBx 
could be detected in vector- or HBV ∆HBx-transfected cells (Fig. 3.2C). These results indicate 
that HBx up-regulates SREBP-1a transcription. 
To further characterize SREBP-1a transcription up-regulation by HBx, Huh-7 cells were 
co-transfected with a luciferase reporter under the control of human SREBP-1a promoter (-1008) 
[205] and increasing amounts of HBx-expressing plasmid. The total amounts of plasmid DNA 
used for transfection were kept constant by adding appropriate amounts of the vector plasmid. 
Luciferase assay showed that HBx significantly activated SREBP-1a promoter activity in a dose-
dependent manner in comparison to vector control (Fig. 3.2D). Similarly, HBV plasmid 
transfection resulted in significantly higher luciferase activity than vector- or HBV ∆HBx- 
transfection (Fig. 3.2E). 
Next, we wanted to map the regions on the SREBP-1a promoter that were required for its 
activation by HBx. We used five truncatedSREBP-1a promoters -889, -717, -436, -398, and -360 
(Fig. 3.3A). Luciferase assay results showed that deletion from -1008 to -436 in the SREBP-1a 
promoter did not affect its activation by HBx, whereas the activation was abolished when the -
398 and -360 promoters were used. These results indicate that the sequence between -436 and -
398 in the SREBP-1a promoter is required for its activation by HBx. 
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Fig. 3.2. HBx up-regulates SREBP-1a transcription. (A and B) Huh-7 cells were transfected 
with vector or HBx-expressing plasmids (A), vector, HBV, or HBV ∆HBx (B). The levels of 
SREBP-1a transcript were analyzed by reverse-transcription real-time PCR. These experiments 
were performed three times. (C) The protein levels of HBx and β-actin in Huh-7 cells after 
transfection with vector, HBV, or HBV ∆HBx were determined by immunoblotting. This 
experiment was performed three times. (D and E) Huh-7 cells were co-transfected with a human 
SREBP-1a promoter (-1008/+194)-luciferase reporter plasmid with increasing amounts of HBx-
expressing plasmid (D) or vector, HBV, or HBV ∆HBx (E). Luciferase activities were expressed 
as fold changes relative to vector control. The statistical differences between samples were 
demonstrated as NS for not significant, * if p ≤ 0.05, or *** if p ≤ 0.001. These experiments were 
performed three times.  
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3.6.3 Effects of C/EBP and E4BP4 on SREBP-1a regulation by HBx 
 
Sequence analysis by the MatINSPECTOR prediction program indicated that the -436 to -
398 region in the SREBP-1a promoter contains binding motifs for transcription factors C/EBP 
and E4BP4 (Fig. 3.3B). To gain the first insights into the role of these two factors in SREBP-1a 
regulation by HBx, we mutated the binding sequences for each of the factors in the SREBP-1a 
promoter (Fig. 3.3C). These mutant SREBP-1a promoters were used in co-transfection 
experiments to test their activity after HBx expression. As shown in Fig. 3.3C, HBx failed to 
activate these mutant SREBP-1a promoters. These results suggested that the integrity of C/EBP 
and E4BP4 binding sequences is necessary for SREBP-1a regulation by HBx. Previous research 
has established that C/EBP and E4BP4 have divergent effects on transcription, although both 
belong to a family of basic leucine zipper (bZIP) proteins [208,209]. 
To determine the effects of these transcription factors in SREBP-1a regulation by HBx, 
we studied SREBP-1a promoter activity after ectopic expression of C/EBPα or E4BP4. There are 
six isoforms in the C/EBP family and C/EBPα was isolated from the liver [31,34]. 
Therefore, we used a plasmid expressing C/EBPα. As shown in Fig. 3.3D, transfection 
with increasing amounts of C/EBPα resulted in dose-dependent SREBP-1a promoter activation in 
both vector and HBx expressing cells. In contrast, increasing amounts of E4BP4 resulted in dose-
dependent decrease in SREBP-1a promoter activity in both vector and HBx expressing cells (Fig. 
3.3E). These results indicate that C/EBPα is as an activator, whereas E4BP4 is a repressor for 
SREBP-1a promoter regulation by HBx. 
Opposing effects of C/EBP and E4BP4 on SREBP-1a promoter regulation by HBx raised 
a question as to whether the inhibitory effect of E4BP4 can be overcome by C/EBP. To answer 
this question, Huh-7 cells were co-transfected with HBx-expressing plasmid and SREBP-1a 
promoter (-436) - luciferase reporter, together with E4BP4 alone or with C/EBPα. Corresponding 
vectors were used as controls. As shown in Fig. 3.3F, the inhibition of SREBP-1a promoter 
activity by E4BP4 was significantly reversed upon ectopic expression of C/EBPα. These results 
suggest that C/EBPα has a dominantly activating effect on SREBP-1a promoter activity.  
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Fig. 3.3. The roles of transcription factors C/EBP and E4BP4 in SREBP-1a promoter 
regulation by HBx. (A) Huh-7 cells were transfected with SREBP-1a promoters of different 
lengths together with HBx-expressing plasmid or vector control. SREBP-1a promoter activity 
was determined by luciferase assay. (B) SREBP-1a promoter sequence -436 to -397. The binding 
motifs as well as the mutated sequences for C/EBP and E4BP4 are shown. (C) Sequence integrity 
of the SREBP-1a promoter -436 to -398 region is required for its activation by HBx. Huh-7 cells 
were co-transfected with wild-type or mutant SREBP-1a promoters with HBx-expressing plasmid 
or vector control. SREBP-1a promoter activity was determined by luciferase assay. (D and E) 
Huh-7 cells were co-transfected with SREBP-1a-promoter luciferase reporter (-436/+194), HBx-
expressing plasmid or vector control, together with increasing amounts of C/EBPα (D) or E4BP4 
(E). SREBP-1a promoter activity was determined by luciferase assay. (F) Huh-7 cells were co-
transfected with SREBP-1a-promoter luciferase reporter (-436/+194), HBx-expressing plasmid, 
together with vector, E4BP4-expressing plasmid, and C/EBPα-expressing plasmid. SREBP-1a 
promoter activity was determined by luciferase assay. The statistical differences between samples 
were demonstrated as NS for not significant, * if p ≤ 0.05, ** if p ≤ 0.01, or *** if p ≤ 0.001. All 
experiments were performed three times.  
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3.6.4 Effect of SREBP-1 in HBV enhancer II/core promoter activation by HBx 
 
 Our results so far have shown that HBx activates SREBP-1a. Previous studies 
demonstrated that HBx increases HBV enhancer II/core promoter activity [11,196]. We therefore 
were interested in determining whether SREBP-1a is involved in this process. For this purpose, 
we used a miRNA to knock down SREBP-1 expression in Huh-7 cells. As shown in Fig. 3.4A, 
the levels of both precursor and mature SREBP-1 proteins were reduced by SREBP-1 miRNA in 
comparison to control miRNA. When Huh-7 cells were transfected with vector or HBx-
expressing plasmids together with pGL4-HBV EN2/CP, modest but significant 1.5-fold 
transactivation of enhancer II/core promoter by HBx was observed (Fig. 3.4B). This result is 
consistent with other studies showing activation of enhancer II/core promoter by HBx [11,196]. 
Upon knocking down SREBP-1, HBx was no longer able to transactivate enhancer II/core 
promoter (Fig. 3.4C). These results demonstrate that SREBP-1 is involved in HBV enhancer 
II/core promoter transactivation by HBx. 
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Fig. 3.4. The role of SREBP-1 in HBV enhancer II/core promoter activation by HBx. (A) 
Huh-7 cells were transfected with control or SREBP-1 miRNAs. The levels of precursor and 
mature SREBP-1 were determined by immunoblotting. This experiment was performed three 
times. (B) Huh-7 cells were co-transfected with HBV enhancer II/core promoter-luciferase 
reporter pGL4 HBV EN2/CP and vector or HBx-expressing plasmids. Luciferase activities after 
HBx expression were expressed as fold changes relative to vector control. (C) Huh-7 cells were 
co-transfected with pGL4 HBV EN2/CP, HBx-expressing plasmid, and control or SREBP-1 
miRNA. Luciferase activities after SREBP-1 knockdown were expressed as fold changes relative 
to control miRNA-transfection. The statistical differences between samples were demonstrated as 
* if p ≤ 0.05. These experiments were performed three times. 
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3.7 Discussion 
 
HBx is a multifunctional protein. Here, we demonstrated that HBx activates SREBP-1a, a 
transcription factor involved in several (patho)-physiological conditions such as lipogenesis and 
carcinogenesis [176,210]. We further demonstrated that SREBP-1 is involved in HBV enhancer 
II/core promoter activation by HBx. To become an active transcription factor, SREBP-1a needs 
to enter the nucleus and therefore nuclear SREBP-1a level reflects its activity. As such, we first 
demonstrated that HBx expression is associated with increased level of SREBP-1a in the nucleus 
(Fig. 3.1A). An SRE-driven luciferase reporter assay confirmed that SREBP-1a in HBx-
transfected cells is indeed transcriptionally active (Fig. 3.1B). 
The expression of SREBP-1a can be regulated at the transcription level [205]. Our results 
demonstrated that HBx can significantly up-regulate the activity of SREBP-1a promoter in a 
dose-dependent manner (Fig. 3.2D). More importantly, we showed that HBx in the context of 
HBV can also transactivate SREBP-1a transcription using a plasmid-based HBV model (Fig. 
3.2B and E). Mapping the sequences in the SREBP-1a promoter required for activation by HBx 
led us to concentrate on two bZIP transcription factors, namely C/EBP and E4BP4. Mutating the 
C/EBP binding sequence on the SREBP-1a promoter canceled SREBP-1a promoter activation by 
HBx (Fig. 3.3C). Consistently, ectopic expression of C/EBPα demonstrated that it can further 
enhance SREBP-1a promoter activation by HBx (Fig. 3.3D). These results suggest that C/EBP is 
required for SREBP-1a activation by HBx. 
Ectopic expression of E4BP4, on the other hand, has an opposing, inhibiting effect on 
SREBP-1a promoter activity (Fig. 3.3E). This finding is consistent with the established repressor 
activity of E4BP4 on transcription [208]. However, when the E4BP4 binding sequence was 
mutated on the SREBP-1a promoter, we did not see the expected increase of the promoter 
activity (Fig. 3.3C). The underlying reason is not clear. Several possible mechanisms exist. The 
binding sequences on gene promoters for bZIP transcription factors are similar, which may result 
in DNA binding competition by these factors [208]. In fact, it has been shown that C/EBP and 
E4BP4 can compete with each other in DNA binding and regulate transcription in a competitive 
manner [211,212]. Therefore, we cannot exclude the possibility that C/EBP can also bind the 
E4BP4 sequence on SREBP-1a promoter and positively regulate its activity. As such, elimination 
of E4BP4 binding sequence can potentially affect the activities of both E4BP4 and C/EBP. 
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Another possibility is that mutating the E4BP4 binding motif might somehow negatively affect 
the binding of C/EBP to its recognition sequence on the SREBP-1a promoter because they are in 
a very close proximity. In addition, b-ZIP factors regulate transcription by forming homo- and/or 
hetero-dimers [213]. According to a molecular interaction model, C/EBP and E4BP4 may 
interact with each other due to the presence of an asparagine residue in the “a” position of their 
bZIP domains which would favor heterodimerization [214]. It is reasonable to assume that 
elimination of E4BP4 binding sequence on the SREBP-1a promoter may increase the amount of 
free E4BP4. Then it is possible that more E4BP4 proteins can interact with C/EBP and interfere 
with the activity of C/EBP, resulting in reduced SREBP-1a promoter activation. If this is true, 
one would expect that increasing the amount of C/EBP should increase SREBP-1a promoter 
activity in the presence of E4BP4. This has been actually observed in our experiments (Fig. 3.3F). 
However, the exact mechanisms warrant further investigation. 
Recent studies have shown that HBx can activate SREBP-1c, the other isoform of 
SREBP-1, through liver X receptor [109,110,215]. Adding to these previous findings, our study 
has demonstrated that HBx can also activate SREBP-1a through a different and complex 
mechanism involving at least two transcription factors, C/EBP and E4BP4. More importantly, 
SREBP-1a is a more potent transcription activator for both fatty acid and cholesterol synthesis 
pathways [68-70]. In contrast, SREBP-1c is less active and only activates fatty acid synthesis. 
The functional significance of SREBP-1 activation in HBV biology and pathogenesis has not 
been characterized. Towards this goal, we showed that knocking down SREBP-1 abolishes 
activation of HBV enhancer II/core promoter activation by HBx (Fig. 3.4). Since the miRNA 
sequence we used does not distinguish between SREBP-1a and -1c, further experiments are 
needed to determine isoform-specific effects of SREBP-1. 
In conclusion, our results demonstrated that HBx activates the SREBP-1a activity by a 
complex mechanism involving two bZIP transcription factors C/EBP and E4BP4 with the former 
being the dominant factor leading to SREBP-1a promoter activation. Furthermore, we showed 
that SREBP-1 is involved in HBV enhancer II/core promoter activation by HBx.  
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4.0 THE EFFECT OF HBX LOCALIZATION ON THE REGULATION OF SREBP-1 
ACTIVITY  
 
 In the previous chapter, we demonstrated that HBx increases mature SREBP-1a protein 
level in the nucleus and its activity as a transcription factor. Moreover, we observed that this 
process is involved in up-regulation of HBV enhancer II/core promoter activity. Therefore the 
up-regulation of SREBP-1a activity by HBx may be involved in the context of HBV replication. 
HBx contains 154 amino acids and is localized into the nucleus, cytoplasm, and mitochondria. 
Different subcellular localizations of HBx display different transactivational activities. SREBP-
1a is a transcription factor, the mechanisms of how HBx regulates SREBP-1a is still not fully 
understood. In order to understand the role of HBx in the regulation of SREBP-1a and HBV 
replication, in the following chapter we set to determine if different subcellular localizations of 
HBx differentially regulate SREBP-1a and HBV enhancers. 
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5.3 Abstract 
 
 We previously showed that hepatitis B virus (HBV) X protein activates the sterol 
regulatory elementbindingprotein-1a (SREBP-1a). Here we examined the role of nuclear 
localization of HBx in this process. In comparison to the wild-type and cytoplasmic HBx, nuclear 
HBx had stronger effects on SREBP-1a and fatty acid synthase transcription activation, 
intracellular lipid accumulation and cell proliferation. Furthermore, nuclear HBx could activate 
HBV enhancer I/X promoter and was more effective on up-regulating HBV mRNA level in the 
context of HBV replication than the wild-type HBx, while the cytoplasmic HBx had no effect. 
Our results demonstrate the functional significance of the nucleus-localized HBx in regulating 
host lipogenic pathway and HBV replication.  
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5.4 Introduction 
 
 Hepatitis B virus (HBV) is a partially double-stranded circular DNA virus belongs to the 
Hepadnavirus family [216]. HBV infection causes acute and chronic liver disease and is a high 
risk factor for the development of hepatocellular carcinoma (HCC) [217]. HBV X protein (HBx) 
functions as a transcriptional transactivator of host genes and promotes cell growth and possibly 
HCC [18,100]. HBV gene expression is regulated by two HBV promoters/enhancers [218]. HBx 
activates both elements and thus increases HBV replication [11,12]. HBx localizes in the nucleus 
and the cytoplasm, which has functional implications [123-125]. Different subcellular 
localizations of HBx display different transactivation activities. In comparison to the wild-type 
HBx, nucleus-localized HBx significantly activates HBV enhancer I/X but not NF-κB or AP-1; 
on the other hand, cytoplasmic HBx is crucial for activating the Ras-Raf-MAP kinase, NF-κB 
and AP-1 [126,127]. Nuclear, but not cytoplasmic, HBx is required for HBV replication in cell 
culture [129]. 
 Sterol regulatory element-binding protein-1a (SREBP-1a) is a potent transcription factor 
for genes involved in fatty acid synthesis and cholesterol synthesis [69,70]. Our previous study 
showed that HBx activates SREBP-1a at the transcription level involving two transcriptional 
factors C/EBP and E4BP4 [137]. However, whether the subcellular localization of HBx plays a 
role in this process has not been investigated. In this study, we demonstrated that, in comparison 
to the cytoplasmic HBx, the nucleus-localized HBx has stronger effects on up-regulating SREBP-
1a, fatty acid synthase (FASN), lipid accumulation, cell proliferation, HBV enhancer I/X 
promoter, and HBV mRNA in the context of HBV replication. 
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5.5 Materials and Methods 
 
5.5.1 Plasmids 
 
 A plasmid expressing HBx with a myc-tag at the C-terminus under the control of the 
elongation factor-1a promoter, HBV enhancer II/core promoter luciferase reporter, SREBP-1a 
and FASN promoter luciferase reporters, and a greater-than-unit-length HBV genome without 
expressing HBx (payw 1.2*7) were described previously [137,163,219]. A nuclear localization 
signal (NLS, PKKKRKVFL) [126] or a nuclear export signal (NES, LALKLAGLDI) [129] was 
added to the N-terminus of the HBx coding sequence to create NLS-HBx or NES-HBx, 
respectively. The HBV enhancer I/X promoter sequence [220] was cloned upstream of the 
luciferase gene into the pGL4.14 vector (Promega), generating the pGL4-HBV enhancer I/X 
promoter. 
 
5.5.2 Cell culture, transfection, and nuclear fractionation 
 
 Huh-7 cells [207] were maintained in Dulbecco's modified Eagle's medium (DMEM) with 
10% (v/v) fetal bovine serum (FBS). Transfection and nuclear fractionation were described 
previously [163,167]. 
 
5.5.3 Western blotting and antibodies 
 
 Western blotting was performed as described [164,167]. Fibrillarin, β-actin and myc 
epitope antibodies were from Sigma-Aldrich and Cell Signaling Technology, respectively. 
 
5.5.4 Reverse transcription and real-time PCR 
 
 RNA extraction, reverse transcription, and real-time PCR were performed as described 
[137,221]. The primers for the real-time PCR were SREBP-1a-FD (5' CGCTGCTGACCGACAT 
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3') and SREBP-1a-rev (5' CAAGAGAGGAGCTCAATG 3'), FASN-FD (5' 
TCATCCCCCTGATGAAGAAG 3') and FASN-rev (5' ACTCCACAGGTGGGAACAAG 3'), 
HBV-FD (5' AGAAACAACACATAGCGCCTCAT 3') and HBV-rev (5' 
TGCCCCATGCTGTAGATCTTG 3'), and β-glucuronidase (GUSB)-FD (5' 
GGTGCTGAGGATTGGCAGTG 3') and GUSB-rev (5' CGCACTTCCAACTTGAACAGG 3'). 
 
5.5.5 Luciferase assay 
 
 Cells were lysed in a Passive Lysis Buffer (Promega) and the luciferase activity was 
determined using the luciferase assay reagents (Promega) in a TD 20/20 Luminometer (Turner 
Designs).After normalization against the total protein concentration in the same sample, the 
luciferase results were analyzed for statistical differences using Student's t test. A p value of ≤ 
0.05 was considered statistically significant. 
 
5.5.6 Oil Red O staining and MTT assay 
 
 The amounts of the neutral lipids were measured at 500 nm [168] after Oil Red O (ORO) 
staining as previously described [163]. The MTT assay was performed as described [221]. 
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5.6 Results and Discussion 
 
5.6.1 HBx subcellular localization analyzed by nuclear fractionation 
 
 Previous studies have shown that HBx in different subcellular compartments may have 
different functions [126,127,129]. However, the impact of the subcellular localization of HBx on 
lipogenic gene expression has not been studied. To specifically study the function of nucleus- and 
cytoplasm-localized HBx, a nuclear localization signal (NLS, PKKKRKVFL; NLS-HBx) [126] 
or a nuclear export signal (NES, LALKLAGLDI; NES-HBx) [129] was added to the N-terminus 
of the HBx coding sequence [137]. This is a widely used experimental approach 
[126,129,222,223]. To determine the intracellular distribution of the HBx proteins, nuclear and 
cytoplasmic fractions as well as total cell lysates were prepared and subjected to Western blotting 
after transfecting Huh-7 cells with the HBx-expressing plasmids. As shown in Fig. 5.1, wild-type 
HBx was present in both nuclear and cytoplasmic fractions as expected; NES-HBx was found 
predominantly in the cytoplasmic fraction, whereas NLS-HBx was predominantly nuclear. These 
results demonstrated that addition of a nuclear export signal to HBx efficiently excludes HBx 
from the nucleus and a nuclear localization signal renders nuclear localization of HBx. 
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Fig. 5.1. Expression and subcellular localization of HBx proteins. Huh-7 cells were 
transfected with plasmids expressing wild-type (WT) HBx, HBx with a nuclear export signal 
(NES-HBx) or a nuclear localization signal (NLS-HBx) at the N-terminus, or vector. A myc tag 
is present at the C-terminus of HBx. At 48 h after transfection, total cell lysates, nuclear and 
cytoplasmic fractions were analyzed by Western blotting using antibodies against the myc tag, β-
actin or fibrillarin. This experiment was performed five times. 
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5.6.2 Nuclear HBx is more effective on up-regulating SREBP-1a and FASN 
 
 We previously demonstrated that HBx activates SREBP-1a transcription [137]. To 
examine the role of subcellular localization of HBx in this process, we co-transfected Huh-7 cells 
with plasmids expressing wild-type HBx, NES-HBx, NLS-HBx, or empty vector, together with 
an SREBP-1a promoter luciferase reporter [137]. Consistent with our previous study [137], we 
observed significant activation of SREBP-1a promoter by wild-type HBx (Fig. 5.2A). Addition 
of a nuclear localization signal to HBx resulted in significantly higher SREBP-1a promoter 
activation than the wild-type HBx (Fig. 5.2A). In contrast, HBx with a nuclear export signal, 
NES-HBx, did not activate the SREBP-1a promoter (Fig. 5.2A). Since FASN is one of the target 
genes of SREBP-1a, we examined the effects of HBx subcellular localization mutants on FASN 
promoter activity using a FASN promoter luciferase reporter [163]. As shown in Fig. 5.2C, wild-
type HBx resulted in significantly higher FASN promoter activity in comparison to vector. 
Addition of an NLS further enhanced FASN promoter activation by HBx, whereas the NES-HBx 
could no longer activate the FASN promoter (Fig. 5.2C). To substantiate the promoter-reporter 
results, we determined the transcript levels of endogenous SREBP-1a and FASN. As shown in 
Fig. 5.2B and D, the effects of HBx in different subcellular compartments on endogenous 
SREBP-1a and FASN transcript levels were in agreement with those obtained from promoter-
reporter based assays (Fig. 5.2A and C). These results indicated that nucleus-localized HBx is 
more effective on the activation of SREBP-1a and FASN transcription. Since we previously 
showed that HBx activates SREBP-1a through transcriptional factor C/EBP [137] and others 
showed that HBx can enhance C/EBP activity through direct protein-protein interaction 
presumably in the nucleus [11], it is conceivable that the nuclear HBx is more readily for 
interacting with and activating C/EBP, which in turn increases SREBP-1a transcription. 
 
5.6.3 Nuclear HBx is more effective on enhancing intracellular lipid accumulation and cell 
proliferation 
 
 To determine the effects of HBx subcellular localization on intracellular lipid 
accumulation, we measured the amounts of neutral lipids. As expected, wild-type HBx 
expression was associated with significantly more neutral lipids than vector (Fig. 5.2E). Lipid 
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accumulation was further enhanced by the NLS-HBx or returned to baseline by the NES-HBx 
(Fig. 5.2E). Since increased lipogenesis and lipid accumulation have been recognized as one of 
the major factors driving cell proliferation [224], we also determined the effects of HBx and its 
mutants on cell proliferation by a standard MTT assay. As shown in Fig. 5.2F, cell proliferation 
was significantly increased by wild-type HBx in comparison to vector control. Once again, this 
effect was enhanced by a nuclear localization signal and dampened by a nuclear export signal 
(Fig. 5.2F). These results indicated that nucleus-localized HBx is more effective on stimulating 
lipid accumulation and cell proliferation, probably as a consequence of enhanced SREBP-1a and 
FASN activity. 
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Fig. 5.2. Nuclear HBx has a stronger effect on SREBP-1a and FASN transcription 
activation, intracellular lipid accumulation and cell proliferation than wild-type and 
cytoplasmic HBx. (A and C). Huh-7 cells were co-transfected with plasmids expressing WT, 
NES-, or NLS-HBx, or vector, together with an SREBP-1a promoter (A) or a FASN promoter (C) 
luciferase reporters. Luciferase assay was performed at 48 h after transfection and normalized 
against the protein concentration to determine the promoter activities. (B and D). Huh-7 cells 
were transfected with plasmids expressing WT, NES-, or NLS-HBx, or vector. At 16 h after 
transfection, the transcript levels of SREBP-1a (B) and FASN (D) were determined by reverse 
transcription real-time PCR. The levels of β-glucuronidase (GUSB) were also determined and 
used for normalization. (E and F). Huh-7 cells were transfected with plasmids expressing WT, 
NES-, or NLS-HBx, or vector. At 48 h after transfection, cells were subjected to either Oil Red O 
staining (E) or MTT assay (F). Statistical differences between samples were analyzed by 
Student's t test and demonstrated as * if p ≤ 0.05, or ** if p ≤ 0.01. All experiments were 
performed three times. 
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5.6.4 Nuclear HBx is more effective on up-regulating HBV mRNA 
 
 HBx also activates HBV enhancers and thus increases HBV replication [11,12]. To 
examine how HBx in different subcellular compartments regulates HBV enhancers, we co-
transfected Huh-7 cells with plasmids expressing HBx, NES-HBx, NLS-HBx, or empty vector, 
and luciferase reporters under the control of HBV enhancer I/X [11] or HBV enhancer II/CP 
[123,137]. As expected, we observed more than 1.5-fold activation of HBV enhancers I and II by 
the wild-type HBx (Fig. 5.3A and B). NES-HBx did not activate either enhancers (Fig. 5.3A and 
B). NLS-HBx increased HBV enhancer I activity more than 2-fold than baseline (Fig. 5.3A); 
although higher than the wild-type HBx, it just fell short of reaching statistical significance (p = 
0.052). NLS-HBx did not significantly increase HBV enhancer II/CP activity than vector or wild-
type HBx (Fig. 5.3B). These results indicated that while the cytoplasmic HBx does not activate 
HBV enhancers/promoters, nuclear HBx can increase HBV enhancer I/X activity, but has a 
marginal effect on HBV enhancer II/CP activity. It has been shown that nuclear HBx can no 
longer activate NF-κB [126]. Interestingly, HBV enhancer II has an NF-κB binding motif 
whereas HBV enhance I does not [225]. Therefore, it is possible that the differential effects of 
nuclear HBx on two HBV enhancers/promoters are due to its ability to activate NF-κB activity. 
However, the exact mechanisms warrant further investigation. It is worth mentioning that only 
nuclear, but not cytoplasmic, HBx can rescue HBx-deficient virus replication [129]. The 
demonstration of HBV enhancer I/X activation by NLS-HBx by our results may have provided a 
possible mechanistic explanation. 
To further understand the biological significance of the results we have so far, we 
determined the effect of HBx in different subcellular compartments on HBV mRNA levels in the 
context of HBV replication in a plasmid-based HBV replication system using a greater-than-unit-
length HBV genome plasmid. We used an HBV genome without expressing HBx, payw 1.2*7 
[219], which is a common approach to study the role of HBx in HBV replication [129,196]. Huh-
7 cells were co-transfected with plasmids expressing WT, NES-, or NLS-HBx, or vector, together 
with HBV genome plasmid payw 1.2*7. At 48 h after transfection, the level of HBVmRNA was 
determined. As shown in Fig. 5.3C, wild-type HBx significantly increased HBV mRNA level by 
more than two folds in comparison to vector. This is consistent with the enhancing role of HBx in 
HBV replication [226]. While cytoplasmic HBx had no effect on HBV mRNA level, nuclear 
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HBx increased HBV mRNA level by six folds, which was significantly higher than wild-type 
HBx (Fig. 5.3C). These results demonstrated that the nuclear HBx is more effective on enhancing 
HBV mRNA levels in the context of HBV replication than the wild-type HBx. While our results 
are in agreement with those from the Slagle's group [129], they are not consistent with the results 
from the Ryu's group [223]. The reason for this discrepancy is not clear, but it may be due to 
different cell lines and/or the assays used. This has been thoroughly discussed recently [226]. 
Although HBV infection and HBx expression are risk factors for developing 
hepatocellular carcinoma, the molecular mechanisms are not well understood. A hallmark of 
carcinogenesis is the abnormally high demand for lipid synthesis by cancer cells. Therefore, 
activation of SREBP-mediated lipogenic pathways have been recognized as a critical oncogenic 
mechanism [227]. Clinical studies have found HBx mutations conferring nuclear localization in 
cancerous tissues at a high frequency [228,229]. Our study demonstrated a stronger activation of 
the SREBP-1a mediated lipogenic pathway by the nuclear HBx. As such, our results may help 
understand the biological significance of these clinical findings. 
In summary, we have investigated the role of nuclear and cytoplasmic localization of HBx 
in modulating host lipogenic expression, lipid accumulation, cell proliferation, HBV regulatory 
elements, and HBV mRNA levels. Our results indicated that nucleus-localized HBx is more 
effective on activating SREBP-1a and FASN transcription, increasing intracellular lipid 
accumulation, and cell proliferation. While cytoplasm-localized HBx has no effect on HBV 
enhancer/promoter activities, nuclear localization plays an important role in enhancing HBV 
enhancer I/X promoter activity and HBV mRNA level by HBx. Our work sheds more light on the 
contribution of HBx to the pathogenesis and oncogenesis associated with HBV infection. 
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Fig. 5.3. The effect of HBx on HBV enhancer/promoter and HBV mRNA levels. Huh-7 cells 
were co-transfected with plasmids expressing WT, NES-, or NLS-HBx, or vector, together with 
luciferase reporters under the control of HBV enhancer I/X promoter (A) or HBV enhancer 
II/core promoter (B). Luciferase assay was performed at 48 h after transfection and normalized 
against the protein concentration to determine the HBV enhancer/promoter activities. (C). Huh-7 
cells were co-transfected with plasmids expressing WT, NES-, or NLS- HBx, or vector, together 
with a greater-than-unit-length HBV genome plasmid payw 1.2*7 (no HBx). At 48 h after 
transfection, the level of HBV mRNA was determined by reverse transcription real-time PCR. 
The level of β-glucuronidase (GUSB) was used for normalization. Statistical differences between 
samples, analyzed by Student's t test, were demonstrated as * if p ≤ 0.05, or ** if p ≤ 0.01. All 
experiments were performed three times.  
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6.0 DOMAIN OF HBX THAT REGULATES SREBP-1A AND HBV REPLICATION 
 
 In Chapter 3, we attempted to determine that HBx acts as a transcription factor which 
enhances the mature SREBP-1a protein level. In Chapter 5, we further demonstrated that nucleus-
localized HBx, in comparison to the wild-type and cytoplasm-localized HBx, has stronger effects 
on SREBP-1a and FASN transcription activation, intracellular lipid accumulation and cell 
proliferation. HBx is a small protein consisting of 154 amino acids. Truncated forms of HBx are 
often found in the tissues after HBV infection. Truncated forms of HBx play different roles in 
HBx stability and functions. In the following chapter we set to determine if different truncated 
forms of HBx differentially regulate SREBP-1a and HBV replication.  
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 All the experiments within this chapter were performed by Qi Wu. The manuscript was 
written by Qi Wu and edited by Qiang Liu. 
 
7.3 Abstract 
 
 As master transcription factors for lipogenesis, sterol regulatory element-binding protein-
1 (SREBP-1) has two isoforms, SREBP-1a and SREBP-1c. Hepatitis B virus X (HBx) can up-
regulate the transcription of both SREBP-1a and SREBP-1c. HBx is a small protein consisting of 
154 amino acids. Truncated forms of HBx, often found in the tissues after HBV infection, may 
have a role in the pathogenesis associated with HBV infection. In this study, we examined the 
effects of two HBx truncation mutants, HBx aa. 1-127 and HBx aa. 43-154, on the transcription 
of SREBP-1a and SREBP-1c. HBx 1-127 can up-regulate SREBP-1c, but not SREBP-1a 
transcription, whereas HBx 43-154 can activate SREBP-1a, but not SREBP-1c transcription. We 
further determined the activities of two HBV enhancers after the expression of the truncated HBx 
proteins. HBx 1-127 and HBx 43-154 can only up-regulate HBV enhancer I or HBV enhancer II, 
respectively. Knocking down SREBP-1 abrogates enhancer activation by HBx proteins, 
suggesting a role of SREBP-1. In addition, using HBV enhancer mutants, we found that the 
binding sequence for AP-1 on enhancer I is essential for its activation by HBx 1-127, whereas 
C/EBP and Sp1 sites are required for enhancer II activation by HBx 43-154. Finally, we showed 
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that both HBx 1-127 and HBx 43-154 can increase HBV transcription and HBV replication 
dependent upon SREBP-1 because knocking down SREBP-1 abrogates the up-regulation. 
Furthermore, upon ectopic expression of either SREBP-1a or SREBP-1c, we showed that 
SREBP-1a is involved in HBV transcription and replication up-regulation by HBx 43-154, 
whereas SREBP-1c is involved in HBV transcription and replication up-regulation by HBx 1-127. 
Our results should help understand the interactions between HBV and the SREBP-1-mediated 
lipogenic pathway. 
 
7.4 Main Text 
 
 Sterol regulatory element-binding proteins (SREBPs) are key regulators of lipogenic gene 
transcription [67,230,231]. In humans, two SREBP genes encoding three proteins have been 
identified. SREBP-1a and -1c are translated from alternative transcripts encoded by a single gene, 
whereas SREBP-2 has its own gene. The newly synthesized precursor SREBPs are bound to the 
ER forming a complex with SREBP-cleavage activating protein (SCAP) [193]. Upon stimulation, 
the precursor SREBP proteins are transported from ER to the Golgi apparatus by SCAP 
[232].Once in the Golgi, the N-terminal domain of SREBP is released after proteolytic digestions 
and transported to the nucleus. The mature SREBP (mSREBP) proteins are active transcription 
factors. SREBP-1a functions as a potent activator of all SREBP-responsive genes involved in 
fatty acid synthesis and cholesterol synthesis, while SREBP-1c only activates fatty acid synthesis 
but not cholesterol synthesis [69]. 
 Hepatitis B virus (HBV) X protein (HBx) is a multi-functional protein [225,226]. In 
comparison to non-tumor tissues, truncated forms of HBx are more commonly found in HBV-
associated tumor tissues, presumably after the integration of HBV genomic DNA into the host 
genome [130-132]. The pathobiological significance of this finding is not well understood. 
Several studies have demonstrated that the C-terminal region of HBx is essential for HBx 
stability [132-134]. In addition, the C-terminal region of HBx plays important roles in stimulating 
HBV replication by HBx in cell culture [12,133,135]. Deletion of 23 amino acids at its C-
terminal end of HBx abrogates its ability to activate NF-κB [133]. Amino acids 58-119 of HBx 
are required for activating the MAP kinase pathway [128]. 
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 HBV transcription is regulated by two viral enhancers and four promoters [225]. HBx 
protein has been shown to be able to activate both enhancers [11,12]. The regions of HBx for this 
function have not been mapped. From the pathobiological standpoint, the effects of truncated 
HBx proteins often expressed by the integrated HBV DNA on HBV enhancers are not well 
understood, although it has been suggested that HBV enhancers are kept intact upon integration 
[233]. As such, it is necessary to study the effects of truncated HBx on the activity of HBV 
enhancers. 
 Several studies including ours have reported that either full-length or truncated HBx 
proteins can activate the transcription of SREBP-1a and SREBP-1c [110,137,234]. To extend 
these findings, we demonstrated in this study that the N- and C-terminally truncated forms of 
HBx differentially modulate the transcription of SREBP-1a and SREBP-1c, the activities of two 
HBV enhancers, and HBV replication. 
 To determine how truncated forms of HBx regulate the transcription of SREBP-1a and 
SREBP-1c, we generated two truncated forms of HBx, aa. 1-127 and 43-154 with an N-terminal 
Flag-tag [135,235], using a plasmid expressing full-length HBx (aa. 1-154) [137]. Huh-7 and 
HepG2 cells were transfected with these plasmids using the calcium phosphate precipitation 
method [236]. The expression of HBx proteins was confirmed by Western blotting [163] with a 
Flag-specific antibody (Sigma-Aldrich) (Fig. 7.1A). As sample loading controls, the levels of β-
actin were also determined by a β-actin-specific antibody (Cell Signaling Technologies) (Fig. 
7.1A). IRDye 800 CW goat anti-mouse IgG and IRDye 680RD goat anti-rabbit IgG (Li-Cor 
Biosciences) were used as secondary antibodies. 
 To study the effects of HBx truncations on SREBP-1a and SREBP-1c transcription, we 
determined the transcript levels of SREBP-1a and -1c by quantitative real-time PCR as described 
[137,221]. The primers for the real-time PCR were SREBP-1a-FD (5' CGCTGCTGACCGACAT 
3'), SREBP-1c-FD (5' GCCATGGATTGCACTTT 3'), and SREBP-1a/1c-rev (5' 
CAAGAGAGGAGCTCAATG 3'). The level of a housekeeping gene β-glucuronidase (GUSB) 
amplified by GUSB-FD (5' GGTGCTGAGGATTGGCAGTG 3') and GUSB-rev (5' 
CGCACTTCCAACTTGAACAGG 3') was used for normalization. Results were analyzed for 
statistical differences by Student's t test. A p value of ≤ 0.05 was considered statistically 
significant. As shown in Fig. 7.1B and C, full-length HBx could up-regulate the transcript levels 
of both SREBP-1a and -1c, consistent with previously published results [110,137]. Deletion of 27 
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amino acids from the C-terminus, HBx 1-127, could no longer increase SREBP-1a transcription, 
but remained the ability to up-regulate SREBP-1c transcription (Fig. 7.1B and C). In contrast, 
deletion of the N-terminal 42 amino acid, HBx 43-154, demonstrated the opposite effects: it 
could up-regulate SREBP-1a transcription, but had no effect on SREBP-1c transcription (Fig. 
7.1B and C). These data demonstrate that HBx N- and C-terminal truncations exhibit differential 
effects on the transcription of SREBP-1a and -1c. 
SREBP-1a and -1c are two isoforms of SREBP-1 with overlapping and distinct functions. 
The activity of SREBP-1 proteins is conferred by the mature SREBP-1 (mSREBP-1) proteins in 
the nucleus. We therefore determined the levels of SREBP-1 and mSREBP-1 proteins after 
expressing HBx truncations. Because of the lack of isoform-specific antibodies, we could only 
determine the overall SREBP-1 levels. As shown in Fig. 7.2, both HBx 1-127 and 43-154 could 
increase the SREBP-1 and mSREBP-1 levels in total cell lysates in comparison to vector control. 
More importantly, both HBx truncations could increase mSREBP-1 in the nuclear fractions (Fig. 
7.2). As expected, wild-type HBx could up-regulate SREBP-1 and mSREBP-1 levels (Fig. 7.2). 
The nuclear fractions were prepared as described previously [137]. Antibodies for SREBP-1 
(Santa Cruz Biotechnology), β-actin, and fibrillin (Sigma-Aldrich) were used in Western blot 
analysis. These results demonstrate that both HBx N-and C-terminal truncations can increase the 
amounts of SREBP-1 and mSREBP-1. 
  
 65 
 
 
 
 
Fig. 7.1. Modulation of SREBP-1 transcripts by HBx truncations. Huh-7 and HepG2 cells 
were transfected with vector, plasmids expressing the full-length HBx 1-154, a C-terminally 
truncated (HBx 1-127) or a N-terminally truncated (HBx 43-154) mutants with an N-terminal 
Flag tag. (A). The expression of HBx proteins was analyzed by Western blotting using a Flag-
specific antibody at 48 h after transfection. The levels of β-actin were also determined by a β-
actin-specific antibody. This experiment was performed three times. (B and C). The transcript 
levels of SREBP-1a (B) or SREBP-1c (C) were determined by reverse transcription real-time 
PCR using gene-specific primers 16 h after transfection. The transcript level of β-glucuronidase 
was used for normalization. Statistical differences between samples were analyzed by the 
Student's t test and indicated as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, or NS = not 
significant. These experiments were performed three times. 
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Fig. 7.2. Modulation of SREBP-1 at the protein level by HBx truncations. Huh-7 and HepG2 
cells were transfected with vector, plasmids expressing the full-length HBx 1-154, or truncated 
HBx, HBx 1-127 and HBx 43-154. The protein levels of SREBP-1, mature SREBP-1 (mSREBP-
1) in total lysates or in the nuclear fractions were analyzed by Western blotting using an SREBP-
1-specific antibody at 48 h after transfection. The levels of β-actin or fibrillarin were also 
determined. Band intensities were analyzed by the Quantity One software (BioRad). The relative 
amounts of SREBP-1 or mSREBP-1 were calculated. This experiment was performed three times.  
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HBx activates HBV enhancers and thus increases HBV replication [11,12]. To examine 
how HBx truncations regulate HBV enhancers, we used HBV enhancer I/X promoter and HBV 
enhancer II/core promoter luciferase reporters and measured their activities after HBx expression 
in a luciferase reporter assay [137,237]. Luciferase levels were normalized to the protein 
concentration which was determined by the Bradford assay. The C-terminal truncation HBx 1-
127 could up-regulate HBV enhancer I, but not HBV enhancer II (Fig. 7.3Aand B). In contrast, 
the N-terminal truncation HBx 43-154 could increase the activity of HBV enhancer II, but not 
HBV enhancer I (Fig. 7.3A and B). Wild-type HBx could up-regulate both enhancers as expected 
(Fig. 7.3A and B). These results demonstrate that HBx 1-127 and 43-154 have differential effects 
on the activities of HBV enhancers. 
We previously showed that SREBP-1 is involved in HBV enhancer II activation by full-
length HBx [137]. To determine the role of SREBP-1 in HBV enhancer activation by truncated 
HBx proteins, we knocked down SREBP-1 by a miRNA [137] and measured HBV enhancer 
activities after HBx expression. As shown in Fig. 7.3A and B, knocking down SREBP-1 negated 
the activation of both HBV enhancers by HBx 1-127 and HBx 43-154. These results demonstrate 
that SREBP-1 is involved in HBV enhancer activation by the truncated HBx proteins. 
 The activities of HBV enhancers are regulated by numerous transcription factors [225]. 
To gain insights on which transcription factors are involved in HBV enhancer activation by HBx 
1-127 and 43-154, we generated two mutant HBV enhancer I constructs with the binding 
sequences of CREB (cAMP-response element-binding protein) and AP-1 mutated [238,239], as 
well as three HBV enhancer II mutants without the binding sequences for FXR (farnesoid X 
receptor) [202], C/EBP (CCAAT/enhancer-binding protein) [240], or Sp1 [241]. While HBx 1-
154 and HBx 1-127 could still activate HBV enhancer I without the CREB binding sequence, 
albeit to a lower level than wild-type enhancer I, removal of the AP-1 site completely abolished 
HBV enhancer I activation by HBx proteins (Fig. 7.3C). These results suggest that the binding 
sequence for AP-1 is essential for HBV enhancer I activation by HBx 1-127. 
 Regarding HBV enhancer II, HBx and HBx 43-154 could increase the enhancer activity 
without the FXRE sequence (Fig. 7.3D), suggesting the nuclear receptor farnesoid X receptor 
was not essential. While removal of the C/EBP and the Sp1 binding sites reduced the activation 
of HBV enhancer II by full-length HBx, it completely negated HBV enhancer II up-regulation by 
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HBx 43-154 (Fig. 7.3D). These results suggest that C/EBP and Sp1 binding sequences are 
essential for HBV enhancer II up-regulation by HBx 43-154. 
 We next investigated the effects of HBx truncations on HBV transcription in HepG2 cells. 
We used plasmids containing a greater-than-unit-length HBV genomic DNA, wild-type (payw1.2) 
or a mutant without expressing HBx (payw1.2*7), with HBV endogenous regulatory elements 
[219]. Because we wanted to study the role of SREBP-1 in HBV transcription regulation by HBx, 
the effects of SREBP-1 knocking down and over-expression on HBV transcription were 
investigated. HBV transcription was determined by reverse transcription real-time PCR using 
HBV-specific primers HBV-FD (5' AGAAACAACACATAGCGCCTCAT 3') and HBV-rev (5' 
TGCCCCATGCTGTAGATCTTG 3') targeting the 3.5-kb pregenomic mRNA as previously 
described [196,237]. As shown in Fig. 7.4A and C, knocking down SREBP-1 by miRNA 
significantly reduced HBV transcript level in comparison to control miRNA, whereas expression 
of mSREBP-1a and mSREBP-1c significantly increased HBV mRNA levels. A Flag-tagged 
mSREBP-1a (aa. 1-517)-expressing plasmid was described previously [137] and a Flag-tagged 
mSREBP-1c (aa. 1-487) was amplified by PCR from the SREBP-1c cDNA (OriGene 
Technologies) and cloned into the pCMV2 Flag vector (Sigma-Aldrich). The expression of 
mSREBP-1a and mSREBP-1c proteins was confirmed in Western blotting using a Flag-specific 
antibody (Fig. 7.4E). These results suggest a role of both SREBP-1a and SREBP-1c in regulating 
HBV transcription. 
 To study the effects of HBx truncations on HBV transcription, we used a greater-than-
unit-length HBV genomic DNA without expressing HBx (payw1.2*7) and determined HBV 
transcript levels after HBx expression. We found that both HBx 1-127 and HBx 43-154 could 
increase the HBV transcript level, which was abrogated after knocking down SREBP-1 (Fig. 
7.4B). These results demonstrate that HBx truncations up-regulate HBV transcription in an 
SREBP-1-dependent manner. 
 To specifically investigate the roles of SREBP-1a and SREBP-1c in HBV transcription 
up-regulation by HBx truncations, we determined HBV mRNA levels after the expression of 
mSREBP-1a or mSREBP-1c. As shown in Fig. 7.4D, HBV mRNA levels were further increased 
by HBx in combination with either mSREBP-1a or mSREBP-1c expression, suggesting that the 
full-length HBx can up-regulate HBV transcription through both SREBP-1a and SREBP-1c. In 
contrast, the enhancement was only observed after mSREBP-1c expression for HBx 1-127 or 
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after mSREBP-1a expression for HBx 43-154 (Fig. 7.4B). These results demonstrate that both 
SREBP-1a and SREBP-1c are involved in HBV transcription up-regulation by the full-length 
HBx, but they have differential effects on HBV transcription up-regulation by the truncated HBx 
proteins.  
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Fig. 7.3. Modulation of HBV enhancers by HBx truncations. Huh-7 and HepG2 cells were 
transfected with vector, plasmids expressing HBx 1-154, HBx 1-127, or HBx 43-154. (A and B). 
Cells were co-transfected with control or SREBP-1 miRNA, HBV enhancer I/X promoter (A) or 
HBV enhancer II/core promoter (B) luciferase reporters. (C and D).Cells were co-transfected 
with wild-type HBV enhancer I/X promoter or mutant promoters indicated (C) or wild-type HBV 
enhancer II/core promoter or mutant promoters indicated (D). At 48 h after transfection, 
luciferase activities were determined and normalized against the protein concentrations. 
Statistical differences between samples were analyzed by the Student's t test and indicated as * = 
p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, or NS = not significant. All experiments were performed 
three times. 
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Fig. 7.4. Up-regulation of HBV transcription by HBx truncations dependent on SREBP-1. 
(A and C). HepG2 cells were co-transfected with an HBV genome plasmid pawy1.2, control or 
SREBP-1 miRNA (A), or vector, plasmids expressing mSREBP-1a or mSREBP-1c (C). (B and 
D). HepG2 cells were co-transfected with an HBV genome plasmid pawy1.2*7 (no HBx), vector 
or HBx-expressing plasmids, control or SREBP-1 miRNA (B), or vector, plasmids expressing 
mSREBP-1a or mSREBP-1c (D). At 48 h after transfection, HBV mRNA levels were determined 
by reverse transcription real-time PCR using HBV-specific primers. The transcript level of β-
glucuronidase was used for normalization. Statistical differences between samples were analyzed 
by the Student's t test and indicated as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, or NS = not 
significant. These experiments were performed three times. (E). Expression of mSREBP-1a and 
mSREBP-1c with a Flag-tag was analyzed by Western blotting with a Flag-specific antibody at 
48 h after transfection. The levels of β-actin were also determined. This experiment was 
performed three times. 
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Finally, we studied the effects of HBx proteins on HBV replication in HepG2 cells. 
Capsid-associated HBV DNA was extracted and the HBV DNA copy number determined as per 
a published protocol [135]. As shown in Fig. 7.5A, expression of full-length HBx, HBx 1-127, 
and HBx 43-154 could significantly increase the HBV DNA levels. Knocking down SREBP-1 
negated the up-regulation. These results suggest that HBx 1-127 and 43-154 retain the ability to 
up-regulate HBV replication, dependent on SREBP-1. 
 To further study the roles of two isoforms of SREBP-1 in HBV replication modulation by 
HBx, we once again expressed mSREBP-1a and mSREBP-1c. As shown in Fig. 7.5B, HBV 
DNA levels were further increased by full-length HBx in combination with either mSREBP-1a or 
mSREBP-1c expression, whereas this effect could only be observed for the combination of HBx 
1-127 and mSREBP-1c or HBx 43-154 and mSREBP-1a. These results demonstrate that SREBP-
1a and SREBP-1c are differentially involved in HBV replication up-regulation by the truncated 
HBx proteins. 
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Fig. 7.5. Up-regulation of HBV replication by HBx truncations dependent on SREBP-1. 
HepG2 cells were co-transfected with an HBV genome plasmid pawy1.2*7 (no HBx), control or 
SREBP-1 miRNA (A), or vector, plasmids expressing mSREBP-1a ormSREBP-1c (B). At 48 h 
after transfection, capsid-associated HBV DNA was purified and its copy number determined by 
real-time PCR using HBV-specific primers. Statistical differences between samples were 
analyzed by the Student's t test and indicated as * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, or 
NS = not significant. These experiments were performed three times. 
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HBx plays an important role in the HBV life cycle and HBV pathogenesis [226]. 
Although different truncated forms of HBx have been consistently found in the tissues with 
chronic HBV infections [131,132,229,235,242,243], the pathobiological significance is poorly 
characterized. The worst outcome of chronic HBV infection is hepatocellular carcinoma and the 
abnormal lipogenesis mediated by SREBP-1 is believed to be a critical risk factor for 
carcinogenesis [18]. Therefore, understanding the modulation of SREBP-1 by HBx should have 
broad implications. It has been shown that HBx can up-regulate SREBP-1a and SREBP-1c 
transcription [110,137]. The results presented here further demonstrate that a C-terminally 
truncated HBx (HBx 1-127) can only up-regulate SREBP-1c transcription, while an N-terminally 
truncated HBx (HBx 43-154) can only up-regulate SREBP-1a transcription. Our previous work 
has identified that the transcriptional factors C/EBPα and E4BP4 are involved in SREBP-1a 
transcription modulation by HBx [137]. How HBx regulates SREBP-1c transcription has not 
been thoroughly studied. Because HBx can activate the activity of a nuclear receptor LXRα [110] 
and the SREBP-1c promoter contains the binding motif for LXRα [166], it is possible that HBx 
up-regulates SREBP-1c transcription through LXRα. Future studies should formally test this 
hypothesis and also investigate whether HBx truncation mutants retain the same mechanisms as 
the full-length HBx in modulating SREBP-1 transcription. 
Activation of HBV enhancers is another important function of HBx. Our data showed that 
HBx 1-127 and HBx 43-154 can only respectively up-regulate either HBV enhancer I or 
enhancer II, dependent upon SREBP-1. We further showed that the binding sequences for AP-1, 
C/EBP, and Sp1 are involved in this process. In addition, we showed that HBx 1-127 and HBx 
43-154 can up-regulate HBV transcription and replication. SREBP-1a can further enhance the 
activation by HBx 43-154 whereas SREBP-1c can do so for HBx 1-127. 
Our study and those of others have suggested an important role of SREBP-1 in the 
functions of HBx and the HBV life cycle. The functions of SREBP-1 are exerted by the 
processed and mature form in the nucleus. The two isoforms, SREBP-1a and SREBP-1c, have 
common and unique functions through regulating shared or isoform-specific effector genes 
[68,244,245]. It will be interesting to determine the effector genes that are differentially 
modulated by the two HBx truncated mutants and understand their roles in HBV life cycle and 
pathogenesis. 
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In conclusion, we demonstrated that the N- and C-terminally truncated forms of HBx can 
differentially modulate SREBP-1a and SREBP-1c transcription, HBV enhancer I and HBV 
enhancer II activities. Furthermore, these two HBx mutants can activate HBV transcription and 
replication with SREBP-1a and SREBP-1c being differentially involved. Our research advances 
our understanding on the complex interactions between HBV and SREBP-1. 
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8.0 THE ROLE OF PTEN IN HCV INFECTION 
 
 Data presented in Chapter 3 to 7 establishes that HBx enhances the activities of SREBP-
1a and SREBP-1c which are involved in the up-regulation of HBV enhancers and thus 
contributes to HBV replication. In the following chapter, we will determine the mechanisms of 
how HCV infection regulates PTEN and how PTEN regulates HCV life cycle. Our lab has 
previously established that HCV core activates SREBP-1 and FASN through the PI3K/Akt 
pathway. PTEN is a suppressor of the PI3K/Akt pathway. Previous studies have been reported 
that HCV infection inhibits PTEN. Both HCV core and NS5A proteins can drive a feedback loop 
of NF-κB/PTEN/Akt which results in decreasing the PTEN protein level and contributes to HCC 
development. However, the mechanisms of how PTEN affects HCV infection needs to be further 
studied. 
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9.2 Abstract 
 
Hepatitis C virus (HCV) infection leads to severe liver diseases including hepatocellular 
carcinoma (HCC). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a tumor 
suppressor, is frequently mutated or deleted in HCC tumors. In this study, we determined the 
effects of PTEN on the HCV life cycle. We showed that PTEN inhibits HCV entry through its 
lipid phosphatase activity. PTEN has no effect on HCV RNA translation. PTEN decreases HCV 
replication and secretion and the protein phosphatase activity of PTEN is essential for this 
function. PTEN interacts with HCV core protein. HCV core aa. R50 in domain I and PTEN aa. 1-
186 are essential for the interaction. PTEN no longer inhibits HCV replication in the absence of 
the interaction with the core protein. The interaction between PTEN and HCV core reduces 
PTEN levels which in turn regulates HCV replication. HCV core domain I protein increases the 
lipid phosphatase activity of PTEN in an in vitro assay, suggesting that HCV infection can also 
regulate PTEN. Taken together, our results demonstrated an important regulatory role of PTEN in 
the HCV life cycle. 
 
9.3 Introduction 
 
More than 185 million people are estimated to be infected by hepatitis C virus (HCV) 
worldwide [246]. HCV infection leads to severe liver diseases such as steatosis, cirrhosis and 
hepatocellular carcinoma (HCC). HCV is an enveloped positive-sense single-stranded RNA virus 
in the Flaviviridae family [247]. HCV has a genome of about 9,600 nucleotides, consisting of 
two untranslated regions (UTRs) at both ends of the genome and a large open reading frame. 
HCV life cycle begins with entry into the target cells through numerous cellular receptors. Then 
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the HCV genomic RNA is translated into a polyprotein through an internal ribosomal entry site 
(IRES) within the 5'-UTR [248]. The polyprotein is processed by cellular and viral proteases to 
generate structural and non-structural proteins. The endoplasmic reticulum membrane is modified 
by viral and cellular factors to generate a membranous web that is the major site of viral RNA 
replication. The newly synthesized RNAs are packaged into nucleocapsids. Viral particle 
maturation and secretion are achieved after envelope acquisition. HCV core is a structural protein 
that forms the viral nucleocapsid. In addition, HCV core has regulatory functions in cell signaling 
and lipid metabolism [249]. It has been reported that HCV core is associated with the 
development of HCC in a transgenic mouse model [143]. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a phosphatase 
which contains both lipid and protein phosphatase activities. PTEN contains a short N-terminal 
PtdIns(4,5)P2-binding domain (PBD) (aa. 1-6), a phosphatase domain (aa. 7-185), a C2 domain 
(aa. 186-351), and a C-terminal tail containing PEST (Pro, Glu, Ser, Thr) sequences (aa. 352-401) 
and a postsynaptic-density protein of 95 kDa, discs large, PDZ domain-interaction motif (aa. 401-
403) [45,250]. PTEN acts as a tumor suppressor by down-regulating the phosphatidylinositol 3-
kinase (PI3K)/Akt signaling pathway, one of the most critical cancer-promoting pathways [45]. 
PTEN is frequently mutated or deleted in tumors including HCC [45,49]. Two naturally 
occurring mutations in the phosphatase domain disrupt the phosphatase activities of PTEN: 
C124S mutation abrogates both lipid and protein phosphatase activities; and G129E mutation 
abrogates lipid phosphatase activity only. The Y138L mutation, identified in 2010, abrogates 
protein phosphatase activity only [50]. Of note, the human hepatoma cell line Huh-7 that is 
widely used in HCV research contains a functional PTEN [251,252].   
It has been reported that HCV activates the PI3K/Akt pathway with the involvement of 
core, NS4B, and NS5A proteins [161,164,253,254]. Consequently, the PI3K/Akt pathway 
enhances HCV entry, translation, and replication [255-258]. However, the possible influence of 
PTEN on the HCV life cycle has not been well characterized. A very early study showed that 
HCV infection increases PTEN phosphorylation with no effect on the total PTEN level [160]. In 
contrast, the Kumar group showed that HCV infection is associated with less nuclear PTEN 
which favors HCV replication [158]. Additional studies demonstrated that HCV core and NS5A 
proteins can down-regulate PTEN protein levels [147,149,156,259]. As for the effects of PTEN 
on HCV, PTEN has been shown to down-regulate HCV secretion with no effect on HCV RNA 
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replication [259]. Together, the exact role of PTEN in HCV life cycle is not clear and requires 
further investigation.  
In this study, we showed that PTEN inhibits HCV entry, replication and secretion, but has 
no effect on HCV RNA translation. HCV core protein interacts with PTEN through domain I. 
The interaction between HCV core and PTEN decreases the level of PTEN and likely contributes 
to HCV replication inhibition by PTEN. The presence of HCV core domain I protein enhances 
the lipid phosphatase activity of PTEN, suggesting mutual regulatory processes. These results 
demonstrated a broad regulatory role of PTEN in the HCV life cycle.  
 
9.4 Materials and Methods 
 
9.4.1 Plasmid constructs and in vitro transcription 
  
 Plasmids for generating lentiviral particles, pMD2.G, psPAX2, pCMV-HCV-2a J6 core-
E1-E2, and pTRIP-CMV-Luc-puro, were described previously [164,221]. The pGIPZ lentiviral 
plasmid expressing PTEN-specific shRNA with the target sequence 5' 
GAGACAGACTGATGTGTAT 3' located in the 3'-UTR of PTEN mRNA and non-silencing 
control shRNA were purchased from Open Biosystems. Inducible PTEN shRNA was constructed 
by transferring the shRNA sequence into a Tet-On pTRIPZ lentiviral vector (Open Biosystems). 
Plasmid expressing PTEN with an N-terminal Flag-tag, pCMV5 Flag-Human PTEN, was 
received from Dr. Jack Dixon [260] and used to generate plasmids expressing truncations and 
point mutations of PTEN: aa. 1-185, aa. 186-403, C124S, G129E, Y138L [259]. We also 
constructed PTEN-expressing plasmids with a 3xFlag-tag or GST fusion in the pEF-cyto-myc 
vector for use in some experiments. To allow the expression of the PTEN protein from the wild-
type and shRNA-sensitive transcript, the 3'-UTR sequence of the PTEN mRNA, 1000 bps in 
length, was amplified by reverse transcription - PCR using RNA extracted from Huh-7 cells and 
cloned 3' to the coding sequence of PTEN, generating plasmid PTEN-3'-UTR WT. The target 
sequence of the shRNA was then removed from the 3'-UTR by site-directed mutagenesis, 
resulting in a shRNA-resistant PTEN-expressing plasmid PTEN-3'-UTR Mut. The wild-type and 
mutant 3'-UTR sequences were also cloned into the RNA interference vector psiCHECK-2, a gift 
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from Dr. Robert Blelloch (Addgene plasmid # 31882) [261]. Plasmids expressing GST-PTEN 
fusion proteins in the pGEX-6P-1 vector were described previously [262]. Plasmid pFLneo-
J6/JFH-1 (p7-rLuc-2A) containing the full-length HCV-2a J6/JFH-1 genomic sequence with an 
internal renilla luciferase reporter gene and plasmid pFLneo-J6/JFH-1 (p7-rLuc-2A) GNN, the 
replication-deficient version, were obtained from Dr. Charles Rice [263]. Plasmid HCV-2a J6 
core-Flag/JFH-1 (p7-rLuc-2A) was constructed by insertion of a Flag-tag between the amino 
acids S2 and T3 of the core protein as previously described [264]. Plasmid HCV-2a J6 core-
R50A Flag/JFH-1 (p7-rLuc-2A) contains the R50A mutation [264]. A subgenomic replicon 
plasmid pSGR-rLuc-Neo-HCV-2a JFH-1 NS3-5B with rLuc reporter was constructed as 
previously described [265]. A monocistronic HCV RNA translation reporter pT7 HCV-2a JFH-1 
5'-UTR-core
aa1-16
-Luc2-NS5B
5
-3'-UTR was constructed as described [51,257,266] using the JFH-
1 sequence from the plasmid pHCV-2a JFH-1_pUC provided by Dr. Takaji Wakita [267]. To 
generate a plasmid expressing HCV core protein, the core coding sequence was amplified by 
PCR using the plasmid pFLneo-J6/JFH-1 (p7-rLuc-2A) as template and cloned into the pEF 
vector. Plasmids expressing the individual domains (as EGFP fusions), truncations, or point 
mutations of HCV core were constructed. To allow protein expression in E. coli, the coding 
sequences for HCV core, full-length or domain I with or without R50A mutation, were cloned 
into the pT7 His6-SUMO vector (Lucigen). BFP (blue fluorescent protein)-expressing plasmid in 
the pT7 His6-SUMO vector was described previously [268]. All plasmids were constructed using 
standard methods and confirmed by DNA sequencing. HCV genomic RNAs and translation 
reporter RNAs were generated by in vitro transcription using the MEGAscript T7 In Vitro 
Transcription reagents (Ambion). 
 
9.4.2 Cell culture, transfection, and generation of stable cell lines 
 
Huh-7 cells, Huh-7.5 cells and 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% (v/v) fetal bovine serum (FBS). Cells were transfected with plasmid 
DNA or HCV RNA using the calcium phosphate precipitation method [163]
 
or the DMRIE-C 
reagent (Thermo Fisher Scientific), respectively. For establishing HCV replicating cells, Huh-7 
cells were transfected with HCV RNA and selected by G418 (Enzo Life Sciences) [164].  
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9.4.3 Luciferase and MTT assays  
 
For luciferase assay, cells were lysed in Passive Lysis Buffer (Promega) and the firefly or 
renilla luciferase activities were measured by Luciferase Assay reagents (Promega) in a TD 20/20 
Luminometer (Turner Designs). Firefly or renilla luciferase levels were normalized to the protein 
concentrations determined by the Bradford assay (Bio-Rad Laboratories). Cell viability MTT 
assay was performed as previously described [266]. These assays were performed at least three 
times and the results analyzed for statistical differences by the Student's t test. A p value of ≤ 0.05 
was considered statistically significant. 
 
9.4.4 Real-time reverse transcription-polymerase chain reaction (RT-PCR)  
 
Real-time RT-PCR was performed as previously described [137]. RNA was isolated from 
cells with TriZol (Thermo Fisher Scientific) followed by DNase I (Thermo Fisher Scientific) 
digestion. Reverse transcription was carried out by Superscript II (Thermo Fisher Scientific) and 
random priming. HCV RNA levels were determined by real-time RT-PCR using HCV-specific 
primers HCV-FD (5' AGAGCCATAGTGGTCTGCGGAAC 3') and HCV-rev (5' 
CCTTTCGCAACCCAACGCTACTC 3') [269]. The transcript levels of GUSB, a house keeping 
gene, were used for normalization [137]. Each sample was quantified in triplicates. Relative 
changes in RNA levels were analyzed by the 2
-∆∆ct
 method using the iQ5 program (Bio-Rad 
Laboratories). 
 
9.4.5 HCV entry, replication, translation and secretion assays 
 
HCV entry was determined using HCV lentiviral pseudoparticles carrying the luciferase 
reporter gene (HCVpp-Luc) as previously described [221]. The replication of HCV-2a J6/JFH-1 
(p7-rLuc-2A) RNA in Huh-7 cells harboring HCV replicating RNA or after infection with the 
HCV-2a J6/JFH-1 (p7-rLuc-2A) virus was analyzed by determining the renilla luciferase activity 
by luciferase assay or HCV RNA levels by real-time PCR. HCV-2a J6/JFH-1 (p7-rLuc-2A) virus 
was collected from the supernatant of Huh-7 cells harboring HCV-2a J6/JFH-1 genomic RNA 
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and titrated by focus forming assay as described [263]. HCV RNA translation assay was 
performed as previously described [258]. To determine the effects of PTEN on HCV secretion, 
Huh-7 cells with HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were transfected with 
plasmids expressing PTEN, wild-type or phosphatase mutants. At 48 hours after transfection, 
intracellular HCV RNA levels were determined by luciferase assay and recorded as “donor 
levels”. At the same time, virus-containing supernatants were collected and used for infecting 
native Huh-7.5 cells. At 72 hours after infection, luciferase assay was preformed to determine the 
levels of HCV RNA and normalized against the corresponding “donor” levels.   
 
9.4.6 GST pull-down, co-immunoprecipitation (co-IP), and Western blotting  
 
GST pull-down assay was performed using cell lysates in radioimmunoprecipitation assay 
(RIPA) buffer and Glutathione Sepharose 4B (GE Healthcare) according to a standard protocol 
[262]. For Flag co-IP experiments, cells were harvested by RIPA buffer and incubated with an 
anti-Flag (Sigma-Aldrich) antibody at 4 ℃ overnight and then incubated with Protein G 
Sepharose (GE Healthcare) at 4 ℃ for 4 hours. The mixtures were centrifuged at 10,000 rpm for 
10 minutes and the supernatants removed. The pellets were resuspended in a lysis buffer 
containing SDS and boiled for 10 minutes to elute the proteins. For Western blotting, proteins 
were subjected to SDS-PAGE and then blotted onto nitrocellulose membranes. The membranes 
were blocked in 5% skim milk in PBS and incubated with a primary antibody overnight at 4 ℃. 
Membranes were washed and incubated with a secondary antibody for 1 hour at room 
temperature. After a wash with PBST (PBS+0.1% Tween 20), membranes were scanned using 
Li-Cor Odyssey scanner (ODY-CLx) and band intensities were determined by the Quantity One 
software (Bio-Rad Laboratories). The antibodies used were: HCV core (Anogen), GST (Cell 
Signaling Technology, CST), PTEN (CST), β-actin (CST), Flag (Sigma-Aldrich), His6-tag 
(Roche), and secondary antibodies IRDye 800CW goat anti-mouse IgG and IRDye 680RD goat 
anti-rabbit IgG (Li-Cor Biosciences).   
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9.4.7 Purification of recombinant proteins  
 
Expression of recombinant proteins in E. coli was induced by IPTG (Thermo Fisher 
Scientific). GST-PTEN fusion proteins were purified by Glutathione Sepharose 4B (GE 
Healthcare). For use in PTEN phosphatase assay, the PTEN protein was cleaved from GST using 
the PreScission protease (GE Healthcare) as previously described [270]. His6-tagged HCV core 
and PTEN proteins were purified by Ni-NTA agarose (Qiagen).  
 
9.4.8 PTEN lipid phosphatase activity assay  
 
The lipid phosphatase activity of PTEN in the presence of HCV core domain I protein 
was measured using the PTEN Activity ELISA kit (Echelon Biosciences) according to 
manufacturer’s instructions. Briefly, 20 nM of PTEN was incubated with 0 - 2.852 µM of HCV 
core domain I proteins, wild-type or R50A mutant, at 37 °C for 5 minutes prior to the addition of 
16 µM of the PtdIns(3,4,5)P3 substrate at 37°C for 1 hour. Activity was detected using a 
SpectraMax M5 spectrophotometer (Molecular Devices) at 450 nm and presented as the 
percentage increases in the presence of HCV core domain I proteins compared to PTEN alone.  
 
9.5 Results 
 
9.5.1 PTEN negatively regulates HCV RNA levels after HCV infection 
 
Although the mutual interactions between the PI3K/Akt pathway and HCV are well 
documented, the effect of PTEN, a negative regulator of the PI3K/Akt pathway, on HCV is less 
clear [161,164,253-258]. We therefore started off by determining the effect of PTEN on HCV 
RNA levels after HCV infection. As shown in Fig. 9.1A, overexpression of full-length PTEN, or 
the aa. 1-185 fragment, but not aa. 186-403, significantly reduced HCV RNA levels. Because the 
aa. 1-185 fragment contains the phosphatase domain of PTEN, these data indicate that the 
phosphatase activities are required for inhibiting HCV RNA accumulation after infection. To test 
this idea, we used three phosphatase-deficient mutants. The lipid phosphatase deficient G129E 
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mutant behaved the same as wild-type, whereas the protein phosphatase deficient Y138L and the 
lipid and protein phosphatase deficient C124S mutants had no effect (Fig. 9.1A). The expression 
of wild-type or mutant PTEN proteins, demonstrated by Western blotting (Fig. 9.1B), had no 
effects on cell viability as measured by MTT assay (Fig. 9.1C).    
To confirm the inhibitory effects of PTEN on HCV, we wanted to determine whether 
decreasing PTEN enhances HCV RNA levels. We used an inducible shRNA targeting the 3'-UTR 
of PTEN to achieve PTEN knockdown. We first determined the efficiency and specificity of the 
PTEN shRNA using a bicistronic RNA interference reporter system.  As shown in Fig. 9.1F, 
PTEN shRNA significantly decreased the luciferase activity linked to wild-type PTEN-3'-UTR in 
comparison to non-silencing control shRNA, indicating an effective knockdown. In contrast, 
PTEN shRNA did not affect the luciferase activity linked to a mutant PTEN-3'-UTR without the 
target sequence of the shRNA. These data indicate that the shRNA can effectively and 
specifically reduce PTEN levels. We then generated Huh-7.5 cells that express the PTEN shRNA 
or non-silencing control shRNA upon induction with Doxycycline.  
Expression of PTEN shRNA resulted in significantly higher HCV RNA level after HCV 
infection than control shRNA (Fig. 9.1D, compare Vector transfection in Ctrl and PTEN shRNA 
cells). To demonstrate whether the altered HCV RNA level detected was specifically due to 
changes in PTEN levels, the inducible knockdown cell lines were transfected with increasing 
amounts of plasmids expressing PTEN-3'-UTR WT, or shRNA resistant PTEN-3'-UTR Mut. As 
shown in Fig. 9.1D, increasing the levels of PTEN protein after PTEN-3'-UTR WT or PTEN-3'-
UTR Mut transfection in Ctrl shRNA cells was associated with decreasing HCV RNA levels. In 
contrast, increasing the levels of PTEN protein after PTEN-3'-UTR WT transfection in PTEN 
shRNA cells had no effect, whereas transfection with PTEN-3'-UTR Mut in PTEN shRNA cells 
decreased HCV RNA levels in a dose-dependent manner (Fig. 9.1D). The overall PTEN levels in 
these cells were determined by Western blotting using a PTEN-specific antibody (Fig. 9.1D). 
Knocking down PTEN had no effects on cell viability (Fig. 9.1E). Taken together, these data 
indicate that PTEN decreases HCV RNA levels after HCV infection dose-dependently.  
Because the HCV RNA levels measured may represent the combined effects of PTEN on 
HCV entry, replication, and translation, it is therefore necessary to study the effect of PTEN on 
each of these steps in HCV life cycle.       
 87 
 
 
  
 88 
 
Fig. 9.1. PTEN protein phosphatase activity is required for decreasing HCV RNA level 
after HCV infection. (A) Huh-7.5 cells were transfected with plasmids expressing wild-type 
Flag-PTEN (PTEN WT), truncated mutants, phosphatase deficient mutants, or empty vector. 
Forty eight hours after transfection, cells were infected with HCV-2a J6/JFH-1 (p7-rLuc-2A) 
virus at a multiplicity of infection (MOI) of 1. Seventy two hours post-infection (hpi), luciferase 
assay was performed using the cell lysates. This experiment was performed in triplicate. (B). The 
protein levels of PTEN proteins and β-actin after transfection were determined by Western 
blotting using anti-Flag and anti-β-actin antibodies, respectively. (C). Cell viability was 
determined by MTT assay 72 hpi. This experiment was performed in triplicate. (D). Huh-7.5 cells 
expressing an inducible PTEN shRNA or non-silencing control shRNA were treated with 1 
μg/mL of Doxycycline for 48 hours. Cells were then infected with HCV-2a J6/JFH-1 (p7-rLuc-
2A) virus at an MOI of 1. At 24 hpi, cells were transfected with increasing amounts of plasmids 
expressing Flag-tagged PTEN with wild-type or mutant 3'-UTR, or empty vector. Luciferase 
assay was performed 48 hours after transfection (left panel). In the right panel, the protein levels 
of PTEN and β-actin at 36 hours after transfection were determined by Western blotting using 
anti-PTEN and anti-β-actin antibodies, respectively. Relative PTEN band intensities against β-
actin were given underneath each sample. This experiment was performed in duplicate. (E). Cell 
viability was determined by MTT assay in parallel with luciferase assay. This experiment was 
performed in duplicate. (F). Huh-7 cells were co-transfected with plasmids expressing non-
silencing control shRNA or shRNA targeting the 3'-UTR of PTEN, together with bicistronic 
RNA interference reporter plasmids with (PTEN-3'-UTR wt) or without (PTEN-3'-UTR mut) the 
shRNA target sequence. Dual luciferase assay was performed 48 hours after transfection. The 
renilla luciferase (rLuc) activity representing the knockdown efficiency was normalized against 
firefly luciferase activity driven by a constitutive promoter on the reporter plasmid. Luciferase 
activities were expressed as fold changes relative to vector control. The statistical differences 
between samples were demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, or NS for not significant. 
This experiment was performed in triplicate.   
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9.5.2 PTEN lipid phosphatase activity inhibits HCV entry  
 
HCV entry is the first step in the HCV life cycle. To study the effect of PTEN on HCV 
entry, we used the HCVpp approach. As shown in Fig. 9.2A, overexpression of full-length PTEN 
(PTEN WT) and the aa. 1-185 fragment significantly inhibited HCVpp entry, whereas aa. 186-
403 had no effect, suggesting a role of the phosphatase activities in this process. To test this, we 
once again used three phosphatase-deficient mutants. The protein phosphatase deficient Y138L 
mutant inhibited HCVpp entry as effectively as the wild-type PTEN, whereas the lipid 
phosphatase deficient G129E and the lipid and protein phosphatase deficient C124S mutants had 
no effect on HCV entry (Fig. 9.2A). These data collectively indicate that PTEN lipid phosphatase 
but not protein phosphatase activity is required for the inhibition of HCV entry. The expression 
of wild-type or mutant PTEN proteins was demonstrated by Western blotting (Fig. 9.2B). 
To further determine the effect of PTEN on HCV entry, we measured HCV entry after 
knocking down PTEN levels. We also determined whether the observed effects were indeed due 
to PTEN, and not an off-target effect of the shRNA used. To this end, inducible PTEN 
knockdown and non-silencing control Huh-7.5 cells were transfected with vector, or plasmids 
expressing PTEN cDNA linked to wild-type 3'-UTR or mutant 3'-UTR without the shRNA target 
sequence. After induction with Doxycycline, cells were infected with HCVpp-Luc. As shown in 
Fig. 9.2C, knocking down endogenous PTEN by shRNA significantly enhanced HCV entry 
(compare HCV entry after Vector transfection in Ctrl and PTEN shRNA cells). Overexpression 
of wild-type PTEN in Ctrl shRNA cells significantly decreased HCV entry, but exhibited no 
inhibitory effect in PTEN shRNA cells. More importantly, expression of PTEN which could not 
be knocked down by shRNA significantly inhibited HCV entry in PTEN shRNA-expressing cells. 
The overall PTEN levels in these cells were determined by Western blotting using a PTEN-
specific antibody (Fig. 9.2D). Taken together, these data indicate an inverse relationship between 
PTEN levels and HCV entry. 
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Fig. 9.2. PTEN inhibits HCV entry through its lipid phosphatase activity. (A). Huh-7.5 cells 
were transfected with plasmids expressing wild-type Flag-PTEN (PTEN WT), truncated mutants, 
phosphatase deficient mutants, or empty vector. Forty eight hours after transfection, cells were 
infected using HCV-2a J6 pseudoparticles with a firefly luciferase reporter (HCVpp-Luc). 
Luciferase activity was measured 24 hours after infection and normalized to total protein amount. 
Luciferase activities were expressed as fold changes relative to vector control. Statistical 
differences between samples were demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, or NS for not 
significant. This experiment was performed in triplicate. (B). The protein levels of Flag-tagged 
PTEN after transfection were determined by Western blotting using an anti-Flag antibody. The β-
actin levels were determined by blotting cell lysates with a β-actin antibody as loading controls. 
(C and D). Huh-7.5 cells expressing inducible PTEN shRNA or non-silencing control shRNA 
were transfected with plasmids expressing Flag-tagged PTEN with wild-type or mutant 3'-UTR, 
or empty vector. Cells were treated with 1 μg/mL of Doxycycline for 48 hours. Cells were then 
infected with HCVpp-Luc and luciferase activity was determined 24 hours after infection (C). 
This experiment was performed in triplicate. In (D), the protein levels of PTEN and β-actin in 
Huh-7.5 cells were determined by Western blotting using anti-PTEN and anti-β-actin antibodies, 
respectively. Relative PTEN band intensities against β-actin were given underneath each sample.   
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9.5.3 PTEN protein phosphatase activity is required for the inhibition of HCV replication  
 
To study whether PTEN regulates HCV replication, we determined the level of HCV 
replication in HCV genomic replicon cells upon ectopic expression of PTEN and its mutants by 
transfection. As shown in Fig. 9.3A, overexpression of full-length PTEN, or the aa. 1-185 
fragment, but not aa. 186-403, significantly inhibited HCV replication. These data indicate that 
the phosphatase domain of PTEN is required for inhibiting HCV replication. We further observed 
that PTEN with G129E mutation, but not C124S or Y138L mutations, inhibited HCV replication 
(Fig. 9.3A). The expression of wild-type or mutant PTEN proteins was demonstrated by Western 
blotting (Fig. 9.3B). These data suggest that the protein phosphatase activity of PTEN is essential 
for the inhibition of the replication of HCV genomic RNA. To study the roles of viral structural 
and non-structural proteins in HCV replication inhibition by PTEN, we determined the effects of 
PTEN on the replication of an HCV subgenomic replicon. Interestingly, we found that PTEN did 
not inhibit HCV replication in the absence of HCV structural proteins (Fig. 9.3C). These data 
collectively indicate that PTEN inhibits HCV replication with the possible involvement of viral 
structural proteins.     
 
9.5.4 PTEN does not affect HCV RNA translation  
 
To examine whether PTEN affects HCV RNA translation, we used a well-established 
system that we reported previously [258,266]. Huh-7 cells were co-transfected with a 
monocistronic HCV translation rLuc reporter RNA (Fig. 9.4A) or HCV genomic RNA that is 
replication-deficient (Fig. 9.4C), together with plasmid vector or PTEN-expressing plasmid. No 
significant changes in RNA translation were observed in both cases, suggesting that PTEN has no 
effect on HCV RNA translation. To confirm these results, the monocistronic HCV translation 
rLuc reporter (Fig. 9.4B) or genomic RNAs (Fig. 9.4D) were transfected into the inducible PTEN 
knockdown cells or non-silencing control cells. Knocking down PTEN did not affect HCV RNA 
translation. These data indicate that PTEN has a little effect on HCV RNA translation.  
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Fig. 9.3. PTEN protein phosphatase activity is required for inhibition of HCV replication in 
HCV genomic replicon cells. (A) Huh-7 cells with an HCV-2a J6/JFH-1 (p7-rLuc-2A) genomic 
replicon were transfected with plasmids expressing wild-type Flag-PTEN (PTEN WT), truncated 
mutants, phosphatase deficient mutants, or empty vector. Forty eight hours after transfection, 
luciferase assay was performed using the cell lysates. This experiment was performed in triplicate. 
(B). The protein levels of PTEN and β-actin were determined by Western blotting using anti-
PTEN and anti-β-actin antibodies, respectively. (C). Huh-7 cells with an HCV-2a JFH-1 rLuc 
subgenomic replicon were transfected with plasmid vector or PTEN expressing plasmid. This 
experiment was performed in triplicate. Luciferase assay was performed 48 hours after 
transfection. Luciferase activities were expressed as fold changes relative to vector control; ** p 
≤ 0.01, *** p ≤ 0.001, or NS for not significant.  
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9.5.5 PTEN protein phosphatase activity is required for inhibition of HCV secretion  
 
Data presented so far indicate various effects of PTEN on HCV entry, replication, and 
translation. A previous study found no effect of PTEN on HCV replication, but identified an 
inhibition of HCV secretion by PTEN [259]. Given the apparent discrepancy, we felt necessary to 
examine whether PTEN regulates HCV secretion in our hands. To this end, Huh-7 cells harboring 
HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were transfected with vector or plasmids 
expressing PTEN, wild-type or phosphatase mutants, as per the publication that reported the 
effect of PTEN on HCV secretion [259]. Virus-containing supernatants were used to infect Huh-
7.5 cells and the luciferase activity measured. Because we found negative effects of PTEN on 
HCV RNA replication, it thus becomes necessary to normalize the luciferase activities measured 
against the corresponding HCV RNA levels in the initial Huh-7.5 cells as an indication of HCV 
secretion. As shown in Fig. 9.4E, overexpression of PTEN significantly reduced HCV secretion. 
To determine if any of the phosphatase activities of PTEN were required for this effect, we once 
again used phosphatase deficient mutants of PTEN. The results showed that the lipid phosphatase 
deficient mutant G129E inhibited HCV secretion, whereas the protein phosphatase deficient 
Y138L and the lipid and protein phosphatase deficient C124S mutants had no effect on HCV 
secretion (Fig. 9.4E). These data indicate that PTEN protein phosphatase activity is required for 
inhibiting HCV secretion. Interestingly, this finding is consistent with the previous study just 
mentioned [259]. 
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Fig. 9.4. PTEN has no effect on HCV translation, but inhibits HCV secretion. (A and C). 
Huh-7 cells were co-transfected with a monocistronic HCV-2a translation rLuc reporter RNA (A) 
or a full-length HCV-2a J6/JFH-1 (p7-rLuc-2A) GNN RNA (C), and plasmid vector or PTEN-
expressing plasmid. Luciferase assay was performed 24 hours after transfection. (B and D). Huh-
7.5 cells expressing inducible PTEN shRNA or non-silencing control shRNA were treated with 1 
μg/mL of Doxycycline for 48 hours. Then the cells were transfected with a monocistronic HCV-
2a translation rLuc reporter RNA (B) or a full-length HCV-2a J6/JFH-1 (p7-rLuc-2A) GNN 
RNA (D). Luciferase assay was performed six hours after transfection. (E). Huh-7 cells harboring 
HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were transfected with plasmid vector, or 
plasmids expressing PTEN, wild-type or phosphatase deficient mutants. Forty eight hours after 
transfection, (i) the HCV RNA levels in these “donor” cells were determined by luciferase assay, 
and (ii) the supernatants were collected to infect Huh-7.5 cells. Luciferase assay was performed 
72 hpi and normalized against those in the corresponding “donor” cells. The statistical 
differences between samples were demonstrated as ** if p ≤ 0.01, or NS for not significant. All 
experiments were performed in triplicate. 
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9.5.6 PTEN interacts with HCV core  
 
Our results indicated a role of HCV structural proteins in viral replication inhibition by 
PTEN (Fig. 9.3). Among the three HCV structural proteins, the core protein is more likely to play 
a role in regulating viral replication than the two envelope proteins. In addition, both PTEN and 
HCV core proteins often exert their functions through protein-protein interactions [271-273]. 
Therefore, we investigated whether PTEN interacts with the core protein. Huh-7 cells harboring 
HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were transfected with plasmids expressing 
GST-PTEN or GST and GST-pull down assay was performed. As shown in Fig. 9.5A, HCV core 
protein was present in the pulled down complex by GST-PTEN, but not GST itself, suggesting an 
association between these two proteins. To determine the key regions of PTEN responsible, we 
used truncated PTEN in the GST pull-down assay. Results showed that PTEN aa. 1-186, but not 
aa. 187-403, was able to pull down the HCV core protein (Fig. 9.5A). We also determined 
whether the phosphatase deficient mutants of PTEN could pull down HCV core. Fig. 9.5A 
showed that the C124S, G129E, and Y138L mutants were able to pull down HCV core protein, 
suggesting these amino acid residues were not involved. These data indicate that the PTEN aa. 1-
186 fragment is essential for the association with HCV core protein.  
To determine whether PTEN directly interacts with HCV core, His6-HCV core and GST-
PTEN proteins were purified from E. coli and used in the GST pull-down assay. Purified His6-
BFP and GST proteins were used as the control proteins. Fig. 9.5B showed that His6-HCV core 
was pulled down by GST-PTEN, but not by GST itself. No His6-BFP was detected in the pull 
down complexes by GST or GST-PTEN. These data indicate that PTEN directly interacts with 
HCV core protein. 
 
9.5.7 HCV core R50 in domain I is the key residue required for the interaction with PTEN  
 
Next, we determined the regions and residues of HCV core for the interaction with PTEN. 
HCV core contains two domains, domain I and domain II [274]. To determine which domain of 
HCV core was required for the interaction with PTEN, Huh-7 cells were co-transfected with 
plasmids expressing GST-PTEN, and Flag-tagged HCV core fused with EGFP. Results of the 
GST pull down assays showed that full-length core as well as domain I interacted with PTEN, 
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whereas domain II did not (Fig. 9.5C). No interactions were detected between proteins involving 
control proteins EGFP and GST (Fig. 9.5C and D). These data suggest that the domain I of HCV 
core is required for the interaction with PTEN.  
To map the interacting region within domain I (aa. 1-118), we constructed plasmids 
expressing truncated domain I and used them in GST pull down assays. We observed that PTEN 
interacted with HCV core ∆aa. 1-41, but not ∆aa. 1-59 (Fig. 9.6A). These data indicated that 
HCV core aa. 42-59 contains the residues for interaction with PTEN. To identify the residue(s) 
responsible for interaction with PTEN, we employed the alanine scanning approach by mutating 
groups of two or three amino acid residues at a time into alanines. We found that the 
P42AR43AL44A and T49AR50A mutants did not interact with PTEN, whereas the 
G45AV46AR47A, K51AT52AS53A, E54AR55AS56A, and Q57AP58AR59A mutants could 
still be pulled down by GST-PTEN (Fig. 9.6B). These data suggested that the amino acid 
residues P42, R43, L44, T49, or R50 of HCV core are likely involved in the interaction with 
PTEN. We therefore substituted these residues with alanines, one by one, and performed GST 
pull down assays. PTEN interacted with the P42A and R43A mutants, but not the L44A, T49A or 
R50A mutants (Fig. 9.6C). These data indicated that, when aa. 1-41 is deleted, the amino acid 
residues L44, T49 and R50 of HCV core are involved in the interaction with PTEN.  
Because the aa. 1-41 of HCV core contains a helix-loop-helix structure as per molecular 
modeling [275], deletion of this structure may have an impact on the overall conformation of the 
HCV core protein and thus affect protein-protein interactions. We therefore tested each of the 
L44A, T49A and R50A mutations in the context of full-length HCV core and determined the 
interaction with PTEN. GST pull-down assay results showed that the full-length L44A and T49A 
mutant core proteins could still interact with PTEN, whereas the R50A mutation abolished the 
interaction completely (Fig. 9.6D). Taken together, these data indicated that R50 of HCV core 
domain I is the key residue responsible for the interaction with PTEN. 
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Fig. 9.5. PTEN interacts with the domain I of HCV core. (A). Huh-7 cells harboring HCV-2a 
J6/JFH-1 (p7-rLuc-2A) replicon were transfected with plasmids expressing GST, GST-PTEN 
wild-type or GST-PTEN mutants. At 48 hours after transfection, cell lysates were subjected to 
GST pull-down assay. Input and pull-down products were analyzed by Western blotting (WB) 
using anti-HCV core and anti-GST antibodies, respectively. (B). Purified His6-BFP (blue 
fluorescent protein), His6-HCV core, GST and GST-PTEN proteins were subjected to GST pull-
down assay. Pull-down products were analyzed by Western blotting (WB) using anti-His6, anti-
GST and anti-PTEN antibodies, respectively. (C and D). Huh-7 cells were co-transfected with 
plasmids expressing Flag-tagged HCV core, either full-length, domain I (D-I; aa. 1-118), or 
domain II (D-II, aa. 119-178), together with plasmids expressing GST (C) or GST-PTEN (D). 
The core proteins were expressed as fusion proteins with EGFP (enhanced green fluorescent 
protein). Flag-tagged EGFP-expressing plasmid was included as negative control. At 48 hours 
after transfection, cell lysates were subjected to GST pull-down assay. Input and pull-down 
products were analyzed by Western blotting (WB) using anti-Flag and anti-GST antibodies, 
respectively. 
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Fig. 9.6. HCV core R50 is the key residue for interaction with PTEN. Huh-7 cells were co-
transfected with GST-PTEN-expressing plasmid, together with plasmids expressing truncated 
HCV core, either wild-type (A), with multiple (B) or single (C) amino acid mutations, or full-
length (FL) HCV core with single amino acid mutations (D). The core proteins have a Flag-tag at 
the N-termini. At 48 hours after transfection, cell lysates were subjected to GST pull-down assay. 
Input and pull-down products were analyzed by Western blotting (WB) using anti-Flag and anti-
GST antibodies, respectively. 
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9.5.8 HCV core interacts with endogenous PTEN through R50  
 
Data generated so far have shown an interaction between HCV core and PTEN after 
ectopic expression. It is necessary to demonstrate whether HCV core interacts with endogenous 
PTEN in HCV replicating cells.  Therefore, we generated Huh-7 cells harboring HCV-2a J6 core-
Flag/JFH-1 (p7-rLuc-2A) replicating RNA. The addition of a Flag tag to the core sequence does 
not have measurable effects on HCV replication [264] and allows convenient co-
immunoprecipitation (co-IP) using a Flag-specific antibody. As shown in Fig. 9.7A, PTEN was 
present in the immunoprecipitates with anti-Flag antibody, suggesting that HCV core interacts 
with the endogenous PTEN protein in HCV replicating cells. To determine the role of R50 of 
HCV core in this interaction, we also generated Huh-7 cells harboring HCV-2a J6 core R50A-
Flag/JFH-1 (p7-rLuc-2A) replicating RNA. PTEN protein was not detected in the 
immunoprecipitates using the R50A lysates (Fig. 9.7A). These data demonstrated that HCV core 
R50 is the key residue for the interaction with endogenous PTEN in HCV replicating cells.  
 
9.5.9 The interaction between PTEN and HCV core is required for inhibiting HCV 
replication by PTEN  
 
To determine whether PTEN-HCV core interaction plays a role in regulating HCV 
replication, HCV RNA levels were quantified in wild-type and R50A HCV replicating cells after 
overexpression of PTEN. We observed that overexpression of PTEN inhibited HCV replication 
in wild-type, but not in R50A, HCV replicating cells (Fig. 9.7B and C), suggesting a role of 
PTEN - HCV core interaction. To study whether the interaction between PTEN and HCV core 
can regulate the PTEN level as a mechanism of modulating HCV RNA replication, we 
determined the amounts of PTEN in the HCV RNA replicating cells by Western blotting. As 
shown in Fig. 9.7D, the PTEN protein levels in Huh-7 cells harboring wild-type replicating HCV 
RNA (HCV J6/JFH-1 (p7-rLuc-2A) and HCV J6 core-Flag/JFH-1 (p7-rLuc-2A)) were lower 
than those in Huh-7 cells harboring HCV R50A replicating RNA (HCV J6 core R50A-Flag/JFH-
1 (p7-rLuc-2A)) and in the parental Huh-7 cells. These results suggested that the PTEN level is 
reduced in HCV replicating cells most likely due to its interaction with HCV core.  
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9.5.10 HCV core domain I increases the lipid phosphatase activity of PTEN  
 
The data presented so far have demonstrated that the phosphatase activities of PTEN are 
required for its inhibitory effects on HCV. In addition, we showed that the interaction between 
HCV core and PTEN is involved in inhibiting HCV replication by PTEN. Because the 
phosphatase activities of PTEN can be modulated upon interacting with a protein [51], we wanted 
to determine whether the HCV core - PTEN interaction has an effect on the phosphatase activities 
of PTEN. We employed an enzymatic malachite green assay to measure the lipid phosphatase 
activity of PTEN after incubating with HCV core protein. Because we encountered some 
difficulty in obtaining the full-length core protein in the quantity and purity required by the assay, 
we instead used HCV core domain I protein, the interacting domain with PTEN. To determine 
the effect of the HCV core - PTEN interaction on PTEN’s phosphatase activities, we also used 
HCV core domain I R50A mutant protein in the phosphatase assay. The lipid phosphatase 
activity of PTEN at 20 nM was measured after incubating with increasing amounts of HCV core 
domain I protein, either wild-type or with the R50A mutation. As shown in Fig. 9.7E, in the 
presence of the wild-type HCV core domain I protein at the three lowest concentrations tested, 
there was a steady increase in the lipid phosphatase activity of PTEN, whereas no activity was 
measurable in the presence of the R50A protein. With increasing amounts of the core domain I 
proteins, the lipid phosphatase activity of PTEN also increased. Except for the highest 
concentration tested, incubation with the wild-type core protein resulted in significantly higher 
lipid phosphatase activity of PTEN than the R50A protein. These data indicated that the presence 
of the HCV core domain I protein increases the lipid phosphatase activity of PTEN with the wild-
type core being more efficient than the R50A core.   
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Fig. 9.7. PTEN-HCV core interaction inhibits HCV replication and increases lipid 
phosphatase activity of PTEN. (A). The lysates prepared from Huh-7 cells harboring HCV-2a 
J6 core-Flag/JFH-1 (p7-rLuc-2A) or HCV-2a J6 core R50A-Flag/JFH-1 (p7-rLuc-2A) replicating 
RNAs were subjected to immunoprecipitation (IP) using an anti-Flag antibody. Input and IP 
products were analyzed by Western blotting (WB) using anti-PTEN and anti-HCV core 
antibodies, respectively. This experiment was performed in duplicate. (B and C). Huh-7 cells 
harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) (B) or HCV-2a J6 core R50A-Flag/JFH-1 
(p7-rLuc-2A) (C) replicating RNAs were transfected with vector or PTEN-expressing plasmid. 
At 48 hours after transfection, HCV RNA level was determined by reverse transcription real-time 
PCR using HCV-2a-specific primers. The transcript level of β-glucuronidase (GUSB) was used 
for normalization. The statistical differences between samples were demonstrated as * if p ≤ 0.05, 
** if p ≤ 0.01, or NS for not significant. This experiment was performed in duplicate. (D). The 
protein level of PTEN in parental Huh-7 cells, Huh-7 cells harboring HCV-2a J6/JFH-1 (p7-
rLuc-2A), HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) or HCV-2a J6 core-Flag R50A /JFH-1 (p7-
rLuc-2A) was determined by Western blotting using anti-PTEN antibody. The level of β-actin 
was also determined using anti-β-actin antibody. Relative PTEN band intensities against β-actin 
were given underneath each sample. This experiment was performed in triplicate. (E). Purified 
PTEN protein (20 nM) was incubated with increasing amounts of HCV core domain I (HCV core 
D-I) proteins, wild-type or R50A, as indicated. The phosphatase activity of PTEN towards 
PtdIns(3,4,5)P3 was determined in the presence of increasing concentrations of the HCV core D-I 
proteins and presented relative to PTEN alone (set to a value of 1). The statistical differences 
between samples were demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, or NS for not significant. 
This experiment was performed in triplicate.  
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9.6 Discussion 
 
Although the effects of the PI3K/Akt signaling pathway on the HCV life cycle are 
relatively well documented [255-258], the role of PTEN is less well defined. In this study, we 
showed that PTEN inhibited HCV entry, replication and secretion through its different PTEN 
phosphatase activities. Furthermore, we showed that HCV core interacts with PTEN, regulates 
the steady level and lipid phosphatase activity of PTEN.   
We first determined the HCV RNA levels after HCV infection upon ectopic expression of 
PTEN protein. We showed an approximately 50% reduction in HCV RNA levels after PTEN 
overexpression with no measurable effects on cell viability (Fig. 9.1). Moreover, the regulation of 
HCV RNA was confirmed by decreasing PTEN levels by PTEN-specific shRNA. More 
importantly, the inhibitory effects of PTEN on HCV RNA levels were dose-dependent and 
PTEN-specific (Fig. 9.1). Because PTEN can potentially regulate different steps of the HCV life 
cycle, we next studied the effects of PTEN on HCV entry, replication, and translation.        
HCV entry occurs through viral interaction with numerous cellular receptors [247]. A 
recent study has demonstrated that the PI3K/Akt signaling pathway stimulates HCV entry [256]. 
Because one of the major functions of PTEN is to supress the PI3K/Akt signaling pathway [45], 
one would expect an inhibitory effect of PTEN on HCV entry. Indeed we showed that 
overexpression of PTEN reduced, whereas knocking down PTEN enhanced, HCV entry (Fig. 
9.2). Furthermore, we showed that the lipid phosphatase activity of PTEN is involved in 
inhibiting HCV entry (Fig. 9.2).  
We next studied the effect of PTEN on HCV replication in HCV replicon cells to bypass 
the entry step. Interestingly, we found that PTEN inhibited the replication of HCV genomic RNA, 
but not subgenomic RNA (Fig. 9.3). These results suggested a role of viral structural proteins in 
replication inhibition by PTEN. A previous study found that overexpression of PTEN does not 
have a significant effect on HCV replication using an HCV Jc1 virus [259]. The reasons for the 
discrepancy are not clear and whether it is due to different experimental conditions or viral strains 
should be investigated.  
HCV RNA translation is primarily mediated by the internal ribosomal entry site within 
the viral 5'-UTR with viral and cellular factors playing a regulatory role [248]. We recently 
demonstrated that the PI3K/Akt signaling pathway positively regulates HCV RNA translation 
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[258]. Interestingly however, no effect of PTEN on HCV RNA translation was observed in the 
current study (Fig. 9.4). This is not entirely unexpected because there exist examples where the 
phenotypes of PTEN (down-regulation) may not always result in altered Akt (up-regulation) 
[45,276]. Our results imply that the PI3K/Akt and PTEN modulate HCV RNA translation 
through different mechanisms, which warrant further investigation.   
To understand how PTEN inhibits HCV genomic RNA replication, but not subgenomic 
RNA replication, we sought to determine whether PTEN interacts with the HCV core proteins as 
we reasoned that the core protein will more likely to be involved than E1 and E2 proteins. We 
indeed found that PTEN interacted directly with HCV core protein (Fig. 9.5). Furthermore, we 
identified the arginine residue at position 50 (R50) within domain I of HCV core protein as the 
key residue required for mediating the interaction (Fig. 9.6). More importantly, when R50 was 
mutated, PTEN could no longer inhibit HCV replication (Fig. 9.7), suggesting a functional 
significance of this interaction. Previous studies have shown that the R50 residue of HCV core 
protein is involved in interacting with the NS5A protein and is required for HCV infectivity 
[264,277]. As an additional function of this residue, our results have demonstrated that R50 has a 
role in regulating HCV replication by interacting with PTEN.  
Previous studies have demonstrated that the expression of HCV core results in decreased 
levels of PTEN protein through either blocking PTEN mRNA translation [147] or activation of 
NF-κB [149]. Therefore we were interested in determining the role of HCV core - PTEN 
interaction in modulating PTEN levels. We found that the replication of wild-type HCV was 
associated with decreased PTEN protein level, which was restored to a significant extent when 
R50 was mutated into alanine (Fig. 9.7). These data indicate that HCV core decreases the steady 
level of PTEN through protein - protein interaction as yet another mechanism. 
Protein - protein interactions play an important role in modulating the phosphatase 
activities [51]. We showed that the phosphatase activities of PTEN were involved in regulating 
different steps in the HCV life cycle (Fig. 9.1, 9.2 and 9.3). These data prompted us to determine 
whether the HCV core - PTEN interaction has an effect on the phosphatase activities of PTEN in 
an in vitro enzymatic assay. We found that the presence of HCV core domain I protein increased 
the lipid phosphatase activity of PTEN in a dose-dependent manner (Fig. 9.7). In contrast, the 
HCV core domain I R50A mutant protein was only able to enhance the lipid phosphatase activity 
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at high concentrations tested (Fig. 9.7). These results strongly suggest that PTEN - HCV core 
interaction plays a role in the regulation of PTEN activities.   
In summary, we presented evidence to support an inhibitory role of PTEN in regulating 
HCV entry, replication and secretion. This suggests that liver cancers with reduced expression of 
PTEN could be more susceptible to HCV infection [278]. Mechanistically, we demonstrated that 
HCV core interacts with PTEN and may modulate the functions of PTEN through multiple 
mechanisms. Our results should provide an additional avenue for developing therapeutics for 
HCV infection and the resultant hepatocellular carcinoma. 
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10.0  THE ROLE OF PTEN-LONG ON HCV REPLICATION 
 
In the previous chapter, we showed that PTEN inhibits HCV entry, replication and 
secretion. HCV core interacts with PTEN and inhibits PTEN expression, which enhances HCV 
replication. PTEN has an isoform called PTEN-Long which can export into extracellular 
compartments, enter neighboring cells, and induce signaling events in recipient cells. In the 
following chapter, we set to determine if PTEN-Long affects HCV replication and if HCV core 
interacts with PTEN-Long. 
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11.1 Authors’ contribution 
 
 All the experiments within this chapter were performed by Qi Wu. The manuscript was 
written by Qi Wu and edited by Qiang Liu. 
 
11.2 Abstract 
  
Hepatitis C virus (HCV) infection is a confirmed risk factor for hepatocellular carcinoma 
(HCC). Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) possesses tumor 
suppression function that is frequently defective in HCC tumors. PTEN-Long, an isoform of 
PTEN, functions in a cell non-autonomous manner. In this study, we demonstrated that 
intracellular overexpression of PTEN-Long inhibits HCV replication. More importantly, we 
showed that treatment with extracellular PTEN-Long protein inhibits HCV replication in a dose 
dependent manner. Furthermore, we showed that PTEN-Long interacts with HCV core protein 
and this interaction is required for HCV replication inhibition by PTEN-Long. In summary, we 
demonstrated, for the first time, that PTEN-Long protein, an isoform of the canonical PTEN and 
in the form of an extracellular protein treatment, inhibits HCV replication. Our study offers an 
opportunity for developing additional anti-HCV agents. 
 
11.3 Introduction 
 
Despite the approval of anti-viral drugs, hepatitis C virus (HCV) infection continues to be 
a significant public health problem with hepatocellular carcinoma (HCC) as the most deadly 
clinical outcome [246]. HCV has a single-stranded RNA genome encoding a polyprotein that is 
processed by cellular and viral proteases to generate structural and non-structural proteins [247]. 
Although it is a structural protein, HCV core has been reported to possess many regulatory 
functions including tumorigenesis [143,249]. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a dual 
phosphatase with lipid and protein phosphatase activities [45,250]. These phosphatase activities 
render PTEN to function as a tumor suppressor [45]. PTEN has been characterized as one of the 
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most frequently mutated or deleted genes in various tumors including HCC [45,49]. For instance, 
three single amino acid mutations in the phosphatase domain have been identified: C124S (lipid 
and protein phosphatase defective), G129E (lipid phosphatase activity defective), and Y138L 
(protein phosphatase defective) [50]. As a protein product translated from an alternative start 
codon 519 bp upstream of the ATG initiation sequence of PTEN, a longer isoform of PTEN, 
termed PTEN-Long, was discovered very recently [59,61,279]. PTEN and PTEN-Long possess 
comparable phosphatase activities [59]. PTEN-Long has 173 N-terminal extra amino acids with a 
poly-arginine region. This region enables PTEN-Long to be exported into extracellular 
compartments, enter neighboring cells, and induce signaling events in recipient cells [59]. 
We previously demonstrated that PTEN can inhibit HCV replication through interacting 
with HCV core protein (Chapter 9). Whether PTEN-Long affects HCV replication has not been 
studied. In this study, we showed that intracellular expression of or extracellular treatment with 
PTEN-Long protein can inhibit HCV replication. Furthermore, we showed that PTEN-Long 
HCV core protein interaction is involved in the inhibitory effect of PTEN-Long on HCV 
replication. 
 
11.4 Materials and Methods 
 
11.4.1 Plasmid constructs 
 
Plasmid expressing Flag-tagged PTEN was described previously (Chapter 9). Plasmids 
expressing PTEN-Long-V5-His6 (Addgene plasmid #49417) and PTEN-V5-His6 (Addgene 
plasmid #49420) in the bacterial JpExpress404 vector or in the pcDNA3 vector were obtained 
from Addgene or Dr. Ramon Parsons [59]. Bacterial or eukaryotic expression plasmids encoding 
RFP (red fluorescent protein) fusion proteins with PTEN or PTEN-Long were constructed as 
described [59]. Plasmids expressing PTEN-Long mutants with single amino acid substitutions 
C297S, G302E, or Y311L were generated in reference to the corresponding mutations of PTEN 
[259]. His6-BFP (blue fluorescent protein)-expressing plasmid in the pT7 His6-SUMO vector 
(Lucigen) was described previously [268]. All plasmids were constructed using standard methods 
and confirmed by DNA sequencing. 
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11.4.2 Cell culture and transfection 
 
Huh-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% 
(v/v) fetal bovine serum (FBS). Huh-7 cells with replicating HCV-2a J6 core-Flag/JFH-1 (p7-
rLuc-2A) or HCV-2a J6 core R50A-Flag/JFH-1 (p7-rLuc-2A) RNAs were maintained with 
culture medium plus G418 (Enzo Life Sciences) as described previously (Chapter 9). Cells were 
transfected with plasmid DNA using the calcium phosphate precipitation method [163] or the Jet-
PEI transfection reagent (Polyplus Transfection) [258]. 
 
11.4.3 Luciferase assay 
 
Cells were lysed in Passive Lysis Buffer (Promega) and the firefly or renilla luciferase 
activities were measured by Luciferase Assay reagents (Promega) in a TD 20/20 Luminometer 
(Turner Designs). Firefly or renilla luciferase levels were normalized to the protein 
concentrations determined by the Bradford assay (Bio-Rad Laboratories). These assays were 
performed at least three times and the results analyzed for statistical differences by the Student's t 
test. A p value of ≤ 0.05 was considered statistically significant. 
 
11.4.4 Co-immunoprecipitation (Co-IP) and Western blotting 
 
Co-IP and Western blotting were performed as described previously (Chapter 9). For Flag 
co-IP experiments, cells were harvested by radio immunoprecipitation assay (RIPA) buffer and 
incubated with anti-Flag (Sigma-Aldrich) antibody at 4 ℃ overnight and then incubated with 
Protein G Sepharose (GE Healthcare) at 4 ℃ for 4 hours. The mixtures were centrifuged at 
10,000 rpm for 10 minutes and the supernatants were removed. The pellets were resuspended in 
SDS lysis buffer and boiled for 10 minutes to elute the proteins. For Western blotting, proteins 
were subjected to SDS-PAGE and then blotted onto nitrocellulose membranes. The membranes 
were blocked in 5% skim milk in PBS and incubated with a primary antibody overnight at 4 ℃. 
Membranes were washed and incubated with a secondary antibody for 1 hour at room 
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temperature. After a wash with PBST (PBS+0.1% Tween 20), membranes were scanned using 
Li-Cor Odyssey scanner (ODY-CLx) and band intensities were determined by Quantity One 
software (Bio-Rad Laboratories). These primary antibodies were used: HCV core (Anogen), 
PTEN (Cell Signaling Technology), β-actin (CST), and Flag (Sigma-Aldrich). The secondary 
antibodies used were IRDye 800CW goat anti-mouse IgG and IRDye 680RD goat anti-rabbit IgG 
(Li-Cor Biosciences). 
 
11.4.5 Purification of recombinant proteins 
 
The expression of recombinant proteins in E. coli was induced by IPTG (Thermo Fisher 
Scientific). His6-tagged PTEN, PTEN-Long, and BFP proteins were purified by Ni-NTA agarose 
(Qiagen) as previously described [266].  
 
11.5 Results 
 
11.5.1 Intracellular PTEN-Long inhibits HCV replication 
 
We previously showed that ectopic expression of PTEN inhibits HCV replication 
(Chapter 9). Whether PTEN-Long, a longer isoform of PTEN, can also regulate HCV replication 
has not been studied. To investigate the effect of PTEN-Long on HCV replication, we transfected 
Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) replicating RNA with vector, 
plasmids expressing PTEN or PTEN-Long and measured HCV replication by luciferase assay. 
We also used a set of plasmids expressing fusion proteins with RFP, which will enable 
subsequent experiments – see below. Consistent with our previous results, overexpression of 
PTEN significantly inhibited HCV replication in comparison to vector (Fig. 11.1A). Expression 
of the fusion protein PTEN-RFP also inhibited HCV replication as effectively as PTEN itself, 
while RFP expression had no effect (Fig. 11.1A). Overexpression of PTEN-Long or PTEN-Long-
RFP could reduce HCV replication to the same extent as PTEN (Fig. 11.A). The intracellular 
expression of these proteins was demonstrated by Western blotting (Fig. 11.1B). These results 
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indicated that both PTEN and PTEN-Long can inhibit HCV replication when expressed 
intracellularly. 
 
11.5.2 Extracellular PTEN-Long protein treatment inhibits HCV replication 
 
In comparison to the canonical PTEN, a unique feature of PTEN-Long lies in its ability to 
enter cells as a secreted protein [59]. We therefore were interested in determining whether PTEN-
Long as an extracellular protein regulates HCV replication. To this end, we purified His6-tagged 
PTEN and PTEN-Long proteins with or without fusion with RFP as previously described [59]. 
Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) replicating RNA were treated 
with increasing amounts of PTEN or PTEN-Long protein and HCV replication quantified. PBS 
and BFP protein were used as controls. As shown in Fig. 11.2A, while HCV replication was not 
affected by treatment with PBS, BFP, or PTEN proteins in three escalating doses, HCV 
replication was reduced upon PTEN-Long protein treatment in a dose-dependent manner. These 
results indicated that extracellular PTEN-Long protein can inhibit HCV replication. 
We previously showed that the lipid phosphatase deficient G129E mutant of PTEN can 
inhibit HCV replication as effectively as the wild-type PTEN, whereas the protein phosphatase 
deficient Y138L and the lipid and protein phosphatase deficient C124S mutants have no effect 
(Chapter 9). Next, we wanted to determine whether this is also the case for PTEN-Long as an 
extracellular protein. We therefore transferred the phosphatase point mutations of PTEN to the 
corresponding positions in PTEN-Long and purified these proteins for use in the treatment. Fig. 
11.2B showed that while mutations in protein phosphatase activity C297S and Y311L no longer 
inhibited HCV replication, the lipid phosphatase G302E mutant protein had the same inhibitory 
effect as the wild-type PTEN-Long. These results indicated that the protein phosphatase activity 
of PTEN-Long is required for inhibiting HCV replication.  
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Fig. 11.1. Intracellular expression of PTEN-Long inhibits HCV replication. Huh-7 cells 
harboring HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were transfected with plasmid vector, 
or plasmids expressing RFP (red fluorescent protein), PTEN-RFP, PTEN-Long-RFP (PTEN-L-
RFP), PTEN, or PTEN-Long (PTEN-L). All proteins have a C-terminal V5-His6 tag. (A) At 48 
hours after transfection, luciferase assay was performed and the statistical differences between 
samples were demonstrated as ** if p ≤ 0.01, or NS for not significant. This experiment was 
performed three times. (B) The expression of RFP, PTEN, and PTEN-Long proteins was 
demonstrated by Western blotting using an anti-PTEN antibody. The levels of β-actin were also 
determined as loading controls. This experiment was performed three times. 
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To confirm that PTEN-Long but not PTEN protein can enter the cells, we fused PTEN-
Long or PTEN with RFP and detected red fluorescence after treatment. As shown in Fig. 11.2C, 
red fluorescence was observed after treatment with PTEN-Long-RFP, but not with PTEN-RFP or 
RFP, indicating that only extracellular PTEN-Long protein can enter the cells. Fusion with RFP 
did not affect the function of PTEN and PTEN-Long in regulating HCV replication (compare Fig. 
11.1D and 11.1A). 
Taken together, these results demonstrated that extracellular PTEN-Long protein can 
enter the cells and inhibit HCV replication. 
 
11.5.3 PTEN-Long inhibits HCV replication through interaction with HCV core 
 
We previously showed that HCV core protein interacts with PTEN through the arginine 
residue at position 50 (R50) and the interaction is required for the inhibitory effect of PTEN on 
HCV replication (Chapter 9). To determine whether HCV core also interacts with PTEN-Long 
and the role of R50, we performed Flag co-immunoprecipitation experiment after transfecting 
PTEN-Long expressing plasmid into HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) and HCV-2a J6 
core R50A-Flag/JFH-1 (p7-rLuc-2A) replicating cells. As shown in Fig. 11.3A, PTEN-Long was 
detected in the immunoprecipitates using lysates containing wild-type, but not R50A, HCV core. 
Since PTEN is translated (internally) from the PTEN-Long coding sequence, PTEN protein was 
also present/absent in the immunoprecipitates (Fig. 11.3A). These results indicated that HCV 
core interacts with PTEN-Long and requires R50. 
Next, we wanted to investigate the role of HCV core - PTEN-Long interaction in 
regulating HCV replication. HCV-2a J6 core R50A-Flag/JFH-1 (p7-rLuc-2A) replicating Huh-7 
cells were treated with 24 nM of BFP, PTEN, PTEN-Long and phosphatase mutant proteins, and 
PBS before HCV replication measured. As shown in Fig. 11.3B, no effects on HCV replication 
were observed. These results indicated that PTEN-Long interacts with HCV core, which is 
required for HCV replication inhibition. 
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Fig. 11.2. Extracellular treatment with PTEN-Long protein inhibits HCV replication. Huh-7 
cells with HCV-2a J6/JFH-1 (p7-rLuc-2A) replicating RNA were treated with BFP, RFP, PTEN, 
PTEN-Long, PTEN-RFP, or PTEN-Long-RFP proteins or equal volume of PBS (phosphate-
buffered saline). All proteins had a His6-tag and were purified from E. coli through affinity 
chromatography. In (A), 1.5, 6, and 24 nM of PTEN or PTEN-Long proteins and 24 nM of BFP 
protein were used. In (B, C and D), cells were treated with 24 nM of proteins. At 24 hours after 
treatment, luciferase assay was performed (A, B and D). The statistical differences between 
samples were demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, *** if p ≤ 0.001, or NS for not 
significant. These experiments were performed three times. (C) At 6 hours after treatment, cells 
were stained with DAPI. Images were collected by confocal microscopy and analyzed by the 
Image J software. This experiment was performed two times. 
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Fig. 11.3. PTEN-Long protein inhibits HCV replication by interacting with HCV core. (A) 
Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) or HCV-2a J6 core R50A-
Flag/JFH-1 (p7-rLuc-2A) replicating RNAs were transfected with plasmid expressing PTEN-
Long. Forty eight hours after transfection, cell lysates were subjected to co-immunoprecipitation 
(co-IP) using an anti-Flag antibody. Input and co-IP products were analyzed by Western blotting 
(WB) using anti-PTEN and anti-HCV core antibodies, respectively. This experiment was 
performed three times. (B) Huh-7 cells harboring HCV-2a J6 core R50A-Flag /JFH-1 (p7-rLuc-
2A) replicating RNA were treated with 24 nM of BFP, PTEN, PTEN-Long proteins or equal 
volume of PBS. Luciferase assay was performed at 24 hours after treatment. The statistical 
differences between samples were demonstrated as NS for not significant. This experiment was 
performed three times. 
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11.6 Discussion 
  
 Viruses are the etiologic agents for more than 10% of tumors in human [280]. However, 
the mutual interactions between PTEN-Long and oncogenic viruses have yet to be characterized. 
As an extension to our recent study on the effect of the canonical PTEN on HCV replication 
(Chapter 9), we characterized the role of PTEN-Long in this study. We showed that intracellular 
expression of PTEN-Long could inhibit HCV replication as effectively as the PTEN protein (Fig. 
11.1). More importantly, we found that HCV replication was inhibited by incubation with 
purified PTEN-Long protein in a dose-dependent manner (Fig. 11.2). This inhibition is due to the 
permeability feature of the PTEN-Long protein because we showed that PTEN-Long in the form 
of an extracellular protein, but not the PTEN protein, can enter HCV replicating cells (Fig. 11.2). 
As for the mechanisms, we found that the C297S and Y311L mutants of PTEN-Long do not 
inhibit HCV replication (Fig. 11.2) and PTEN-Long - HCV core protein interaction is required 
for inhibiting HCV replication by PTEN-Long (Fig. 11.3). Taking our previou study on how 
PTEN inhibits HCV replication (Chapter 9) into consideration, these results suggest that PTEN-
Long, once present inside the cell, exerts its inhibitory effects on HCV replication through similar 
mechanisms as the canonical PTEN. 
 In summary, we demonstrated that PTEN-Long inhibits HCV replication. To the best of 
our knowledge, this is the first report on characterizing the effect of PTEN-Long on a viral 
replication. The fact that PTEN-Long exerts this inhibitory function in the form of an 
extracellular protein should provide an additional avenue for developing therapeutics for HCV 
infection and the resultant hepatocellular carcinoma. 
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12.0 HOW HBV AND HCV REGULATES PTEN AND SREBP-1 AND WHETHER THIS 
PROCESS ALTERS HBV AND HCV REPLICATION IN HBV HCV CO-
INFECTION 
 
In Chapters 3 to 11, we showed that HBx stimulates SREBP-1 activity and enhances 
HBV replication. We also observed that HCV core inhibits PTEN expression and enhances HCV 
replication. Loss of PTEN results in activation of the PI3K/Akt pathway which leads to SREBP-1 
activation. Previous studies have established that both HBx and HCV core can inhibit PTEN and 
enhance SREBP-1 activity in HBV or HCV mono-infection. However, the role of HBx and HCV 
core on the PTEN/SREBP-1 pathway is still not fully understood. On the other hand, whether 
regulation of the PTEN/SREBP-1 alters HBV and HCV replication in HBV HCV co-infection is 
not clear. In the following chapter, we set to determine how the PTEN/SREBP-1 pathway affects 
HBV HCV co-infection. 
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13.1 Authors’ contribution 
 
 All the experiments within this chapter were performed by Qi Wu. The manuscript was 
written by Qi Wu and edited by Qiang Liu. 
 
13.2 Abstract 
 
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections cause a wide range of 
liver diseases including hepatocellular carcinoma (HCC). Because these viruses have the same 
modes of transmission, HBV HCV co-infections are found in approximately seven to twenty 
million people globally. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a 
tumor suppressor, suppresses phosphatidylinositol 3-kinase (PI3K)/Akt pathway and its 
downstream factor sterol regulatory element binding protein-1 (SREBP-1). In this study, we 
examined whether HCV affects HBV replication in HCV replicating cells or HBV affects HCV 
replication in HBV replicating cells. We found that HBV and HCV do not interfere with each 
other in HCV replicating cells. However, in HBV replicating cells, HBV enhances the early stage 
of HCV infection. We also showed that HBV replication is regulated by HBx-dependent 
PTEN/SREBP-1 pathway, while HCV replication is mainly regulated by PTEN knockdown and 
is also modestly modulated by SREBP-1 knockdown. Moreover, we found that HBx and HCV 
core do not synergistically inhibit PTEN protein level or enhance SREBP-1 activation. Taken 
together, this study demonstrated the role of PTEN and SREBP-1 in HBV or HCV mono-
infections and HBV HCV co-infection. 
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13.3 Introduction 
 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections cause severe liver disease 
worldwide. Globally, approximately 240 to 400 million people are chronically HBV infected and 
120 to 200 million people are chronically HCV infected [281]. Because HBV and HCV share the 
model of transmission, HBV HCV co-infection is common in highly endemic areas. In general, 
approximately 5%-20% in HBsAg (HBV surface antigen) positive patients are found to be HCV 
positive and 2%-10% HCV positive patients are found to be HBsAg positive [282]. Compared to 
HBV or HCV mono-infections, HBV HCV co-infection leads to more severe liver disease and 
higher incidence of hepatocellular carcinoma (HCC) [283]. 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a phosphatase 
which contains both lipid and protein phosphatase activities. PTEN is considered a tumor 
suppressor since its lipid phosphatase activity can suppress one of the most critical cancer-
promoting pathways, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [45,49]. The 
activation of Akt inhibits proline-reich Akt substrate 40 kDa (PRAS40) and tuberous sclerosis 
1/2 (TSC1/2) and results in the activation of the mammalian target of rapamycin complex 1 
(mTORC1) [78]. Activation of mTROC1 stimulates SREBP-1 transcription, processing and 
nuclear localization [80]. Overall, PTEN negatively regulates SREBP-1 activation through 
PI3K/Akt/mTORC1 pathway [210].  
HBV is a partially double-stranded DNA virus with a genome of 3020-3320 nucleotides 
(for the full-length strand) and 1700 - 2800 nucleotides (for the short length-strand) [8]. There are 
four known HBV genes, called C, X, P, and S [9]. The HBV core protein is coded for by gene C. 
HBeAg is produced by proteolytic processing of the pre-core protein. HBV P proteins are 
encoded by gene P which functions are important for reconstitution of HBV DNA synthesis. 
Gene S is the gene that codes for HBsAgs which include large (L), middle (M), and small (S) 
surface proteins. HBx encoded by gene X is a nonstructural protein which functions as a 
transcriptional transactivator of host genes [7]. HBx modulates HBV replication through an 
SREBP-1 dependent manner [284]. Previous studies have demonstrated that HBx inhibits the 
function of p53 [285] and therefore increases alpha-fetoprotein (AFP) expression [286]. AFP 
associates with PTEN in the cytoplasm and reduces PTEN level [287]. 
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HCV is a small, enveloped, single positive-stranded RNA virus [23]. The RNA genome 
of HCV translates into a single large polyprotein which is processed by host and viral proteases 
to generate ten viral proteins: E1, E2, core, p7, non-structural protein 2 (NS2), NS3, NS4A, 
NS4B, NS5A and NS5B. Previous studies have demonstrated that both HCV core and NS5A 
proteins are involved in the down-regulation of PTEN [147-149]. Previously, we have established 
that the HCV core interacts with PTEN and HCV core R50A is the key residue of the interaction. 
The replication of HCV RNA with the R50A mutation is significantly reduced (Chapter 9). 
In this study, we showed that HBV can replicate in HCV replicating Huh-7 cells with no 
mearuable influence on HBV replication by HCV. HCV can also replicate in HBV replicating 
Huh-7 cells and HBV enhances HCV replication in the early stage of HCV infection. We also 
showed that PTEN inhibits HBV replication through modulating HBx-dependent SREBP-1 
activation. Although HCV replication is enhanced by respective PTEN knockdown or SREBP-1 
knockdown, knocking down SREBP-1 does not affect the PTEN-modulated HCV replication. 
Moreover, we further showed that HBx and HCV core has no synergy in PTEN and SREBP-1. 
 
13.4 Materials and Methods 
 
13.4.1 Plasmid constructs and in vitro transcription 
 
The hygromycin resistance gene was inserted into the pcDNA3.1 vector generating 
plasmid pcDNA3-Hygro
R
. Plasmids HBV payw1.2-Luc (Hygro
R
) or HBV payw1.2*7-Luc 
(Hygro
R
) were constructed by insertion of a greater-than-unit-length HBV genome (payw 1.2) or 
a greater-than-unit-length HBV genome without expressing HBx (payw 1.2*7) [219,237] and a 
firefly luciferase (Luc) gene into the plasmid pcDNA-Hygro
R
. Plasmids pFLneo-HCV-2a J6 
core-Flag/JFH-1 (p7-rLuc-2A) and pFLneo-HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) 
were described previously [264] (Chapter 9). Plasmid pFLneo-HCV-2a J6/JFH-1 (p7-rLuc-2A) 
GNN, the replication-deficient version, was obtained from Dr. Charles Rice [263]. Plasmid 
pFLneo-HCV-2a J6 core R50A/JFH-1 (p7-rLuc-2A) GNN was constructed by introducing the 
R50A mutation. We constructed plasmids expressing HBx, HBV precore, HBV L, HBV M or 
HBV S with a myc-tag at the C-terminus under the control of the elongation factor-1α promoter. 
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We also constructed plasmid expressing HBV P with a Flag-tag at the N-terminus the control of 
the elongation factor-1α promoter. Plasmid expressing human PTEN with an N-terminal Flag-tag, 
non-silencing control shRNA, PTEN shRNA were described previously (Chapter 9). Non-
silencing control microRNA (miRNA) and SREBP-1 miRNA were described previously 
[137,288]. 
 
13.4.2 Cell culture, transfection, nuclear fractionation, and generation of stable cell lines 
  
Huh-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% 
(v/v) fetal bovine serum (FBS). Cells were transfected with plasmid DNA and/or HCV RNAs 
using the calcium phosphate precipitation method [163] or the jetPEI transfection reagent 
(Polyplus Transfection) [288], respectively. Nuclear fractionation was described previously [237]. 
To establish HBV replicating cells, Huh-7 cells were transfected with HBV genome plasmid 
DNA and selected by Hygromycin (Enzo Life Sciences). To establish HCV replicating cells, 
Huh-7 cells were transfected with HCV RNA and selected by G418 (Enzo Life Sciences) [164]. 
Huh-7 cells stably expressing HBx, HCV-2a core, or enhanced green fluorescent protein (EGFP) 
were generated by way of lentivirus transduction as described previously [164]. 
 
13.4.3 Luciferase assay 
 
Cells were lysed in Passive Lysis Buffer (Promega) and the firefly or renilla luciferase 
activities were measured by Luciferase Assay reagents (Promega) in a TD 20/20 Luminometer 
(Turner Designs). Firefly or renilla luciferase levels were normalized to the protein 
concentrations determined by the Bradford assay (Bio-Rad Laboratories). Results were analyzed 
for statistical differences by the Student's t test. A p value of ≤ 0.05 was considered statistically 
significant.  
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13.4.4 Western blotting 
 
Proteins were subjected to SDS-PAGE and then blotted onto nitrocellulose membranes. 
The membranes were blocked in 5% skim milk in PBS and then incubated with a primary 
antibody overnight at 4 ℃. Membranes were washed and incubated with a secondary antibody for 
1 hour at room temperature. After a wash with PBST (PBS+0.1% Tween 20), membranes were 
scanned using Li-Cor Odyssey scanner (ODY-CLx) and band intensities were determined by 
Quantity One software (Bio-Rad Laboratories). The following antibodies were used: HBV M 
(Abcam), HBx (Thermo Scientific), HCV core (Anogen), PTEN (Cell signaling Technology, 
CST), SREBP-1 (Santa Cruz Biotechnology, SCBT), SREBP-2 (SCBT), β-actin (CST), 
fibrillarin (Thermo Scientific), Flag (Sigma-Aldrich), and secondary antibodies IRDye 800CW 
goat anti-mouse IgG and IRDye 680RD goat anti-rabbit IgG (Li-Cor Biosciences). 
 
13.5 Results 
 
13.5.1 HCV does not affect HBV replication in HBV genomic DNA transfected HCV 
replicating Huh-7 cells 
 
We generated Huh-7 cells harboring HBV payw1.2-Luc (Hygro
R
) or HBV payw1.2*7-
Luc (Hygro
R
). Then we confirmed the HBV replication in the cell lines by the detection of the 
expression of HBV M (Fig. 13.1A). And we only detected the expression of HBx in Huh-7 cells 
harboring HBV payw1.2-Luc (Hygro
R
) but not in Huh-7 cells harboring HBV payw1.2*7-Luc 
(Hygro
R
). We observed that the lufierase acitivity in Huh-7 cells harboring HBV payw 1.2-Luc 
(Hygro
R
) is significantly higher in comparison to the luciferase activity in Huh-7 cells harboring 
HBV payw 1.2*7-Luc (HygroR) (Fig. 13.1B). As shown in Fig. 13.1C, we found that in Huh-7 
cells harboring HBV payw1.2*7-Luc (Hygro
R
), without HBx, HBV replication level was 
significantly lower than in Huh-7 cells harboring HBV payw1.2-Luc (Hygro
R
). The data supports 
our previous data that HBx up-regulates HBV replication [237,284]. 
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Next we wanted to determine whether the HBV genome plasmid DNA replicated in HCV 
replicating Huh-7 cells. Therefore, payw1.2-Luc (Hygro
R
) plasmid or HBV payw1.2*7-Luc 
(Hygro
R
) plasmid were transfected into HCV replicating Huh-7 cells. We used Huh-7 cells 
harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) and Huh-7 cells harboring HCV-2a J6 core-
Flag R50A/JFH-1 (p7-rLuc-2A) in which HCV core R50A mutation significantly reduces HCV 
RNA level (Chapter 9). As shown in Fig. 13.1D, we detected the expression of HBV M protein in 
HBV payw1.2-Luc (Hygro
R
) and HBV payw1.2*7-Luc (Hygro
R
) plasmid transfected cells. And 
we only detected the expression of HBx in HBV payw1.2-Luc (Hygro
R
) plasmid transfected cells. 
Neither wild-type HCV nor mutant HCV altered HBV payw 1.2 or HBV payw 1.2*7 replication; 
on the other hand, neither HBV payw 1.2 nor HBV payw 1.2*7 affected HCV replication in Huh-
7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) or in Huh-7 cells harboring HCV-2a 
J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) (Fig. 13.1E). 
 
13.5.2 The effect of PTEN on HBV and HCV replication in HBV or HCV mono-infections 
and HBV HCV co-infection 
 
Previously, we reported that the HCV core interacts with PTEN and reduces PTEN level 
which enhances HCV replication (Chapter 9). On the other hand, several studies have established 
that HBx also inhibits PTEN expression [289-292]. However, whether or not PTEN regulates 
HBV replication has not been characterized. Therefore, we were interested in understanding the 
role of PTEN in HBV and HCV replication in mono-infections and co-infection. Huh-7 cells 
were co-transfected with plasmids expressing HBV payw1.2-Luc (Hygro
R
) (Fig. 13.2A and B) or 
HBV payw1.2*7-Luc (Hygro
R
) (Fig. 13.2C) and plasmids expressing PTEN or empty vector. We 
observed that overexpression of PTEN significantly inhibited both wild-type HBV and mutant 
HBV replication. The protein levels of PTEN in wild-type HBV and PTEN co-transfected cells 
were shown in Fig. 13.2B. Moreover, overexpression of PTEN significantly inhibited HCV 
replication in Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A), but not in Huh-7 
cells harboring HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) (Fig. 13.2D and F), which is 
consistent with our previous study (Chapter 9). The protein levels of PTEN in PTEN 
overexpressed wild-type HCV replicating cells were shown in Fig. 13.2E.  Then Huh-7 cells 
harboring wild-type HCV or mutant HCV replicating RNAs were co-transfected with plasmid 
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expressing PTEN or empty vector and HBV payw1.2-Luc (HygroR) or HBV payw1.2*7-Luc 
(HygroR) genome plasmids. Overexpression of PTEN inhibited both wild-type HBV and mutant 
HBV replication in either Huh-7 cells harboring wild-type HCV or mutant HCV replicating 
RNAs (Fig. 13.2G, I, J and L). While overexpression of PTEN significantly inhibited HCV 
replication in Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) RNA (Fig. 13.2G 
and I) but not in Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) RNA 
(Fig. 13.2J and L). The protein levels of PTEN in wild-type HBV and PTEN transfected Huh-7 
cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) (Fig. 13.2G) or Huh-7 cells harboring 
HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) (Fig. 13.2J) were shown in Fig. 13.2H and K. 
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Fig. 13.1. HBV and HCV do not interfere with each other in HBV genome plasmid 
transfected HCV replicating cells. (A, B) The lysates of Huh-7 cells harboring HBV genome 
payw1.2-Luc (Hygro
R
) replicating DNA or HBV genome payw 1.2*7-Luc (Hygro
R
) replicating 
DNA were performed to luciferase activity and Western blotting assay. (A) The expression of 
HBV M and HBx proteins were determined by Western blotting using anti-HBV M and anti-HBx 
antibodies. The β-actin levels determined by a β-actin antibody were used as loading controls. 
This experiment was performed three times (B). Luciferase assay was performed 48 hours after 
transfection. This experiment was performed three times (C). Huh-7 cells were transfected with 
HBV genome payw1.2-Luc (Hygro
R
) replicating DNA or HBV genome payw 1.2*7-Luc 
(Hygro
R
) replicating DNA. Luciferase assay was performed 48 hours after transfection. This 
experiment was performed three times (D, E). Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-
1(p7-rLuc-2A) replicating RNA or HCV-2a J6 core-Flag R50A/JFH-1(p7-rLuc-2A) replicating 
RNA were transfected with plasmids containing HBV genome payw1.2-Luc (Hygro
R
), HBV 
genome payw1.2*7-Luc (Hygro
R
) or vector (D). The expression of HCV core, HBV M and HBx 
proteins were determined by Western blotting using anti-Flag, anti-HBV M and anti-HBx 
antibodies. The β-actin levels determined by a β-actin antibody were used as loading controls. 
This experiment was performed two times (E). Dual luciferase assay was performed 48 hours 
after transfection. This experiment was performed three times (B, C, E). Luciferase activity and 
dual luciferase assay were measured and normalized to total protein amount. Statistical 
differences between samples were analyzed by Student's t test and demonstrated as ** if p ≤ 0.01, 
*** p ≤ 0.001 or NS for not significant.   
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To further determine the effect of PTEN on HBV and HCV replication, we used PTEN 
shRNA to knock down PTEN. We found that PTEN knockdown significantly enhanced both 
wild-type (Fig. 13.3A, G and J) and mutant HBV (Fig. 13.3B, I and L) replication in HBV and 
PTEN shRNA co-transfected cells. On the other hand, PTEN knockdown significantly enhanced 
HCV replication in Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) RNA (Fig. 
13.3D, G and I) or Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) RNA 
(Fig. 13.3F, J and L). Interestingly, we observed that PTEN knockdown enhanced HBV 
replication around 4-fold (Fig. 13.3A and C) in HBV and PTEN shRNA transfected Huh-7 cells 
while only enhance HBV replication around 1.5-fold in HBV and PTEN shRNA transfected 
HCV replicating Huh-7 cells (Fig. 13.3G, I, J and L). We found that the protein level of PTEN 
reduced around 70% in HBV and PTEN shRNA transfected Huh-7 cells in comparison to HBV 
and control shRNA transfected Huh-7 cells (Fig. 13.3B); whereas, the protein levels of PTEN 
reduced around 40% to 50% in PTEN knockdown HCV replicating Huh-7 cells (Fig. 13.3E, H 
and K). The higher efficiency of PTEN shRNA in Huh-7 cells may result in the stronger effect on 
HBV replication. 
Overall, these data indicate that PTEN inhibits HBV and HCV replication in HBV or 
HCV mono-infections and HBV HCV co-infection.  
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Fig. 13.2. Overexpression of PTEN inhibits HBV and HCV replication in HBV or HCV 
mono-infections and HBV HCV co-infection. Huh-7 cells (A - C), Huh-7 cells harboring HCV-
2a J6 core-Flag/JFH-1 (p7-rLuc-2A) (D, E, G, H and I) or Huh-7 cells harboring HCV-2a J6 
core-Flag R50A/JFH-1 (p7-rLuc-2A) (F, J, K and L) were co-transfected with plasmids 
expressing Flag-PTEN or empty vector and plasmids containing HBV genome payw1.2-Luc 
(Hygro
R
), HBV genome payw1.2*7-Luc (Hygro
R
) or vector. (A, C, D, F, G, I, G, L) Luciferase 
activity was measured 48 hours after transfection and normalized to total protein amount. 
Luciferase activities were expressed as fold changes relative to vector control. Statistical 
differences between samples were analyzed by Student's t test and demonstrated as * if p ≤ 0.05, 
** if p ≤ 0.01, *** if p ≤ 0.001 or NS for not significant. These experiments were performed three 
times. The protein levels of PTEN in A, D, G and J were shown in B, E, H and K. The total 
protein levels of PTEN were analyzed by Western blotting using anti-PTEN antibody. The β-
actin determined by anti-β-actin antibody was used as loading controls. The intensities of the 
bands were analyzed by the Quantity One program. These experiments were performed two times. 
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Fig. 13.3. PTEN knockdown enhances both HBV and HCV replication in HBV or HCV 
mono-infections and HBV HCV co-infection. Huh-7 cells (A - C), Huh-7 cells harboring HCV-
2a J6 core-Flag/JFH-1 (p7-rLuc-2A) (D, E, G, H and I) or Huh-7 cells harboring HCV-2a J6 
core-Flag R50A/JFH-1 (p7-rLuc-2A) (F, J, K and L) were co-transfected with plasmids 
expressing non-silencing control shRNA or shRNA targeting the 3'-UTR of PTEN and plasmids 
containing HBV genome payw1.2-Luc (Hygro
R
), HBV genome payw1.2*7-Luc (Hygro
R
) or 
vector. (A, C, D, F, G, I, G, L) Luciferase activity was measured 48 hours after transfection and 
normalized to total protein amount. Luciferase activities were expressed as fold changes relative 
to vector control. Statistical differences between samples were analyzed by Student's t test and 
demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, *** if p ≤ 0.001 or NS for not significant. These 
experiments were performed three times. The protein levels of PTEN in A, D, G and J were 
shown in B, E, H and K. The total protein levels of PTEN were analyzed by Western blotting 
using anti-PTEN antibody. The β-actin determined by the anti-β-actin antibody was used as 
loading controls. The intensities of the bands were analyzed by the Quantity One program. These 
experiments were performed two times. 
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13.5.3 The effect of PTEN and SREBP-1 on HBV and HCV replication in HBV or HCV 
mono-infections and HBV HCV co-infection 
 
PTEN inhibits PI3K/Akt pathway through its lipid phosphatase activity [45,49] and thus 
inhibits SREBP-1 activation which is a downstream factor of Akt [210]. We next wanted to 
determine whether or not PTEN regulates HBV and HCV replication through modulating 
SREBP-1 activation. We used PTEN shRNA and SREBP-1 microRNA (miRNA) (which was 
used in Chapters 3 and 7) to knockdown PTEN and/or SREBP-1 in HBV or HCV replicating 
Huh-7 cells. As shown in Fig. 13.4A and B, knocking down PTEN significantly enhanced HBV 
replication in Huh-7 cells harboring HBV payw1.2-Luc (Hygro
R
), while knocking down SREBP-
1 significantly inhibited HBV replication. In the PTEN shRNA and SREBP-1 miRNA co-
transfected cells, the protein levels of PTEN and nuclear SREBP-1 were down-regulated around 
50% in comparison to the protein levels in non-silencing shRNA and non-silencing miRNA co-
transfected cells (Fig. 13.4B), which led to inhibiting HBV replication (Fig. 13.4A). This result 
indicates that PTEN modulates HBV replication through regulating SREBP-1 activation. 
However, in Huh-7 cells harboring HBV payw1.2*7 (Hygro
R
), only knocking down PTEN 
significantly enhanced HBV replication; knocking down SREBP-1 did not alter HBV replicating 
(Fig. 13.4C). Overall, these results indicate that HBx plays a role in PTEN/SREBP-1 modulated 
HBV replication. As shown in Fig. 13.4D to F, in Huh-7 cells harboring HCV-2a J6 core-
Flag/JFH-1 (p7-rLuc-2A) RNA and Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 
(p7-rLuc-2A) RNA, PTEN knockdown significantly enhanced HCV replication; SREBP-1 
knockdown significantly inhibited HCV replication; however, knocking down SREBP-1 does not 
affect the PTEN-modulated HCV replication. The data show that PTEN and SREBP-1 can 
modulate HCV replication. However, PTEN does not modulate HCV replication through the 
inhibition of SREBP-1 activation. 
Next, we wanted to determine the role of PTEN and SREBP-1 in HBV and HCV 
replication in HBV HCV co-replicating cells. HCV replicating Huh-7 cells were first transfected 
with HBV genome plasmid DNA and then co-transfected with PTEN shRNA and SREBP-1 
miRNA. The protein levels of PTEN were down-regulated in PTEN shRNA transfected cells in 
comparison to non-silencing shRNA transfected cells; the protein levels of nuclear SREBP-1 
were modulated by PTEN shRNA and SREBP-1 miRNA as expected (Fig. 13.5C). As shown in 
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Fig. 13.5A and B, knocking down PTEN enhanced HBV replication; however, knocking down 
SREBP-1 inhibited wild-type HBV replication. On the other hand, only SREBP-1 knockdown 
inhibited HCV replication and PTEN knockdown enhanced HCV replication irrespective of 
SREBP-1 knockdown. These data suggest that PTEN and SREBP-1 have similar effect on HBV 
and HCV replication in HBV HCV co-infection as well as in HBV or HCV mono-infections. 
 
13.5.4 The effect of HBx and HCV core on PTEN and SREBP-1 
 
In order to determine the effect of HBx and HCV core on PTEN and SREBP-1, we 
established Huh-7 cells stably expressing HBx, HCV core or EGFP. We observed that the protein 
levels of PTEN were significantly lower and the protein levels of nuclear SREBP-1 were 
significantly higher in Huh-7 cells stably expressing HBx and Huh-7 cells stably expressing HCV 
core in comparison to the PTEN protein level and SREBP-1 protein level in EGFP-expressing 
Huh-7 cells (Fig. 13.6A). The data indicate that both the HBx and HCV core can down-regulate 
PTEN and up-regulate the SREBP-1 at the protein level. Then we wanted to determine whether 
the HBx and HCV core synergistically regulate PTEN and SREBP-1. Plasmid expressing HBx 
was transfected into HCV core-expressing Huh-7 cells. We found that the protein levels of PTEN 
and SREBP-1 was not further modulated after HBx expression in Huh-7 cells stably expressing 
HCV core in comparison to the protein levels of PTEN and SREBP-1 in empty vector or EGFP 
transfected cells (Fig. 13.6B). The data imply that the effects of HBx and HCV core on PTEN 
and SREBP-1 are not additive.  
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Fig. 13.4. The role of PTEN/SREBP-1 pathway on HBV and HCV replication in HBV or 
HCV mono-infected cells. Huh-7 cells HBV genome payw1.2-Luc (Hygro
R
) (A, B), Huh-7 cells 
harboring HBV genome payw1.2*7-Luc (Hygro
R
) (C), Huh-7 cells harboring HCV-2a J6 core-
Flag/JFH-1 (p7-rLuc-2A) (D, E) or Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 
(p7-rLuc-2A) (F) were co-transfected with plasmids expressing non-silencing control shRNA or 
shRNA targeting the 3'-UTR of PTEN and non-silencing control miRNA or SREBP-1-targeting 
miRNA. At 48 hours after transfection, (A, C, D, F) Luciferase activities were expressed as fold 
changes relative to vector control. Statistical differences between samples were analyzed by 
Student's t test and demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, *** if p ≤ 0.001 or NS for not 
significant. These experiments were performed three times. (B, E) The total protein levels of 
PTEN were analyzed by Western blotting using anti-PTEN antibody. The β-actin determined by 
anti-β-actin antibody was used as loading controls. The nuclear protein levels of SREBP-1 were 
analyzed by Western blotting using anti-SREBP-1 antibody. The fibrillarin levels determined by 
an anti-fibrillarin antibody were used as loading controls. The intensities of the bands were 
analyzed by the Quantity One program. These experiments were performed two times. 
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Fig. 13.5. The role of PTEN/SREBP-1 pathway on HBV and HCV replication in HBV HCV 
co-infected cells. Huh-7 cells harboring HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) (A, B) or 
Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 (p7-rLuc-2A) (C) were transfected 
with plasmids containing HBV genome payw1.2-Luc (HygroR), HBV genome payw1.2*7-Luc 
(HygroR) or HygroR gene. At 24 hours after transfection, cells were then co-transfected with 
plasmids expressing non-silencing control shRNA or shRNA targeting the 3'-UTR of PTEN and 
non-silencing control miRNA or SREBP-1-targeting miRNA. At another 48 hours after 
transfection, (A, B) Luciferase activities were expressed as fold changes relative to vector control. 
Statistical differences between samples were analyzed by Student's t test and demonstrated as * if 
p ≤ 0.05, ** if p ≤ 0.01, *** if p ≤ 0.001 or NS for not significant. These experiments were 
performed three times. (C) The total protein levels of PTEN were analyzed by Western blotting 
using anti-PTEN antibody. The β-actin determined by anti-β-actin antibody was used as loading 
controls. The nuclear protein levels of SREBP-1 were analyzed by Western blotting using anti-
SREBP-1 antibody. The fibrillarin levels determined by an anti-fibrillarin antibody were used as 
loading controls. The intensities of the bands were analyzed by the Quantity One program. These 
experiments were performed two times. 
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Fig. 13.6. HBx and HCV core reduce PTEN protein level and enhance nuclear SREBP-1 
protein level. (A) The total protein levels of PTEN and nuclear protein levels of SREBP-1 in 
Huh-7 cells stably expressing HBx, EGFP or HCV core were analyzed by Western blotting using 
anti-PTEN and anti-SREBP-1 antibodies. The β-actin and fibrillarin levels determined by anti-β-
actin and anti-fibrillarin antibodies were used as loading controls. (B) Huh-7 cells stably 
expressing HCV core were transfected with plasmids expressing HBx-3xmyc, EGFP-3xmyc or 
empty vector. The total protein levels of PTEN and nuclear protein levels of SREBP-1 in total 
cell lysates or in nuclear fractions were analyzed by Western blotting using anti-PTEN and anti-
SREBP-1 antibodies. The β-actin and fibrillarin levels determined by anti- β-actin and anti-
fibrillarin antibodies were used as loading controls. (A, B) The intensities of the bands were 
analyzed by the Quantity One program. The statistical differences between samples were 
demonstrated as * if p ≤ 0.05 or NS for not significant. Error bars indicated standard error of the 
mean (n=3).  
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13.5.5 HBV enhanced HCV translation and replication only in the early stage of HCV 
infection 
 
Previously, we have shown that HBV and HCV can replicate without interfering with 
each other in HCV replicating Huh-7 cells transfected with HBV genomic DNA. Next, we 
wanted to study HCV replicates in HBV replicating cells. Huh-7 cells, Huh-7 cells harboring 
HBV payw 1.2 (Hygro
R
) or HBV payw 1.2*7 (Hygro
R
) were transfected with wild-type or R50A 
mutant HCV replicating RNA. As shown in Fig. 13.7A, HCV did not affect HBV replication in 
Huh-7 cells harboring HBV payw 1.2 (Hygro
R
) or HBV payw 1.2*7 (Hygro
R
) from 4 - 72 hours 
after transfection. However, at 4 hours after transfection, the value of rLuc activities of mutant 
HCV were significantly higher in Huh-7 cells harboring HBV payw 1.2 (Hygro
R
) or HBV payw 
1.2*7 (Hygro
R
) than in Huh-7 cells (Fig. 13.7A). Therefore, we hypothesized that HBV may 
enhance HCV translation. To examine whether HBV affects HCV translation, Huh-7 cells were 
co-transfected with replication-deficient wild-type or R50A mutant HCV genomic RNA and 
plasmids expressing HBV proteins or empty vectors. We found that HBV S slightly but 
significantly enhanced both wild-type and mutant HCV translation (Fig. 13.7B and C). The 
expression of HBV proteins was shown in Fig. 13.7D. We also noticed that, in Fig. 13.7A, at 24 
hours and 48 hours after transfection, HCV replication level was higher in HCV-2a J6 core-
Flag/JFH-1 (p7-rLuc-2A) RNA transfected Huh-7 cells harboring HBV payw 1.2 (Hygro
R
) in 
comparison to HCV replication levels in HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) RNA 
transfected Huh-7 cells or Huh-7 cells harboring HBV payw 1.2*7 (Hygro
R
). It may indicate that 
HBV enhances the HCV replication. To futher determine the effect of HBV on HCV replication, 
Huh-7 cells, Huh-7 cells harboring HBV payw 1.2 (Hygro
R
) or HBV payw 1.2*7 (Hygro
R
) were 
infected with HCV-2a J6 core-Flag/JFH-1 (p7-rLuc-2A) virus. We found that only at 48 hours 
post infection, HCV replication level was higher in HCV infected Huh-7 cells harboring HBV 
payw 1.2 (Hygro
R
) in comparison to HCV replication levels in HCV infected Huh-7 cells or Huh-
7 cells harboring HBV payw 1.2*7 (Hygro
R
) (Fig. 13.7E). Overall, the data indicate that HBV 
enhances HCV replication only in the early period of HCV infection. HBx plays an important 
role in the regulation of HCV replication. 
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Fig. 13.7. HBV enhances HCV translation in HCV RNA transfected HBV replicating cells 
and up-regulates early stage of HCV replication in HCV infected HBV replicating cells. 
Huh-7 cells, Huh-7 cells harboring HBV genome payw1.2-Luc (Hygro
R
) or Huh-7 cells 
harboring HBV genome payw1.2*7-Luc (Hygro
R
) were transfected with HCV-2a J6 core-
Flag/JFH-1 (p7-rLuc-2A) RNA or Huh-7 cells harboring HCV-2a J6 core-Flag R50A/JFH-1 (p7-
rLuc-2A) RNA. At 4, 24, 48 and 72 hours after transfection, luciferase activities were expressed 
as fold changes relative to vector control. Huh-7 cells were co-transfected with HBV proteins or 
empty vector and a monocistronic HCV-2a translation rLuc reporter RNA (B) or a full-length 
HCV-2a J6/JFH-1 (p7-rLuc-2A) GNN RNA (C). At 48 hours after transfection, luciferase 
activities were expressed as fold changes relative to vector control. (D) Huh-7 cells were 
transfected with HBV proteins or empty vector. At 48 hours after transfection, the expression of 
the proteins was determined by Western blotting assay using anti-Myc and anti-Flag antibodies. 
(E) Huh-7 cells, Huh-7 cells harboring HBV genome payw1.2-Luc (Hygro
R
) or Huh-7 cells 
harboring HBV genome payw1.2*7-Luc (Hygro
R
) were infected with HCV-2a J6 core-Flag/JFH-
1 (p7-rLuc-2A) virus at a multiplicity of infection (MOI) of 1. At 24, 48, and 72 hours after 
transfection, luciferase activities were expressed as fold changes relative to vector control. (A, B, 
C and E) Statistical differences between samples were analyzed by Student's t test and 
demonstrated as * if p ≤ 0.05, ** if p ≤ 0.01, *** if p ≤ 0.001 or NS for not significant. 
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13.6 Discussion 
 
HBV HCV co-infection includes four clinical features: acute HBV/HCV co-infection, 
HCV superinfection in chronic hepatitis B (CHB) patients, HBV superinfection in chronic 
hepatitis C (CHC) patients, and occult hepatitis B (OHB) [93,293,294]. Therefore, how HBV and 
HCV replicate in the cells in the early period after infection is worthy of study. In this study, we 
constructed plasmids HBV payw1.2-Luc (Hygro
R
) or HBV payw1.2*7-Luc (Hygro
R
) and then 
established Huh-7 cells harboring HBV payw1.2-Luc (Hygro
R
) and Huh-7 cells harboring HBV 
payw1.2*7-Luc (Hygro
R
). In HBV genome plasmid transfected HCV replicating Huh-7 cells, we 
observed that HBV and HCV can replicate in HBV genomic DNA transfected Huh-7 cells 
without interfering with each other (Fig. 13.1). On the other hand, in HCV genomic replicon 
RNA transfected HBV replicating Huh-7 cells, we found that HBV enhanced HCV translation 
and replication just within 48 hours after HCV infection (Fig. 13.7). We observed that HBV S 
protein is essential for up-regulating HCV translation and HBx is required for enhancing HCV 
replication. 
HBV or HCV mono-infections and HBV HCV co-infection are risk factors of developing 
HCC [283]. To study the potential mechanism of how HBV and HCV infections cause HCC, we 
focused on a tumor suppressor, PTEN. Interestingly, we found that PTEN can inhibit HBV or 
HCV replication through different mechanisms. When we used PTEN shRNA and SREBP-1 
miRNA to modulate the protein level of PTEN and nuclear SREBP-1, we found that HBV 
replication was inversely correlated with the SREBP-1 level in the nucleus (Fig. 13.4A and B). 
PTEN regulates SREBP-1 activation through its lipid phosphatase activity. Moreover, HBx is 
required in this process (Fig. 13.4C), which supports our previous study [284]. In HCV 
replicating Huh-7 cells, although knocking down SREBP-1 resulted in inhibiting HCV 
replication, PTEN knockdown counteracted this inhibition and even enhanced HCV replication 
(Fig. 13.4C and D). It implies that SREBP-1 activation is important for HCV replication. 
However, PTEN does not regulate HCV replication through modulating SREBP-1. Moreover, we 
found that PTEN and SREBP-1 play similar roles in regulating HBV and HCV replicating in 
HBV or HCV mono-infections as in HBV HCV co-infection (Fig. 13.4 and 13.5). 
Since HBx plays an important role in PTEN/SREBP-1 mediated HBV replication (Fig. 
13.4A to C), and our previous study has shown that the interaction between HCV core and PTEN 
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is involved in HCV replication. We proposed that HBx and HCV core may be essential for 
regulating PTEN and SREBP-1 which leads to modulating HBV and HCV replication in HBV 
HCV co-infection. First, we found that both HBx and HCV core can inhibit PTEN and stimulate 
SREBP-1 activation (Fig. 13.6A). Next, we observed that overexpression of HBx in Huh-7 cells 
stably expressing HCV core did not alert the protein level of PTEN and nuclear SREBP-1 (Fig. 
13.6B). This result indicates that HBx and HCV core may play an independent role in regulating 
PTEN and SREBP-1 in HBV HCV co-infection. It is the potential mechanism in explaining why 
PTEN and SREBP-1 play the same role in HBV or HCV mono-infections as in HBV HCV co-
infection. It also is the potential mechanism in explaining why HBV enhances HCV replication 
only in the early period of HCV infection in HCV infected HBV replicating Huh-7 cells (Fig. 
13.7E). We have previously shown that HCV core can interact with PTEN and reduce the protein 
level of PTEN which enhanced HCV replication (Chapter 9). In Huh-7 cells harboring HBV 
payw1.2-Luc (Hygro
R
), the protein level of PTEN may be lower than in Huh-7 cells or in Huh-7 
HBV payw1.2*7-Luc (Hygro
R
) since HBx inhibits the protein level of PTEN. Therefore, in the 
early period of HCV infection, the HBx mediated low protein level of PTEN may enhance HCV 
replication. After that, HCV core may play the same role as HBx, thus HBV no longer enhances 
HCV replication. 
In summary, we studied an HCC-related signaling pathway, the PTEN/SREBP-1 pathway, 
in HBV or HCV mono-infections and HBV HCV co-infection. We demonstrated that both HBx 
and HCV core inhibit the protein level of PTEN and enhance SREBP-1 activation, and 
modulating the protein level of PTEN and nuclear SREBP-1 can regulate HBV and HCV 
replications. We also studied the early the role of HBV and HCV replication in HBV genomic 
DNA transfected HCV replicating cells or HCV genomic RNA transfected HBV replicating cells. 
This study contributes to understand the pathnogenesis in HCV superinfection in CHB or HBV 
superinfection in CHC. In a further study, we plan to establish HBV HCV co-replicating Huh-7 
cells and study the effect of PTEN/SREBP-1 pathway on HBV and HCV replication in HBV 
HCV co-replicating cells. The study may contribute to develop of the new therapy of HBV HCV 
chornic co-infection.  
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14.0 GENERAL DISCUSSION, CONCLUSION AND FUTURE EXPERIMENTS 
 
 
14.1 General Discussion 
 
 
 HBV infection causes acute and chronic liver disease and has been proved to be a high 
risk factor for the development of HCC [295]. Previous studies have shown that HBx functions as 
a transcriptional transactivator of host genes and promotes cell growth and HCC [18,100]. 
SREBPs are transcription factors which belong to the bHLH-ZIP family [67]. A previous study 
has demonstrated that in HBV-associated HCC specimens, the expression of SREBP-1 is 
significantly increased [110]. Therefore, we hypothesized that if HBx regulates SREBP-1 activity, 
it may occur at different levels including SREBP gene transcription, SREBP cleavage and 
nuclear localization. In Chapter 3, we first determined that the expression of HBx enhances the 
total SREBP-1 protein level and the nuclear SREBP-1a protein level (Fig. 3.1). Then we 
demonstrated that HBx modulates SREBP-1 at the transcription level (Fig. 3.2). Interestingly, we 
observed that SREBP-1a promoter activity is increased around 3-fold in HBV genomic DNA 
transfected cells in comparison to empty vector transfected cells; however, in HBV ∆HBx 
genomic DNA transfected cells, SREBP-1a promoter activity is also slightly increased (Fig. 
3.2E). This result may indicate that besides HBx, other HBV protein(s) may also enhance 
SREBP-1a promoter activity. The mechanism is not understood at this time. The HBV genome 
plasmid payw1.2 can express the HBV pregenomic RNA and HBV proteins. The plasmid with a 
mutant which containing a stop codon affect HBx amino acid position 7 can express other HBV 
proteins but not HBx [200]. Therefore, these HBV genome plasmids are widely used models for 
studying HBV replication. HBV gene expression is regulated by two HBV enhancers [218]. HBx 
also activates HBV enhancers and thus increases HBV replication [11,12]. We found that after 
knocking down SREBP-1, HBx is no longer able to transactivate the HBV enhancer II/core 
promoter (Fig. 3.4). It indicates that SREBP-1 plays an important role in the HBx-associated 
activation of the HBV enhancer II/core promoter. Therefore, we were interested in determining 
the mechanisms of how HBx regulates SREBP-1 and HBV enhancers. Since transcription of 
shRNA targets one specific gene and results in gene knockdown [296]. We planned to use 
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SREBP-1 shRNA to knockdown SREBP-1. However, the SREBP-1 shRNA we designed did not 
reduce the SREBP-1 protein level. Previous study has reported that shRNA sometimes did not 
lead to efficient gene knockdown [297]. Then we tested whether the SREBP-1 miRNA we 
designed can reduce SREBP-1 protein level. As shown in Fig. 3.4A, the SREBP-1 miRNA 
reduced both the total and nuclear SREBP-1 protein levels. 
 HBx contains 154 amino acids with a molecular weight of 17 kDa and is localized in the 
nucleus, cytoplasm, and mitochondria [123-125]. Different subcellular localizations of HBx 
display different transactivational activities [237]. HBx has been reported to induce cell 
proliferation through modulation of the PTEN/PI3K/Akt pathways [290,298]. Moreover, SREBP-
1 is the downstream factor of the PI3K/Akt [176], and activation of SREBP-1a by HBx leads to 
lipid cell proliferation in human liver cells [110,138]. Previous studies have demonstrated that the 
transactivation of SREBP-1a and FASN by HBx induces lipid accumulation [109,215]. In 
Chapter 5, we showed that nuclear HBx, rather than wild-type HBx or cytoplasmic HBx, has 
stronger effects on activating SREBP-1a and FASN transcription, increasing intracellular lipid 
accumulation and cell proliferation (Fig. 5.2). These results indicate that HBx has to localize in 
the nucleus to transactivate SREBP-1a and FASN and induce lipid accumulation and cell 
proliferation. Moreover, we also observed that wild-type HBx and nuclear HBx but not 
cytoplasmic HBx enhances HBV enhancer I/X promoter activity and HBV mRNA level in the 
context of HBV replication; however, only wild-type HBx enhances HBV enhancer II/core 
promoter activity (Fig. 5.3). These results imply that nuclear HBx stimulates HBV replication 
through up-regulation of HBV enhancer I/X promoter activity. However, the mechanism of how 
HBx regulates HBV enhancer II/core promoter activity is still not clear. 
 Truncated forms of HBx are more commonly found in HBV-associated tumor tissues 
[130-132]. The pathobiological significance of this finding is not well understood. Previous 
studies have demonstrated that the C-terminal region of HBx plays important roles in HBx 
stability [132-134]. In addition, the C-terminal region of HBx is involved in HBx-modulated 
HBV replication in cell culture [12,133,135]. Therefore, we were interested in whether different 
truncated forms of HBx regulate SREBP-1 and HBV enhancers differentially. Previous studies 
have reported that HBx plays different role in regulation of HBV replication in HepG2 or Huh-7 
cells [196,219]. Therefore, we used both HepG2 and Huh-7 cells to study how HBx regulates 
HBV replication.We observed that HBx aa. 1-127 can only stimulate SREBP-1c transcription but 
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not SREBP-1a transcription; on the other hand, HBx aa. 43-154 can only enhance SREBP-1a 
transcription but not SREBP-1a transcription (Fig. 7.1). Moreover, HBx aa. 1-127 can only up-
regulate HBV enhancer I/X activation; HBx aa. 43-154 can only stimulate the activity of HBV 
enhancer II/core (Fig. 7.3). Consistent with the results in Chapter 3, we also observed that 
knocking down SREBP-1 abrogated the activation of HBV enhancers by HBx (Fig. 7.3). These 
results confirm that SREBP-1 is involved in the HBx-induced HBV enhancers’ activation. More 
specifically, HBx aa. 1-127 activates SREBP-1c which is involved in the process of HBV 
enhancer I/X activation by HBx aa. 1-127; HBx aa. 43-154 enhances the transactivation of 
SREBP-1a which plays an important role on HBV enhcnaer II/core activation by HBx aa. 43-154 
(Fig. 7.3). We then found that HBx activates SREBP-1 is essential for the regulation of HBV 
replication by HBx (Fig. 7.4 and 7.5). 
 Taken together, from Chapters 3 to 7, we demonstrated the mechanisms of how HBx 
regulates HBV replication through SREBP-1-dependent activation of HBV enhancers. Since in 
Chapter 5, we observed that only nuclear HBx but not cytoplasmic HBx can transactivate 
SREBP-1a and stimulate HBV enhcancer activity, we assumed that both HBx aa. 1-127 and HBx 
aa. 43-154 regulates SREBP-1 and HBV enhancers in the nucleus. However, we do not have data 
to support this now. Further study is required to understand if different subcellular localization of 
truncated forms of HBx regulates SREBP-1 and HBV enhcancers differentially. 
Numerous studies have demonstrated that HCV infection inhibits PTEN through multiple 
mechanisms [147-149]. However, the effect of PTEN on HCV was not fully understood. In 
Chapter 9, we first demonstrated that PTEN inhibits HCV entry, PTEN lipid phosphatase activity 
is required; PTEN has no effect on HCV translation; PTEN inhibits HCV replication and 
secretion, PTEN protein phosphatase activity is required (Fig. 9.1 to 9.4). 
The activity of PTEN can be regulated by protein-protein interaction [45]. HCV core is a 
structural protein of HCV and functions mainly in the formation of the viral nucleocapsid to 
protect viral RNA [23]. Therefore, HCV core contains both lipid and RNA binding activities. 
Moreover, HCV core also interacts with HCV NS5A protein and host proteins [274,299]. 
Therefore, we assumed that HCV core may interact with PTEN and modulate the phosphatase 
activity of PTEN. We found that PTEN interacts with HCV core protein. HCV core aa. R50 and 
PTEN aa. 1-186 are essential for the interaction (Fig. 9.5 to 9.7). Previous studies have 
demonstrated that expression of HCV core can inhibit PTEN translation by blocking PTEN 
 150 
 
mRNA translation in a 3'-UTR dependent manner [147] and activation of NF-κB [149]. Our 
study displays a new mechanism for how HCV core inhibits PTEN. 
Inhibition of PTEN by HCV core may be important for HCV entry, replication and 
secretion. PTEN suppresses PI3K/Akt pathway through its lipid phosphatase activity [45]. 
Previous study has reported that HCV infection antivates PI3K/Akt pathway and enhances HCV 
viral entry, HCV entry receptor CD81 and its co-receptor claudin-1are involved in the process 
[256]. Therefore, PTEN may inhibit HCV entry through suppression of PI3K/Akt pathway (Fig. 
14.1). Loss of PTEN protein phosphatase activity up-regulates HCV secretion through 
accumulation of large lipid droplets [259]. HCV core recruits HCV NS proteins to lipid droplets, 
which is essential for formation of the membrous web and HCV replication [300]. Therefore, 
PTEN may regulate HCV replication and secretion thourhg modulation of lipid metabolism (Fig. 
14.1). 
When we tried to determine whether the interaction of HCV core and PTEN might affect 
PTEN phosphatase activity, we could not purify the full-length HCV core protein. Thus, instead 
of full-length HCV core protein, we purified HCV-2a core domain I and HCV-2a core domain I 
R50A proteins. To determine the binding affinity between purified HCV 2a core domain I and 
PTEN proteins, a dose-dependent GST pull-down assay was performed [301,302]. We found that 
as increasing the concentration of wild type HCV-2a core domain I protein and HCV-2a core 
domain I R50A protein, more pull-down proteins were detected (Fig. 9.7). Therefore, we 
conclude that HCV core interacts with PTEN, mutation of R50A leads to weakening the binding 
affinity. However, we did not detect the interaction between HCV-2a core R50A and PTEN in 
cells. It may be for two reasons. First, previous studies have determined that PTEN associates 
with many cellular proteins [45]; therefore, in cells, HCV-2a core may compete with other 
proteins to interact with PTEN. Second, when the input concentration of HCV 2a core domain I 
R50A protein was very low, it was hardly detected by Western blotting assay (Fig. 9.7). 
Therefore, R50A mutant of HCV core weakens the binding affinity of PTEN and may result in 
reducing the amount of PTEN-interacted HCV-2a core R50A protein to an undetectable level. 
When we determined the effect of HCV core domain I on PTEN PIP3 phosphatase activity, we 
observed that HCV core domain I increased PTEN PIP3 phosphatase activity in a dose-dependent 
manner (Fig. 9.7E). As shown in Fig. 9.2, PTEN lipid phosphatase activity inhibits HCV entry. 
These data imply that HCV-2a core interacts with PTEN may inhibit HCV entry in a dose-
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dependent manner. It is possible that a primary HCV infection followed by a secondary 
reinfection with a distinct HCV at alater time point, this process is called HCV superinfection 
[303]. Our data may indicate HCV-2a may inhibit HCV superinfection through modulation of 
PTEN lipid phosphatase activity in a dose dependent manner. We just used HCV-2a core in the 
PTEN phosphatase assay experiment. In the future, we want to determine if other genotypes of 
HCV core interact with PTEN and regulate PTEN phosphatase activities. 
After demonstrating the effect of PTEN on HCV infection, we were then interested in 
characterizing whether PTEN-Long, an isoform of PTEN, may regulate HCV infection as well as 
PTEN. We first found that intracellular PTEN-Long inhibits HCV replication as effectively as 
intracellular PTEN (Fig. 11.1). Since PTEN-Long allows secretion in exosomes and function 
outside of the cell [59,60], we were then interested in studying whether extracelluar PTEN-Long 
may regulate HCV replication. We observed that extracellular PTEN-Long, but not PTEN, can 
enter the HCV replicating cells and inhibit HCV replication (Fig. 11.2). Moreover, the interaction 
of HCV core and PTEN-Long is essential for the inhibition of HCV replication by PTEN-Long 
(Fig. 11.3). This finding indicates that PTEN-Long treatment may be an option for HCV therapy.  
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Fig. 14.1. Potential mechanisms of how HCV core regulates HCV life cycle through 
inhibition of PTEN.  
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We proposed studying HBV HCV co-infection using four models. To study the acute 
HBV HCV co-infection, we planded to co-transfect both HBV genomic DNA and HCV genomic 
HCV in Huh-7 cells; to study whether HCV affects the early stage of HBV infection, we planned 
to transfect HBV genomic DNA into HCV-replicating Huh-7 cells; to study whether HBV 
regulates the early stage of HCV infection, we wanted to transfect HCV RNA into HCV-
replicating Huh-7 cells; to study whether HBV and HCV interfere with each other in chronic 
HBV HCV co-infection, we planned to establish the HBV and HCV co-replicating Huh-7 cells. 
In Chapter 13, we showed that HBV and HCV do not interfere with each other in HBV genome 
plasmid transfected HCV-replicating Huh-7 cells (Fig. 13.1); HBV enhances the early stage of 
HCV infection in HCV RNA transfected HBV-replicating Huh-7 cells (Fig. 13.7). We will study 
other two models of HBV HCV co-infection in the future study. 
PTEN negatively regulates the activity of SREBP-1 through suppression of the PI3K/Akt 
pathway [45,80]. HBx can also inhibit PTEN through different mechanisms. Previous studies 
have demonstrated that HBx inhibits the function of p53 [285] and therefore increases alpha-
fetoprotein (AFP) expression [286]. AFP associates with PTEN in the cytoplasm and reduces 
PTEN level [287]. MicroRNAs are a family member of small non-coding nucleotide RNA 
molecules which translationally regulate protein expression through targeting messenger RNAs 
(mRNAs). This process results in cleavage of the mRNA, inhibition of translation initiation and 
shortening the poly(A) tail of mRNA [304]. Previous studies have reported that HBx up-regulates 
miR-21, miR-29a, miR-145 and miR-222 which target the 3'-UTR of PTEN mRNA and inhibit 
PTEN protein expression [289,290,305]. Several studies have demonstrated that HBx can 
activate PI3K/Akt pathway [306-309]. Recent studies from Dr. Mengsen Li’s group have 
reported that HBx stimulates AFP expression and AFP interacts and inhibits PTEN [291]. 
Moreover, this group has also reported that HBx enhances AFP expression and thus 
PI3K/Akt/mTORC1 pathway [291,310]. Activation of Akt/mTORC1 pathway leads to activate 
SREBP-1 [81,82]. As shown in Fig. 13.4 and 13.5, we observed that modulating the 
PTEN/SREBP-1 pathway can alter HBV replication in either HBV mono-infected cells or HBV 
HCV co-infected cells. Reduced PTEN levels upon HBx overexpression increased the protein 
level of nuclear SREBP-1 in Huh-7 cells (Fig. 13.6A). These data indicate the possible 
mechanisms of how HBx regulates HBV replication. HBx modulates 
PTEN/PI3K/Akt/mOTRC1/SREBP-1 pathway. In Chapters 3-7, we found that HBx enhances the 
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activation of SREBP-1 and thus stimules HBV replication. Therefore, the regulation of 
PTEN/SREBP-1 pathway by HBx is important for stimulating HBV replication (Fig. 14.2). 
Interestingly, HBx can up-regulates mTORC1/S6K pathway though a PI3K/Akt independent 
manner. HBx activates IKKβ which leads to inhibit TSC1 and up-regulate mTORC1/S6K 
pathway [311]. It is a potential mechanism of how HBx activates SREBP-1 and thus enhances 
HBV replication (Fig. 14.2). 
Unexpectedly, we observed that the HBx and HCV core cannot additively reduce PTEN 
protein level or increase the nuclear SREBP-1 protein level in HCV core-expressing Huh-7 cells 
transfected with HBx expressing plasmid (Fig. 13.6). However, this is just one model to study 
how the HBx and HCV core regulate PTEN and SREBP-1. In this model, the data may indicate 
that HBV superinfection in CHC do not additively modulate PTEN/SREBP-1 pathway. Further 
work is required to determine how the HBx and HCV core modulate PTEN and SREBP-1 in 
HCV superinfection in CHB or HBV HCV chornic co-infection. Therefore, it is necessary to 
repeat this experiment in HBx-expressing Huh-7 cells transfected with HCV core and HBx and 
HCV core stably expressing cells. In Chapter 11, we showed that PTEN-Long treatment inhibts 
HCV replication (Fig. 11.2). In Chapter 13, we demonstrated that overexpression of PTEN 
inhibits HBV replication (Fig. 13.2). However, the role of PTEN-Long in HBV replication has 
not been studied. Therefore, the effect of PTEN-Long on HBV and HCV replications in HBV or 
HCV mono-infections and HBV HCV co-infection is worthy of study in the future.  
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Fig. 14.2. Potential mechanisms of how HBx modulates PTEN/SREBP-1 pathway and 
enhances HBV replication.  
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14.2 Conclusion 
 
 HBx activates SREBP-1 activity at the transcription level which is involved in up-
regulation of HBV enhancers and thus stimulation of HBV replication. Expression of 
HBx stimulates SREBP-1a and FANS transcription activation and induces intracellular 
lipid accumulation and cell proliferation. This effect may partially explain how HBV 
infection causes the development of steatosis and enhances of the risk factor of HCC. 
 PTEN inhibits HCV entry, replication and secretion. However, PTEN has a little effect on 
HCV RNA translation. PTEN interacts with HCV core protein. HCV core aa. R50 and 
PTEN aa. 1-186 are essential for the interaction. The interaction between PTEN and HCV 
core inhibits PTEN levels which enhances HCV replication. These findings may explain 
the mechanisms of how HCV infection inhibits the tumor suppresor, PTEN, and thus 
enhances the risk factor of HCC. 
 PTEN-Long treatment inhibits HCV replication in a dose-dependent manner. This finding 
indicates that PTEN-Long treatment may contribute to HCV therapy. 
 Modulation of PTEN/SREBP-1 pathway alters the HBx-mediated HBV replication. HCV 
replication is stimulated by PTEN knockdown and is modestly inhibited by SREBP-1 
knockdown. HBx and HCV core do not additively decrease PTEN protein level and 
enhance SREBP-1 activation. PTEN and SREBP-1 play the same roles in regulation of 
HBV or HCV replication in either HBV and HCV mono-infections or HBV HCV co-
infection. Our findings suggest that HBx does not alter HCV infection nor does the HCV 
core affect HBV infection in HBV HCV co-infection. 
 
14.3 Future experiments 
 
 In Chapter 5, we observed that only nuclear HBx but not cytoplasmic HBx can 
transactivate SREBP-1a and stimulate HBV enhcancer activity. In Chapter 7, we 
established the role of HBx aa. 1-127 and HBx aa. 43-154 in the regulation of SREBP-1, 
HBV enhancers and HBV replication. However, how different subcellular localization of 
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truncated forms of HBx regulates SREBP-1 and HBV enhcancers is still not clear. We 
will determine the subcellular localization of truncated forms of HBx. Then we will 
determine whether nuclear or cytoplasmic truncated forms of HBx regulate SREBP-1 and 
HBV enhancers differentially. 
 We plan to study the mechanisms of how HBx regulates PTEN/SREBP-1 in the future. 
Previous studies have established several indirect mechanisms as to how HBV inhibits 
PTEN; however, whether HBx directly interacts with PTEN is still unknown. As shown 
in Chapter 7, different truncated forms of HBx differentially regulate the activation of 
SREBP-1a and SREBP-1c. However, which domain of HBx is required for regulation of 
PTEN is still not clear. Future research will clarify these issues. 
 A previous study has established that HCV core R50 is required for interaction of HCV 
core with NS5A protein [264]. Previous studies have demonstrated that NS5A can inhibit 
PTEN thorugh activation of NF-κB [154-157]. No study has reported whether NS5A 
directly interacts with PTEN. However, it is possible that the HCV core interacts with 
both NS5A and PTEN and thus these three proteins may form a trimer in HCV-infected 
cells. As shown in Fig. 9.7, we observed that the HCV core interacts with PTEN and 
reduces the protein level of PTEN. Therefore, future study will be needed to understand 
whether HCV core and NS5A synergistically regulate PTEN through froming the trimer. 
Future research is required to establish whether HCV core, NS5A and PTEN can form a 
trimer and whether this process alters PTEN functions and HCV life cycle. 
 Interactions between the HBV and HCV have been difficult to study because of the lack 
of appropriate co-infection model systems.Therefore, it is important to establish HBV 
HCV co-replicating cell lines. In Chapter 13, we only study HBV HCV co-infection in 
HBV genome plasmid transfected HCV genomic RNA replicating cells and HBV RNA 
transfected HBV replicating cells. Future research is required to determine the role of the 
PTEN/SREBP-1 pathway in HBV and HCV life cycle in HBV HCV co-replicating cells. 
 In Chapter 11, we have established that PTEN-Long treatement can inhibit HCV 
replication. However, whether PTEN-Long treatment regulate HBV replication is still not 
clear. Therefore, future work is required to establish whether PTEN-Long treatment 
inhibits HBV replication in HBV mono-infection and the effect of PTEN-Long treatment 
on HBV and HCV replication in HBV HCV co-infection.  
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